var title_f6_23_6512="TT bacterial biofilm";
var content_f6_23_6512=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69293&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69293&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bacterial biofilm of tympanostomy tube",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bacterial biofilms may form on mucosal surfaces and implanted prostheses, including tympanostomy tubes as depicted above; these bacterial aggregates are resistant to therapy with systemic antibiotics and to standard culture methods.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C. Isaacson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_23_6512=[""].join("\n");
var outline_f6_23_6512=null;
var title_f6_23_6513="ED approach to the ventilated adult in respiratory distress";
var content_f6_23_6513=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77096&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77096&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 580px\">",
"   <div class=\"ttl\">",
"    Emergency department approach to the ventilated adult in respiratory distress",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 560px; height: 700px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    ABG: arterial blood gas; ARDS: acute respiratory distress syndrome; CXR: chest x-ray; ECG: electrocardiogram; ETT: endotracheal tube;&nbsp;PEEP: peak end-expiratory pressure",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_23_6513=[""].join("\n");
var outline_f6_23_6513=null;
var title_f6_23_6514="Peripheral artery disease PI";
var content_f6_23_6514=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F60105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F60105&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 538px\">",
"   <div class=\"ttl\">",
"    Peripheral artery disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 449px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHBAgYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACimMxDYHSjeaLjsPopm80m8+tK4WJKKj3n1pd5ouFh9FM3mjdRcLD6KbuNG6i4WHUU3dRuouIdRTd1GTTAdRTNxzTxQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAQXDbSPeoDMPWm6vIY0jI75FYzXXvWFSpyuxvTp8yubQmHrS+cKxFuuetSrcn1rP2pp7I1/NHrR5orMW496rPfgSMueho9qCotm55vvSiWsuC43pnPepllpe1E6VjQElL5lUhJS+ZVKoTyF3zKQyVS8z3qOSfHen7UPZl8zAd6Y12qjmsiW6PrVSa6J71Lr2LVC50lrcLPKVHYZNXOlYnhkF1nlPOSFFbdb05c0bmFSPLKyCiiitDMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAx/ErbbaJuwbFcwZ8nrXS+LuNIZx/C4NcJ9o56152KlaZ6WEjzQua6ycjmp0krKinqyktc3OdDgaSyVzn9ohpixbqSa1ZLgRQSSE8IpY/hXm9vqOEQs1PnOrCYf2ikz1jTnzaRt/e5q2G5rPsPks4FPUIoP5VaDU1I4JrVltXpd9Vg1Luq+cz5SZnqpPLgHmld+KoXMvWpcy4w1I558d6pyznr2psz5qlcyYUisZTOmMD0Twym3SIm/vkt/T+lalVtMh+z6dbRd0jUH645qzXtU1yxSPFqPmm2FFFFWQFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFeZ/GDw1feJtX8IwacbmCWC4uZkvYlYraTLbuYZHI6DzAvB69O9AHplFeA+GL7xjZ+H4ZdRtNd0EX2o6pdXx03S/tk6Tl1aFBG0b/umzId+3B2qNyg5O6+ofEObwt4j1CaW/tNVstMgks7G3sI3WW5e0UyAZRi+2UnCqeG4ORxQB7DUF9d21haTXd9cQ21rCpeWaZwiIo6lmPAHua8ulHjnTtfuQutaxqNla6tp0EaSadb7bi3mMYuGZkiBwm5iGUjbg7i1cbrWreOPEGneL9NuNN1+TTLrQ70xW13ZEyR3AdQkaslrECSrNgK8uQM7uDkA+iqK4r4qapq+m6PZ/2FFqpnmuQjz6fGH8pQjHLj7PcNtJAHyxE5xkgZrkdKk8deJ9DittWudT0xpdAMk4jsY0aW78yRNhMkZC7kCkqADyCNvcA9jor58Oq+OtM8OeHbPQptbS2j0tVaa80qUPHdqFBheOOxkYxKAMEBC2T+8JFdpd3njFNN8YatJqE1sdKuhJZ2bW0aQzwJDbyyDe6bmU4mRWyMFmyTgbQD0+iud8BXmpan4eTU9XZ1fUJHure3dAhtrdj+6jOBydm0nPO5iOgFdFQAUUUUAFFFFABRRRQAUV5f8XvDOo+I/EnhP+yTPBdWa3lxBeojFLa4VEaIuRwFZl2kHqCRXndrrHj3SvAcZ03RvEGl6zczanqDwxWZkj81rhmWJl+yzMTz8vMSsCfn6YAPpSivKdQvvHE1v4mvbW41C2ktp7JNPtE09GR1kitzMfmQu4Vml6EbSGBPACt8R33jDS/EElna32u3XlC1+wCPS4pYL4vKfO+0SpFti2jAGGjwoB+ck5APWKK8jk174hCOXTRps7N/af8AZi6mLUBwGnLC62kbPJW3wCdp/ed+Kz7XX/iSdd11TA5eFL/7PZS2sphYqrG28uQWqpkkJndcNnceFPAAPZY7u2ku5rSO4he6hVHlhVwXjVs7Sy9QDtbBPXafSp68u+FC383jDxNqN9JrtzHcWGnIt1q+nfYmZ1NyXRU8qMYUsOxPzdSMGvUaACiiigAooooAKKKKACiiigAooooAyPFq7vD17jqqbvyIryhbjJ617Jq0P2jS7yH+/C6/oa8MRjmvKzDSSZ6+Xawkjet5iavRycCsa1bpmtGJs1wczO2URniS6Nv4c1GXPIgcD6kYH868usJHmv8AT7U8maREx9SBXa/ES4MXhZ4xwbiWOL9dx/RTXKeFo1l8daVEeibn/JGI/UVrHZs9jL4qGHlN+b+5Ht8ZqcHiqsZNWFpxZ820SZpCaSmsapslIjlfFZlzJV2duDWVctWUpG0IkEsmKhtU+1ajbwDnzJFX9ahnfGaveC4jc+J7fPKxK0h/AcfqRTp+/NRNZ+5By7I9Tooor6A+eCiiigAooooAKKKKACiiigAooooAKKKKACiiigArn/FOsXdje6Jp2mJCb7U7ryg8yFkiiRGkkcgEEnau0c/eYZ4BroK5/wAU6Pd317omo6Y8IvtMuvNCTOVSWJ0aORCQCQdrbhx95RngmgDm7H4kW7nXLO9Kw6pa3l7bWa/ZJhBN5IZlUykbDJtUkqGBwM4FaGkfELR3stHTVbrytSvLa1lmEVtK0EMk6goryBSke4n5Q7AnjrmoZPhrp02ozXFzqmrT2r3dxfx2LtCIYZ5kZGkXEYckB2wGZgM9KUfDTS1aFItQ1WOyC2gubNJI/LuzbBRE0h2bs4RM7GUHaMigC9F8Q/C8huj/AGn5cdtDJcNLNbyxxyRxttdonZQsoBIHyFuSPWk8F+LD4m1nxDDFDJHZWEsCQGe0mtpWDxB2LpKA3U8HaOPXrWX/AMKr0d7R7S4v9WnsUtpbWztnljCWKSMGPlFUDEgquC5fAGOma6Hwv4ZTQbrU7ptT1DUrzUXjknnvTFuJRAi4EaIoGAO1AFeXx74ZitIbl9UURSpPIv7qTOIXEcmV25BDkLggEsQBkmo/+FgeHfIWQXF8ZGuGtRajTbk3PmBA5UweX5o+QhslcYOapX3wx8PX0viV7lbqRddCieNpAyQkMHJiUghdzgO2cgsOmOKpH4S6P/wjsmjJeSxW0k/2h2i0zTULHaFHyi12DHUMFDAn72MAAHQL430Jry6tvPu1Nohe6lawuFhtgIhKRLKU2RsEIJVmBGQMZOKw9Y8a6TrUen6fYQx30F7qEFjfWupWEsf7iaORg3lyqu4N5Zw2CpwetLdfCnRLzUBc311f3MYszYeSwgUtCYTCVeZYhNINpJw8jDdzjIGF8PfCvRNCNubSWXMF3DdoUtLO3JaJXVVYwwIXGJD97J9COcgG94S1m51GXWbHUY4kv9KvWtZDCpVJEKLJE4BJxlJFBGT8wauhrn/Cei3Omy6ze6k8T3+qXrXUghYskaBFjjQEgZwka5OB8xaugoAKKKKACiiigAooooAKiuZltraWeQSMkSF2EcbSMQBk4VQWY+wBJ7VLWf4g0qHXNDvtLupbiKC8haF5LeTZIoYYJVuxoAxF+IPhs28kr3lzCY7lLN4Z7G4imWZ0LohiZA+WUZHHPQZJFZ2jfE/R75NVe7t9Tsks737HGJNOut1wcLtCqYgTIdx/dAFgBkjFR+HPhTomgSB7S4vC326HUMCO3hQyRIyKNkMSKBhznABJAOeuZNc+GOk60upR3t7fPa3t6uo/ZnS3kihuQoUyKrxNnKjBV9y8ngUAakHjzw7PJYxwXk8s96sjQQpZTtKfLkWOQFAm5SrMAwYAgZJwASL+jeJ9H1qa1i0y9Fw9zZrqEQWNxmBm2hjkfLk5G04PB44OMzwx4E0zw5e2F1ZSSmWztZ7RAILeBGWaWORiUhjRdwMagEAcZzk80z4e+ER4Y/tm4mEQutSvpZ9kLs6Qw72McSkgHA3M2MYDOwHGKAOvooooAKKKKACiiigAooooAKKKKACiiigAIBGD0rwa9hNrf3EB6xSMn5HFe814144hFv4qvlHAZg/5qCf1zXnZjG8VI9PLJe/KPkU7Z60oGzWPA3StG2fmvKPUkjnPiXKWXR7UdJJnlI/3QB/7PWd8OUNx46mkx8sFu7Z9yVUfoTVvxYpvPFNtGOVtrUufYsx/ooqf4RQBrjWLsj5i6RKfzJ/mK2WkD2E1TwEu9vzf+R6hFVlelVYjVhTTifMseaY54pxNROabEivOcCsm6NaU54NZVyetZSOimjMuTzXUfDO23Xt9dEfcQRj8Tk/yFctc9zXoXw8tvJ0AS45nkZ8+w+X+hrfBR5qy8iMbLlovzOnooor3DwgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKr3t5DZxb52x6AdT9KG7DjFydkWKRmCjLEAepNcrd69cy5EAEK+o5b86ypZpJm3SyO59WOaxdZdDvp5dOWs3Y7Z9QtEOGuYs+zA03+1LL/AJ+Y/wA64kAnoM0vlv8A3G/Kp9s+xv8A2dT6yZ3Md7aycJcRE+gcVYByMivPSCOoIqSG4mg/1Msif7rYpqt3RMst/lkd9RXJ2+v3ceBLslHuMH9K2rDWLa7IQnypT/Cx6/Q1pGpFnHVwlWnq1dGlRRRVnMFFFFABRRRQAUUVR1PU4bFcN88p6ID/AD9KTaWrKhCU3yxV2XqZJNHEMyyIg/2mArkbvWbu44V/KT0j4/XrWczFiSxJJ7msnWXQ9Cnl0nrN2O1bVLJetyn4c0g1ax/5+F/I1xio7fdVj9BTvJl/55v/AN8mp9szb+z6XWTO3jvbWX7lxET6bhmrFeelSvUEfUVLBczwH9zK6fRuKard0RLLV9mR3tFcpba/dR4EypKPcYP6VuWGqW97hUbZL/cbr+HrWkakZHHVwlWlq1oX6KKKs5gooooAKKKKACiiigAooooAK8u+Klt5Ws2twB8ssW3Pup/wIr1GuK+Ktr5uhQ3Kj5oJhk/7LDB/XFc2MhzUn5HXgZ8tZeeh5vC3NaFq/IrKjPQ1etmwa8JHvyRkSkNqPiO8JysSJEp9MIM/rmtP4R25i8MSTn/l5uZJB9Bhf/ZTXP3Muzwnq90D/wAfN5Jg+oDECu58C2v2TwlpUZ6mBZD9X+b+tdE9IxR3Yt8uGce7S+5f5nSRmp1aq6VIpqUeCyXdUbnilJqOQ8UNgkVpzWZcVfmNZ1y2AazZvAyr18HFev6Ha/YtItLcjDRxgN/vdT+ua8o0a3/tDxJY25GVMgZh7Lyf0Fey16OXQ+KfyOLMp/DD5hRRRXpnlhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVwl/qCaldSTwuXhDFEPbCkjI9iQTXUeJtSGkeHdT1En/j1tpJR7kKSB+eK8a+E+qx3ugxac7/AOm2+4hWPMiklsj1IyePT8a5q9S0lDue3leEcqU8T/K0vvvf9PvO5gj82VUyFz1J7CvFfGHxveC9ltfCmnWxgjYr9suwXaT/AGlUEAD65+gr2u2cRTqzrlRkEexGDXzF8Rvhrqvhe7muraJr3RWYmK5iBby1zwJB/CR69D+lYTbS0PUw0ac6lqnyEm+K3jW8Y7tbkiU9FgijjA/Jc1d0zxt4qkcF9e1BvrKa89tRlwK6zSo8AVzSnLue7QwtH+Rfcj0PT/HfiaIDdqTSr3WWNHz+YzXT6Z8R84XWNNicd5LY7GHvg8H8xXnNqvFTSgBapVJLqZ1cHQm7cqXpp+R7hpep6ZrKbtJvUmcDJgb5ZV/4Cev1FWDwa+e9PmvItasn0wsL0TKIdvUsTgD8a+jNQ2/bJdvTP6962hPnVzycXhvq01FO6f3m54d1JpD9luGy2PkY9T7Vv154tyLR0nPVHXHucgAfnXoddlKV1ZnzmPoqnJSWzCiiitTgCiiigCG8uY7O0nuZ22wwxtI7eigZJ/IVws0rTyvK5yznJNWPjRqX9m/DrVCrYkuQtqvvvYBv/Hd1cv4I1ePWtEgIb/TIIws8Z68cbx6g/oa5a1Rc/Ie9l2EksM8VbS9vy/zNq6ubawsLu/v3KWlpE00pUZO0DOB7mvBtf+Oetz3MiaDZWWnW2cIzx+bLj1JPy/hj8694vLODUtMvtOvSwt7yB4HZRyu4Y3D3HWvlvxt8PNd8JTvJeW5uNPJ+S9gBaJh2z/dPsfwz1rGbkl7p6WFjSnNqrv07G3Y/GHxx5qs+rJIO6taxYP5KDXofh34nf2pIh1+0jgnIC/aIULxn/eQnI+oJ+leB6Ym6QV3+mwoLdPXpXFXSqx5KmqPWWBoSV+W3pofQNvqls4icQjy5RujktXOxx7f4dqnDqeUfdz9yQYP515n4V1GfS4vImLGydvMBAyYn/vD2PQj/AAr1CC5bUohhoTLgMCcYYeoI6j3rw8RGrhpXpSdnt/k/00PFxND2EtNhREssbPATlfvRt95ff3FRAkEEHBHQilCXdvqlozKiguFYq2cg0swHnSbB8u44+le5l2KniaTdRWknZmKetr3Ra8G6a9vqBki1vV2iXcXsbm4FxE4PQhpAZFwewcD2rTn1XX7PVjDP4eF3prybY7uwu0Z0UnAMscmzGO+xn+lZmiTrDrdkjHBmZo1HqdjN/JTXbV7NKXMjxcbRVKpps9TOn13SbfV49KuNSs4tSkQSJayTKsjqSQCqk5PIPStGqWraVp2s2jWur2FpfWrdYbmFZUP4MCKpatotxLYWlvoeq3Gim0UJELeKOSMqAAFZHU5UAdip960OM2qKxkm1jTNBaW/hTWdRjP3NOiW3Mq7gMhZZCAQMkgvzjil0DxBba0lxstdQs5rfHnQ31o8DJnOMFhtccHlSw96ANiikBDAEEEHkEUtABRRRQAVleKrUXvhzUYMZJhZlHuvI/UVq0jAMpDDIIwRUyjzJoqEuWSkuh8+W/KfSrKyCJGdvuqCx/CoYY2illif7yMVP1BqHW2Mei37DjED4/wC+TXzfU+qS5pJdzndcm+z/AA80uMn55d0jfma9f02NYLK3gXhYo1QfgMV454gj86Lw9YdQ/loR/vMB/WvYLSXIFdFV62OrMv4cF3cn+JpLTh0qNG4qTNQeIwzUUppzGoZW4pMaRWmasq+kwpq/cvgVg6jNwRUM6KaOn+GNqJtUvbxhnyUCLn1Y8/oP1r0iua+H1j9j8NwuwxJcsZj9DwP0AP410te7hYclJI8TGVOes38goooroOYKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPO/j1qH2L4d3MKnD3s8VuD+O8/ohrw7QA0KRyRsyOpyrKcEH1Br0n9pO5Yp4dslb5XkmmZc91ChT/wCPNXBaXFi2H0rycU+at6H6Jw/TVLLk/wCZt/p+h19n48mi2R6rbLcgcGWM7JPqex/SugfxYiKP7MtWw463BznP+yD/AFryudd84UdScV2mkQ+bqdnFjgyqD9M0UqknoLMcFh6aUoxtv6fceQfFEQH4l6ytrFDDEkiJsiQIu4RqGOB6tk0zTF4FZOs3f9o+KtWvQ24XF3LID7FyR+lbenDgVnN3lc7cLHkopeSN61UbabdnC0tucLUF63FHQaV5G98LlVfFMt80aSGwtZLhA4yN/Cj/ANCrv28V3rOWMFpknP8Aqz/jXE/DaLbpPiK7PB2wwqfXLEsPyArVraDairHmYuEateTkr2svwv8Aqa8mt3Wpavoti8cCrPqEG7YpB2q4Y9/avbq8I8Iwi6+IWgxkZEXmzN7YQ4/Wvd66sLd8zZ8/nijB0oRXRv721+gUUUV1HghRRRQB4x+0lf4sdC0xT/rp3uGH+4oUf+hn8q890SWayMc9rK8Uycq6nBFbfx3vPtnxFhtgcrZ2iIR6MxLH9CtZVvHttgfavHry5q0mfpeU0lSy+lB/a1+//gHW2Hjx2mji1OzWQnC+bAdrH3K9D+GK3rTxDLc6lBbWkKxQyuFbed5Ze/t0ry60TfqUQ/2s/lzXW2k4so72+JwLO0nnz6FYzj9cVdKpJ7s5MywdCl8Eeny+48FSVLvWLu4ijSNJpndURQqqCxIAA6D2rtdPgZYlLduRXC6Gp8xcda763L+Qua55bnor3YJI6O3vVNmI9oyK6rwU13BpM0qt+7eXdACM7AoIdh7EkD/gNcVBLClr0G/FeqeGo1RY7UAbUtkhx7lcsfxYk1w42p7Oi0t5Ox5ONajBq39IW/v7qKO4mdo5GgRWUhMDLEDn8Caxf+Ekvf7sH/fH/wBerGpF49FuVkyHNwkR9woY/wCFc5XRlaaw6l1d3+Jz0qUGndHS+FNTudV8f6RFLsCW8c05CjHVCg/9CNewV478J4RN451C46/Z7ERfQs4P8ga9ir2sNdxbfc8bPLRrwhHpFfjd/qFFFFdJ4oU2WNJY3jlRXjcFWVhkMD1BHpTqKAMDRvCGjaHfm60W3ksAwIa2t53S2Oe/kZ8sH3Cg1GT4rtdYHy6PqOkyTdQZLa4t4y3p86ylQf8ApnnFdHRQBgaz4v0TRNQW01q7bTywBW4uoXjt2z2ExHl59t2a3Y3SWNZI2V0YBlZTkEHoQaVlDKVYAqRgg9CKyNe8PwavFbgXeo2EtuCIZbC6eApnHVQdjjgcOrAelAGxRWK0Ws6ZoKx2cqa3qMZ+/fyrbGVc9zHGVDYwOFAJ9KNK1uaawu7jWtLudF+yKXlN1JEyFQCS6ujMCoA74PtQB5brVt5PibVIx/z8OwHsTn+tYfitCnh69I6lQv5sB/Wuo1+8sdR8UT3Wl3lteW0yIwlt5FkQ/KBwVJHauc8cjZoDqP45oh9fnB/pXz1SNqjXmfVYKXPKn52OdmTzPFmgwk52Kp/JS39K9KtZMMK8z07M3jm1Yg/uo2Yf98Ef1r0KB8MKKr95nZmS1hHy/VnRQvkVMDVC2fK1a3VJ47Q5mqvK+AakY1SuXwDQNIpXkvWsnyWu7yG3T78rqg+pOKs3jkkgVe8Ew+d4qsgwyqFnP4KcfriiEeeaj3NpS5IOXZHrMESQQRxRjCRqFUegAxUlFFfRnzQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHzt8ebv7V8QLa2U/La2aAj0ZmZj+m2sqyXZZ/hUHxBuPt/xQ1yTOQkywj22Kq/0q6seyy/CvFm71JM/T8HD2WEo0/JfjqZ9sPM1GEf7Wfy5rq7W4+xR3l90FnaT3Gf92NiP1xXL6Su7UlP90E/pj+tafimf7J4E8SXAPJtltx/20kVT+maqltcxzR3koeSX3s8Q0tckV1+nrhRXLaSvSutsRgCo6nZHSJqRHC1Tvm61bBwtZ183WmyYL3jv/BcfkeAWc8NdX7Ee6qgH881Yp+nx/ZvB3h636EwvOffe5I/SmVtskjyG+acpd2/zsb/wth874g3EpGVt9PI+jM4/pmvZq8r+DcG7WfEVyf4RBCv5Mx/pXqldmFXuX82fOZ7PmxXL2jH8k/1Ciiiug8YKKKOgoA+WPH1wNQ+J2uzL0W4EP/ftQn/stXSNlmPpXNWU51HWry8Jybm4kmz/ALzE/wBa6i9TZZivDvzNyP1eMPZQp0uyS+5FPR136gW/uqT/AE/rV/xbcfZPAXiKcHDNDHbL775FB/QGqugLmSdvQAfzqL4pb4/htuXgT6nFG3uFjc/zxWtP4Tz8wfNXUfT/ADPLtCGJFJrurZgyKK4rRIyWXFdrZR7FUk1hI65aRNG1s2u7q2tov9ZNIsa/UnFepWrsmrtJtKxz5kT/AHe1cN4W2nxLpoHXcSPrtOP1xXoMriTTLCYYzEhXPtivIzh3hFer/L/M8bGzfOo26fnf/IyfEUpazg7eZPI5H0Cgf1rn62PEBKpYIf8Anh5n/fTH+mKx69jBx5KEF5IVFWj952nwThzceI7sj788UIP+4pz/AOhCvUa4D4LQBPC13P8A8/N/NJn2GF/9lrv69bDK1NHzedT5sbU8rL7kl+gUUUVueWFFFFABRRRQAUUUUAFFFFAHgHxL8N6JP8Y7IXOj6dKLjS55pBJbIwdxJAAzZHJALcn1NYfjXwp4cttPszBoGkRPJdKpKWcakjaxI4XpxXb/ABYjNv8AE7w7d/wy6VeR/wDfMtuf/ZhXMeMblLiTSos8eY8n5Lj/ANmrx8Q5Kra59JlVONSUG1/SRy3hzwxoN54ovQ2i6Y8EUHCG0jKgkjnGPY10vgyzttP1DxJbWNvDbW0eortihQIi5tbcnAHA5JNV/hwu/Udblb/pmo/Nz/hWl4fGNa8U/wDYST/0jtqwlJvmu/6udeYQjDEcsVa1vyOzs2ytW6oWHIrRArM4JDGPy1lX0uM1qzcIa5/UWOcd6TKgrsqFjI+K6HwL+58UwBh/rI3Ufln+lZGn2pchj3rX0r/RPE2nN6yhP++hj+tXRdqkX5jr605RXZnqVFFFfQnzgUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFR3Eogt5Zm+7Gpc/QDNAJX0Pkt5ftvi/Vrnr517NJn6uTXR3Z2W2K5PwoDJOHflmOSa6rV2xgDsK8Naps/WZR5ZxguiK+hLm5mf0XH5n/wCtVb4oTmD4fyoDzc38MZHsqSMf1xV7QF/dzN6sB/n86wPjLIY/DehQ/wDPe6nk/wC+VjH/ALMa1hpE83GvmxNvNfgrnB6OvC11lkuQK5vw5bS3U0UMC7pXOFGQP1PFei2nhXV0AzbRn/duI2/k1EKFSprCLa8kaV8dhsPaFapGLfRtJ/iZjjatZF63JrotXsrjTysd3H5bsMgFgSR68VzVwDJMqLyzHA+pqZxcHaSszfDVIVVzwaa7rU9e1OPyItMtun2exgix9Fz/AFqjWr4nYNrt1t4CkKB6YUCsqtpbnjUneCb6novwaiI0XVJ2HzS37gH1Coij9Qa9ArjvhIgHgWykHWaWeQ+/71x/ICuxruoK1NHy2ayvjKvk2vu0/QKKKK1PPCs7xHc/Y/D2qXOceTayyZ9MIT/StGuX+KNx9m+HniB843Wbx/8AfQ2/1qZu0WzbDQ9pWhDu0vxPmfwknzKa6nVGxbhawPCCcKa19WfJIrxI/Cfqs/erE+gLi3lb1fH5D/69XPiDHFe/DG4tAhM8JF4rdsq+CP8AvjJqDRlxYKf7xJ/WusuNNS+8Py2jLzPH5O708yPH/s2azxFd0IQa6tL5M8TGzXt3J9H+R8/6EMMprsY/nRVTrXK+GbV7u5igjKh3OAWOAPrXcW1kbW6a3kkieRVDHy23AA5xz+FbujUcHVUXyrr0Oqti6EKioSmudq6V9bd7fIs+FxKPFOkAHn7VH+W4Z/SvRNP3S6RLGMskbNz7Zrl/BlpjVXvyM+T+6gH96VhgfkMn8q7azhFvp8sHUyyCPjvlsV4WatTcKa31/wCB+R5uMqJyt6fr/mYHivC6t5Q6RRRp/wCOg/1rGPAya0PEEvna3euOnmso+g4/pWTfP5dlcP02xsf0r6KyirLoVh4txjH0PX/hVAYPh/o4YYZ42lPvudmz+tdZWZ4Xt/snhrSbfGPKtIk/JBWnXpU1ywS8j47G1Pa4mpU7yb+9hRRRVnMFFFFABRRRQAUUUUAFFFFAHjXxdnE3xI8O2g58rS7xz7Fpbb/4kVxXiaIRapYjukMjH8dv+FbXiW6/tH4wRTZyi2l5Gv0WS2X+lYni2Tfr92AOILNEP1JY/wAiK8WrLnq839dT63J6bjJR7L80v8y78N7Zjpt5dc/vbgge4Cj+uav+HYs6x4q/7Caf+kdtWh8Nol/4Q2xYjl2lJ/7+MP5AU7w3CDrXi721RP8A0itaxS3f9bkY+rzYmXk3+GhtWK4rSUVWgTaatrUI5JO5BcD5DWHcQb5fxroJFyKqNAN2aGOErBYQqiDI7VWmJbW9OEfL/aI8Y/3hU9zcpBEfWq3gxX1LxbbuF3R24aVz6cYH6kVVNc0lFdwlpGU32PWKKKK+hPnwooooAKKKKACiiigAooooAKKKKACiiigAooooAKyPGM/2bwlrc/QxWM7/AJRsa165X4qTeR8O9ffOM2rJ/wB9fL/Wpm7RbN8LHnrwj3a/M+cPBke51PpW7rB/eNWZ4KXgVo6wf3zfWvFXwn6m9a5Z0JcWbH1c/wAhXJ/G+X9z4Ytv7sM82P8AekA/9krsNIGLBPck/rXBfG6Td4m0iEdItMi492d2/qK2WkDyaz5sV83/AJFLwGm7Vrf2DH/x016XXnnw+XOp5/uxMf5D+teh19zwxG2Db7yf5I/HvEapzZrGPaEV+Mn+py+uvu1eb/YhQfqxrP0KH7V4m0uDqJLuJD9C4qzrDZ1a/PpsX/x3P9an+HUP2nx5pCYziUv/AN8qW/pXzOevmzCfy/JH6XwkvZZDSl/db/Fs7/WH8zVbx+xmbH51n3L+Xbyv/dUn8hU8rmSV3PViTWfrT+XpN03/AEzI/Pj+tebJ6NnoUIXlGHoj234bWwtPAehxjPNssnP+383/ALNXS1T0eAWuk2VuvSKBEH4KBVyvTguWKR8Riqnta86ndt/ewoooqjAK4L45z+T8MdWAPzSNDGPxlTP6A13teYftETeX4AjTP+uvYk+vDN/7LWVd2py9D0Mqjz42kv7y/M8h8Ix4hDe1WdSOWNN8MjbaD6Ul8cvXj/ZP0yOtZs2dMG2whH+zmu+aRIoEtR/rXngUD0ChQa4fTkzDbR+oUV2epsiJc3CY82KZyOOyqT/MVyZjflpxXWS/Jo+axb5ql35/meB+DAG1mJl+6Nx/DB/xro1n261qDDsUT8lH+NYXgFN2oO3ZYj/MVsaXAb7X5IF6z3nlD8wtfXQXLkzX80/8v8jwq1qvFV3/AMu6X6t/qeoeGLQwzafAy8xx+e49XcA8/QFR+FbyMv8Aa9nB0Jcu3tgE/wBKiskVbkXkZ5kZztHYbuP0plykltdSXMn+s+zyyAf3flIH86/OIy9vjIy395fddW/A9KpLnk79n9+pxc7+ZNI/95i1Zuubv7LnVPvOAg/Egf1q9TBGJ9V0a3b7s+oW8Z+hcf4V9XLVM9WhaNSL7a/dqfQ0aCONUX7qgAfhTqKK9Y/PtwooooAKKKKACiiigAooooAKp6veDT9LurtsfuY2cD1IHA/OrlcV8Vb/AOz6FFaK3z3UoBHqq8n9dtZ1p+zg5GtCn7SpGHc8htQf+E30kscltPvSSe/721rP1gGTU/E0vUKY0H4RrWrGuPG+j/8AYOvf/RtrVG+A+xeJZT1N1t/LivEhrb0/zPsct/iyfp+cTufAqeX4R0tR3i3fmSf60vhVc614w/7Csf8A6Q2tWPCKhfDGkgf8+kX/AKAKg8Kf8hvxh/2FY/8A0htaUNmeVi3es35v9TdC/NUwHGaAtObpSsZXIZGwKgMgpbg8Gs24m2DrUNmkY3K+sJlSd2BXVfCqxEWl3V6w+eeTYpP91f8A65P5VxV4813NHbW6mSaRgqqO5NexaTYx6bptvZw/chQLn1Pc/icmu3AU+abn2MMfU5KSh1Zbooor1zxgooooAKKKKACiiigAooooAKKKKACiiigAooooAK4b43MU+GGtFep8kfnNGK7mvPPj1L5fw3vE/wCes0Kf+Phv/Zayrfw5eh3ZYubGUV/ej+Z4z4MX5Pwqxq3+ub603wgNsGfam6q2ZW+teR9lH6ZHWuzX00bbCH/dzXmvxkfd8QZYv+eFrbR/T90p/rXptmNtnAP9hf5V5V8WH8z4m61/svHH/wB8xov9K2fwnjr3sTf1/NGp8OV/0ydvSLH5kf4V3lcX8OU/4/G9FUfnn/Cu0r9A4djbARfdv8z8U49nzZ1UXZRX/kqf6nF6u26/v2/6a4/JVFbHwlXPjDze8FtNJ9Plx/WsLUW3XF4fWd/0OP6V0nwkXGq6zN/zz02UD6llr4zM5c2PqPz/ACP17JoezyKlH+4vxOgqlrCedarB/wA9pY4/zYVdpbWL7Rr2hQYyH1GDI9g2T/KuKSurHZRlyVFPtr92p9CDgUUUV6x+fBRRRQAV5B+0nLjw5o0Gfv32/wD75jYf+zV6/XiP7S8uB4ah7PJO/wCQjH/s1c+KdqUj2MhjzZhSXr+CZxOgjFp+FQ3p+arOkDbZD6VVufmmVfUgV5T2R+iw+Ns67SEzf2UfrIi/qK6wwLJBJcN8yG7kVwD/AA7iD+hrm9BXfrVkB2lB/LmugsQ4tZ43U+Xc7nRs9G715+cS5VT73uvlY+Vray+79TxnwdZSWGpanbTjEts/kv8AUMQf5VrfDqF7jxTZuBkefJcf987n/pV2/jW38VeIZQOJGim+u6MOf1Y1Y+F8fl2Vzdj/AFwgW3iP+1JnJ/BQfzr7HGVI0smoye12/u5j53BzdXPsbW/uQX3xj+p6RpbLHpNvMQclMrj61n3k8s9vqVxLkBYNoz7soqWWyuHshpqaldadLbuHWW1WJmdCD8v71HXHOemeOvXOBqmi6k+n6tIfFmuMFES4MNlhssOuLcenbFfneXUovEwXN8teifyPY5mpu0b3e/qzMqxoUfn+NPDkXX/SvM/75Umue/se+/6GTVv+/dr/APGa0/Bfh+/u/HWmRp4m1iJ4oppRKkVoWT5dvGYCOd2OQa+t5btK/Vfmeg6rjCcuV6Rl2/lfmfRdVNW1C10jSr3UtQl8mys4XuJ5NpbZGilmOACTgA8AE1gf8Ivq/wD0PfiT/vxp3/yLUGt+FNTvPBviXST4iv8AU7jU9OntIDqKW6JE7xsoOYIUOMsM53cDgevpnww+1+IWg3lzp9vZveSzXl3HZiOS0kt3jZ4pJUd0lCMEZYXwwByenfHXV5hJ8NbyBtFvbXVGvNZt7qGW5utRKkeXFa3EUccaxxqu1XnzggEgsSScVyOkfCLxJaLftMPD/kXK2bTabE4itbxoZWZ1dYbWMKjKwxlZG4AYsKAPfaK8L8O+BvEUUbXelaZpGnXEFxq9mbCV5ILeOK4eMq8JWLLKvl8DaoYHqtSx/CXWk1vQrue7trhLK206LfHcpFJatboquIWa0kcqxUthXi3biG65oA9vooooAKKKKACvHvibfef4oeN2Pk2cQU4Ge24n9f0r124mS3t5ZpTiONS7H0AGTXzdBqN/rfiq+vCGgsEkcNuXmeUnJxnoi9MjqfYc8GPl7iiejl0ffcyXRtMj8SQ/bfEel2c8Dtusra7tkkeCMgctuBwzYBI7cDqDXN6h4X0NNJ1uQaJpiul46IRaRgqoJwBxwK9OsxwK4nV2xoesr3a/l/8AQjXBSm7u3Y+jwFKLn7yvqvzOk8OeC/Cs2g6bJJ4a0R3e2jZmawiJYlRkk7etddo2k6dpFsbfSLC0sYGYyNHbQrEpYgDcQoAzgAZ9hWV4MfzPC2kH0tYx+Sgf0rpYRmlFt7s8qvFQqSSXViEcU1+lWWTAqvKMU2jJMpT9DWHqBwK3JjwawtRPPPSsJHVSNr4awLNrtzM67jBD8pPYsf8ADNemVynw508WuiG6P+tvG3n2UEgD+Z/Gurr3MHDkpK54uNmp1nbpoFFFFdJyhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5b+0VL5fgW1XP+s1CNf8Axxz/AEr1KvIf2kpP+Kc0eL+9fbvyjYf1rDEu1KR6mSx5sfSXmefeFl/0Jj7VU1BsyGrvhwbdOb6Vn3vMteU/hR+j0dasmdTZJuaCPHUqteMeP5fP+IviF85xfSp/3yxH9K9w0pd2p2a+syD/AMeFeBa+/neLdYk/v3szfm5raXwni0Na1/I7v4eJiyum9XUfkD/jXW1zPw/XGjzH1mI/8dFdMa/R8kjy4GmvL9WfhPGE+fOsQ/NL7kkcBctuSR/78rt+bGuw+FK4tPEc3923jT/vpj/hXFMc2UZ9QT+Zru/hiuzwz4jk/wCeklun5Fj/AFr4DFvmxlR/3pfmz90w8fZ5VSh/dgvyNSr3hcCTxz4ejIzmd3/75jY1RrY8BxeZ8QdJb/nnDcP/AOOgf1rFateq/Mzm+WnN/wB2X/pLPbaKKK9Q+ECiiigArwv9pRw2o+GI+6rcN+Zj/wAK90r5/wD2jJN3ivQ4v7tqzfm+P6VzYz+Ez3OHFfMIPtf8mYGnDGnqfaqY+e+hHq4/nV+0G3TE+lU7YbtRhH+0DXmPoffwek36nb+GiF1mBz0RXc/ghNdNanZZQRtna6FwPQjvXLaID9pnI6rbyn/xw10SX4a1Zym0R2u1Ae5J5NePnbu4K9tH+h8rWi3K68v1PPfE2EutXkGQRbx5+ogX+hFbHgq3+zeE9ImVTh3aaU/UlF/9A/Wub8R3PnJ4jkHIWV4B/wAARY//AGWuz8EXKQaNpkM67oJrbaD2BEj/ANc19PxG3SybDU+6/wAj5vJryzDHVO0or7os6PV5QXspR98ZQkdxWfefu/D+pZPMksQP55rRngUtAcjy0fv2zWTrsuNMuUU5U3YGfoh/xFfF5S3PFRm+z/I+ghZpRXdfmczXR/C0B/Hs2Rny9Nc59CZE/wADXOV1nwgTf4p1qX/nnbQp+bMf6V9dDWcV5nViny4arL+7+bS/U9Zooor0z4gKKKKACiiigAooooAKKKxPFupahp+mImi2bXeqXcotrYFSYo3IJ8yUj7sagFj64CjlhQBzHxa1fVI7H+ytGieISost7fPH8kUJfb5aEjDSOQRj+FQxPO3PA2a4Va9E+IUc9l4HsrW7u3vLgSRRS3LoqNMwU5YheBkjOBXn1sOleNj5XqJeR7mXRtRb7s2rQcCuA1o5sNUUHn7bNx/wI131r0Feeaw+z+1FbkLeyk/ic1z0tz3MuV5v5fmd98OZlm8JaftIzGrRkZ6EMR/LB/Guzt16V4x4D1h9G82bDS6ZIQZgnLRN03gdx2P0Hpg+z2bpJGkkbK6OAyspyCD3Bq4xszgzOi6VaT6N/wBInccVTmHJq6/Sqc/SnI86Jnzd65/VGxmt6c9a5zVzgNXPI7KR614Vx/wjemY6fZ0/lWrWZ4XGPDeljp/o0Z/8dFadfRU/gR89U+N+oUUUVZAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeL/ALST/wCi+HY/700rfkq/417RXh/7Sb/6V4XQf9PJP/kKufFfwmezw+r5hT+f5M5PRvl0w/SqEylrhR6kVe0o/wDEtA9qrAZvIx6uP515b2R+g0naUmdhoQ3azZD/AKbKf1r50nfzdYvJP78zt+bGvo3w8QNZtWPRW3H8ATXzVZsWlZj1JzW09jx8L/Ffov1PV/AYxoje8zH9BXQSttic+gJrB8C/8gIe8jf0rcuji1mPoh/lX6VlKtgqXoj8C4nfNnOI/wAbPP2/48oP9wfyr0H4ers8C6i//PS/VPyQH+tcA4xaQj/YH8q9F8Frs+HY/wCmmpO35RgV+c1HevN+b/M/f5rlwVOP+EsVvfDU5+IES/3bGVvzZBWDXR/CtQ3j26bummkfnKv+FKHxx9TjxGmHqv8Auv8AyPYqKKK9M+HCiiigAr52/aDfd8QtNTsunofzlk/wr6Jr5v8Ajs+74mRD+5ZRD/x5z/WuTGfwz6DhlXxt/JleMY0uP6VR09c6nF9T/I1eiObCMe1VtPH/ABMUPpn+Rrz3uj7eLtTn6M67Q/8AWXZ/6dnH54H9a1dfaPTrOC5fHlwxmR1H8SKu4j9KzdEXK3hzjMaoPxkX/Csn4o6osPhCVVf55jHaJ65+8/5Bcf8AAq8rMKftsXTh2V/xd/yPn1FyqJLucVau7+DLqWRtzylmYnuS1ejfD++gfR4ILtA8UTtbuO6hjvU/mX/KvOYBjwIP9r/47iuu+G+HXWLVycNaeev+8hGD/wCPGvruIqfPgMPBb8l/wTPmsiiqmIzGb/5+tfc2v1PSbuGNLZkWUvGRw3celc5qi7fD9qSDukuZGbPqAB/StrR83MUMdzn5Xw+fQc1leIiP7F0/A4MsxH/fVfDZKr13Lyf5r/M9yHuyUPP9Gc5XY/BjnWPEx9Psw/8AHX/xrjq7f4LKDN4ikHUzxL+SH/GvqaX8SP8AXRm2OdsHW9F/6VE9Oooor0j4sKKKKACiiigAooooArandiw065uzDPcCCNpPKt4zJJJgZ2qo5JPQCs3wlHrA0xrjxFKv2+6kM5tU27LNSBthVgPmwByxzlixGBgCr4fl1fU9cv8AUr4TWWlR7rSysXTa0m1vmuJM8jcVwi9l5PLYHS0AcL8XGI0WyHY3IJ/75avPbftXoXxdH/Eis29LoD/x1q88g7V4mO/inv4D+AvmbFseBXnHiMhbrXVPVbgH81Br0W3PSuH8U23+na+Qv3lhk/8AHNv/ALLWFPc9rLJKNV38vzReTw7LoujWer6Vvm/0dXvLdjuDgqCzL+vHp09+j8Gaoum3FrZb/M0m9ybSUn/UuefKPsT09+O4xseFZVn8PaZKOQ9tGf8Ax0Vxmp6auja1PpM4K6PqOZLR+0MndQe2D09iPStqburMy9r9ac6NXfX+vVdPK6PXWHFUbjvWX4J1eXUtMktr1s6jZN5M57uP4X/ED8wa17oYpSPGlTdKbhLdGRcdDXN6weG+ldHc9DXMawcK5rnkdVI9o0EY0LTh/wBO0f8A6CKvVW0yPytNtIx/BEi/kBVmvo46JHzk3eTYUUUVRIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeD/tJt/xN/DS9hHOf1SveK8E/aWONZ8N/wDXOf8Amlc2L/hP+up7fDv/ACMIfP8AJnL6S2bECiIZv4v94VHo5H2dR7VPBzqUY9/6V5nY++2U/RnT6U2y6Z/7kMrflGxr5utOGr6IV/Ltr+T+5ZXLflC9fO9r96tp7Hk4Ve/J+n6nrXgb/kAJ7u1bV+cWNwf+mbfyrG8D/wDIvx/77fzrX1M7dNuz6ROf0NfpmV/7nS/wo/n/AIh1zjEf43+Zw0v/AB7x/wC4P5V6R4WGPh5Y+93Ka83m/wBQg/2R/KvSfDHHw904etzMf1r80etST9fzP6DxCth6a81+TH10/wAIwD4y1ViORZIB9N9cxXUfCJT/AMJhrB7fZI//AEI1VP44+pwYr/da3+H9Ueu0UUV6Z8QFFFFABXzP8cGz8UpB6WsI/Q19MV8yfHA/8XUl/wCvaH+Rrjxv8P5n0fC/++P/AAv9Blqd1qv0pNNGb/6A03TyPIx7VJpXN8/sh/mK89bo+0npTmdn4ddYo55WGVEsQI9sk/0ryD4r6rNd+KvsDMPs9ioCKOm+QB2P15C/8Br1nSWIt5kBxvljXPvtevnzWNR/tfxFqGoAYW5uHkUeiknA/AYFYct8TKfZJffqeRhYfvXL+v63O8t1z4Kt19WT/wBGiur8DL5V/fsvQWbp+LMqj+dcvbceD7X/AHo//RorpPClwI7y7U94g35Ov9Mn8K+h4jk44Wg10p/ofJ8Mpynj/wDr9L8z1BdsU5kVcAxqD9duDXOeID/xItK9S8x/8erbe6jkRFV1JK8YrE8SYXSdIQdhMf8Ax4V8Nkk3PETb7fqj2KUWpRv3/RnO13nwTA+xa62OTfYJ/wCALXB13vwTUjTtcPY35/8AQF/xr6qj/ERtmP8AuVT5fmj0iiiivRPjQooooAKKKKACubv31jUPFdrZ2nnWOj2QW4urnaM3bnOyBM/wj7zt/uqOrYk8YyaxLbW+m6ArxXN85jkv8ArZRAZeTnq+OEH945PANblvH5MEcW932KF3Ocs2BjJPc0ASUUUUAch8VIvM8KO+M+VMj/TqP615fan5VNezeMrX7b4X1KHqfJLj6r8w/UV4pZvmNa8fMI2qJ+R7eWyvSa7M27c9KxNfg83VbiPH/HxYYHuUZj/7NWtbNwKp605i13RJD91/OhP/AAIL/ga5aXxo9XDNqpp2f4K/6Gn8N3aTwhp4bqgeP/vl2UfoK2PF2jHXPDlxawhftS4lt2PaReRz2zyPoaw/hy2zT7+1PW2vHUD2IDf1NdxAelXFWdjlxc3SxMpw3TuvzPIvC+vmy1PTtSkJWOQiyv1bjGT8rn6H9M167dDg147400sab4r1G1xi01NPtKem4k7h/wB9ZP0Ir0bwlqT6p4VsLiYkz7DHISeSyEqSfrjP41cndHVmNKM4QxENn+uq+7VfIW74BrmNUXzHVB/EwWunvfumufZfM1WxTrvuEGP+BCua13Y5KbsrntqjCgDoBiloor6U+aCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK8D/aaGNV8NN6pOP1SvfK8G/aeXF34Wb1+0j/0VXNi/4T/rqe3w6/8AhQp/P/0lnF6MT5Kn2q5ZjOqR/j/I1U0Xm2X6VcsP+Qmv0P8AKvLW6Pvpv3J+jNi9bZoWuP6abdfrEw/rXjvgPSdO1i+mg1K7ngZVDRLCikv68k9uOP8ACvXNbbZ4W8QN6afKPzwP614LpU8ltdxzQsVkRgykdjXZTlCFSLqq8eqPn6lKtVo1IYefJNrR72f+Xc9w0/T7bTLYW1nJNJCpyGlADZPXpT7yH7RaTQ7tvmIyZ64yMVX0a/XUtPiuFGGIw6/3W71dYhVLMQFHJJ7V+n4X2fsY+x+Gyt6H885g8SsXUeK/i8z5vW+pzniDT9K06xTZcXklw/yxoyKAcDkk54Arq/DH/JPdO9rqavPtWuTfXL3PPlkbYgey+v49fyr0Dwvz8PLD2upRX55mSw8cVKGHVkt/N9f8j93yj67LLKVXHyvOTTtZKys7LT7ySut+D4/4qbXSe1vAB+bVyVdf8H/+Ri13/rhB/N64qf8AEj/XRnXjP90rei/9KierUUUV6R8UFFFFABXzH8dfl+Kbn1tYT/Ovpyvmb4+Lt+KEZ/vWUR/8ecf0rkxv8P5n0XDD/wBtf+F/oUtPz5GfarOjD/S5T/s/1qGwH+ig+1T6N/x8TfSvOj8SPtar/czNrVb9NL8A+JrwhTKkKJET1V33Rgj3G7P4V892PLCvZPiRIU+HWoqOkl3bL/6MP9K8m8MafLqmox2sDxI7ZOZG2jjmt3BzajBXbPIoThQjUq1HZLVt7JJI9FXjwVCR22f+jRUukXU1tqlrMoDEOAVPRgeCp+oJFW20qdNAXTw0TTAqNyt8v3wc5PtUbwCxu0AmimkiIkYRknbzxnI74r6DO8NU9hQk4u0YpPy23PjeEcdhpYjGUlNNzqycVfda6ryPVdG06OOW8YbisckioWOcKCQKy/ELbrPTvQCX/wBDNb1mw2X4RsjzGZfdScj9KwfECbLHTu/Eg/Hdn+tfneUJRxU1bo/zR9HGTlUvLv8AozDr0L4KDGh6wT31OQf+Q4689r0T4Lf8gHVs/wDQTk/9Fx19TR/iIWZf7nP5fmeg0UUV6B8eFFFFABWfr95dWGj3Vzp1i9/eIuIbZGC+Y5IABJ6Lk5J7AE81oH865rwhDq9xLe6zrrT28t6VW300vlLOBc7QwBwZWzuc9uFHC5IBoeGLG+0/R4YdWv3v9QYtLcTnhS7HJVB/CgzhR6AZycmtWiigAooooAR1V0ZWGVYYI9RXz9c25sdSu7Q9YJmj/I4r6Crxr4j2hs/F00mMJcosq/ltP6gn8a8/MIXgpdj08snabh3X5FK1bpVTxZ8tpp1x08i8jYn2II/mRU1o3SmeLV3+F7sjqhjcfhIpryouzPcw7tWj6/noJ4PvBD461myJwtyizoO2V4OPqG/SvSYRXg15fSWnjGO5tT/pUJWRR/eGOV/EZFe7abcRXtnDc2zboZkEiN6gjIrpa95k5rQcHCp3S+9L/I4j4w2gOl6dqSj57S4CMfRH4P8A48Eqv8NLvC6rp5P+rkW4QH+64wcfiv611Xjy0N94Q1eBRlvs7Og/2lG4fqBXm3w7u9viSDJOLmyZPqylSP0BpS2Zthn7bASg/s/8P/meiXx+Q1k6anm+JtJXH/Lyjfkc/wBK1L0/IapeGl3+MdNU9nZvyUmsqavUivM85u1OT8mevUUUV9EfOhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeGftOplfDD+klwPzEf+Fe514r+01HnS/D7/AN25kX81H+Fc+K/hM9jIHbMKfz/JnAaCM2o+lWbL/kKqPY/yqt4d5tgParNrxrCfj/I15S6H6BL4ai8mXfEp2+DfER/6ciPzkQf1rwWx5kFe8+KP+RL8Sf8AXkP/AEbHXgtgf3wrafQ8vC7v1/Q9H8J3ZtGAJ/dPww/rW/r9xvC2MR5lG6Ug/dT/AOv0/OuT0c/u1rejA+ZsfMwGT3OOlevgc5qYXDToLW/wvt3/AOB5nhZxwphswzGlj5aW+JfzW2/yfdehmaiAq4AwBXf+Ezn4eWnteyD9BXBan0Nd34OOfh3F/s6g4/8AHBXjw+Jn0WMX7mPqv1J67D4PY/t/Xsn5vJt8D2y+a4+us+EHHijWwTybaEgfi1bU/wCJH+uh5eNV8JW9F/6VE9Zooor0j4oKKKKACvmz9oVdvxKsT/e06M/+RJB/SvpOvnX9ouPHjvSZP71gF/KR/wDGuXGfwj3+GnbHL0Zk6cM2I+lSaN/x8zfQfzpmk82Q+lLo3/H7OP8AZ/rXmrdH21T+FUKfxTO34eyf7WowD/yHKa8n0OV4buKWJisiMGBHY16t8Vv+Sen/ALCcP/oqavJNJOJR9a2k3Fpo87DRjOMoyV0/8j2V9VQaSt2i7pGwqx56ue3+e1QWUGy0kMjb55Dvkf1Y/wBO1YmmurRpuGdvK+xxitaG4AQg16mY5zUx1KFN6W382fP5JwrQyatVrQd3J+75R7evmd94V1AyaRHOrb3gItrlT2H/ACzb6FRt+q1c8RYbStNYd3n/APQhXnfh7W00fX4pZzmwuP3F0nYxt3+qnDD6V6X4xs/7OtdMtA5k2CQliMZJIr52jg+TEyxEdmtfW6/M9TEQ9nWiu+q+5/l+Vjl69F+C+P7A1TB5/tKXP/fEdedV6B8FONG1kZ5/tJzj6olepR/iIwzJf7HU+X5notFFFegfHBRRXN+LbXVtWuLHSdPeWy06YmS/v4pdkgjUj9zGQdyu5PL8bVDYO4jAALb6vqPjEz3JmsdF0wbYIklwb+Vk5kfaf9WgYqFPVssR8q56SiigAooooAKKKKACuF+LGmfaNIg1BB89o+G90bA/nj8zXdVV1SzTUdOubSX7k0ZQn0yOD+HWs60PaQcTWhU9lUU+x4XZPkCp/EBB8M6jnoISfy5qnaK0cjRyAq6MVYHsRVzW0MnhrVFHX7NIR+Ck1871PqaelSL80Yek6d/ax8Txxrm5hS2ntz3EiiQgfjyPxrs/hhqAmsLix3ZEBWWL/rnJkgfg24flXO/DVj/wkurEn79vC316/wCNL4JL6Z42SzIKr5lzZY/2R+8Q/kv611L4mdeMXtI1aT6JNfdr+X4nqF5Es0EsTD5XUqR7EYrwzwI7Rax4dLcFvNib/v239QK93l6GvFNDt/K1rSiFwE1G4jA9Mb6Uupy5XJeyqxfVfpI9Evj8pqPwcm7xlYt/dEh/8canX3Q1J4FG7xZFx92Jz+n/ANes6OtWPqcNTSjL0Z6lRRRX0J88FFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV4/8AtLJnwvpEv92/C/nG/wDhXsFeVftIR7/Adq//ADz1CNv/AByQf1rHEa0pHp5M7Y6k/M8p8NH9wPpVuHjWovx/kaoeFmzCKv8ATWIT7/0ryF0P0V/bXky54m58G+Ix/wBOR/8ARiV4HY/64V7/AOIRu8JeIR/04OfyZTXgNgP3oreZ5WF+J+v6HcaQf3a10EX3K57SPuLXQwn5azR6FQzdT6Gu68Dnd8O5PVdUYf8AkJa4bVOhrtfAB3eBL5f7uoBvzjA/pVU/iOfGfwF6ovV1Xwk/5G7Vf+vOP/0M1ytdR8J2C+M9RTu9grflJj+tbU/jj6nlYv8A3Wr/AIf1R67RRRXpHxIUUUUAFfP/AO0im3xNoMn963dfyYf419AV4R+00oW+8MSd2Fyv5GL/ABrmxf8ACZ7fDrtj4Lvf8mcroxzZj6U/SP8AkIzD/Y/qKi0Fs2g+lS6Zxqknuh/mK8xbo+6n/DqIpfFTn4ey+2owH/yHLXkGlf60V7F8T13fD27/ANm+tz/47KK8e0ofvBWszz8Ju/X9Ed3pjfIK1tgZKx9M+4K2lPyVCO2puYuojBIFex6nfNqXhrw3dO26R7Qbye7AKCfzBrx3U/vGvTNIkMvgHw4x6qLhD+EnFXTe6OTHwTVOXZv8U/8AIbXf/Bb/AI8Nb/6/v/ZFrgK734LuBBr0XdbtX/NB/hW1H+Ijysx/3Op8v/SkekUUVHcu8VvLJFE00ioWWJSAXIHCgkgAnpycV6J8aZviiTVk0iRPD0EUmpSsIonmIEcG44MrgkFgo52jknA4zkT6Fpo0jSLWwFzc3ZhTDT3UhkllbOSzE9ySTgcDoAAAKzvB2mahZ2k95rtwZdX1BxPcIkhaG34wsMQ/uqOM4yxyx64HQUAFFFFABRRRQAUUUUAFFFFAHivjG1+w+ML9AMJKwmX33DJ/XNRsvn6dcxDkvEy/mDXQfFu08vUNOvl/jRoW/A5H/oR/Kud0+TkV8/iY8lVo+kw8+alGf9aGT4BZY/FkYHS40xZB7kFf/r1Y1V/sXxKVsY33VrIPo48o/wAqp+GF+z+JfD2Ohgntv++C3/xNW/HB2/EHRyDgt9jz+Fyf8av7R68lfEtfzRf52/Q9SlryS0+TWbMk8HWrwD/vpxXrkleRW7+b4h0yP11i9f8AJpD/AEqn1POy3afp+kjs78cGp/h+AfFJPpbv/Nahvhw1Wfh4ufFEp9LZj/48tZ4f+NH1OSs/3MvQ9Mooor3zwAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvN/2gYvM+Gt2+P9VPC//j4X/wBmr0iuE+OMZl+FuthRkgQt+AmQn9BWVZXpy9DuyyXLjKT/ALy/M8F8KnMYrVk41WA/7QrG8KN+7Fa8x/4mUB/6aL/OvHWyP01r3pLyZqa0N3hjX1/6h8p/IA/0rwrQ9OvdQuCmn2dzdOvJEETOR+Qr6Z8HQQXWvQ213DHPbzq0ckUihldSOQQeCK9js7S2srdYLO3ht4F+7HEgRR9AOK7oUfaK9z5HEZp9RnyqN29dz5E0vwxr8cStJoeqKvq1pIB/KrssE9q3l3MMkMg/hkUqfyNfWtV76ytb+AwXtvDcQnqkqBh+tV9TXRmS4lk379PTyZ8e6ieK7L4btu8J64mfuXEL/nkf0rvvG/wgtr+Np/DUotbjqbeViY2+h5Kn8x9K4bwJp95pMPivTNSge3uo1t2aNxyMOefcc9R1rn9lKnP3j2Pr9DGYZ+yeqa067ovV0PwuIHxAlz1bTHA/7+pXPVv/AA2yvj+E9nsZl/JkNVD4l6nPX1oVF/df5Hs1FFFemfDhRRRQAV4b+07FlPDM3ZJLhPzEZ/8AZa9yrx/9peDd4W0i4x/q78J/31Gx/wDZa58Ur0mevkUuXH036/imjzfw8c2q/SrNhxqx91NUvDjf6Mv0q5Zf8hdfcH+VeWuh+gTXu1PQb8R13fDvUj/durY/+jB/WvLfDvh/WdRCyadpOoXUbHAeC2dwfxAr6g+G9tbXl5dwXtvDcR/I4SVA4BG7Bwe9epqAqhVAAHAA7V3Qw/tFds+Sr5u8FUdOMbvffyR8l2XhLxFbxBp9C1NAOpNs/H6Us8M1qxjuYpIZB1WRSpH4GvrSqmpabZanAYdRtYbmL+7KgbH09Kbwa6MiPEkm/wB5T08mfHWonJNejeGG8z4faZ/0zuJk/Mg10Pjv4O+csl14Wkw3U2czcH/cc/yb865zwhFND4Fmt7mJ4p7fVHjeN12sv7scEdua5/ZypyakezPHUcZQjKk9mrrqtyeu1+DDD7d4lXuJLc/mh/wriq7H4MEjWvEynowtWH5OKul/Ej/XRnHjl/sdb0X/AKXE9Urm9M07UrrxTd6xq7tDBBvtdOs45MqI8jdNJjgu5AwP4VHqWpNe0vUNb1+wt5W8jw/abLubZJh7udWJSIgciNSoc/3jtHQMD0tekfFhRRRQAUUUUAFFFFABRRRQAUUUUAcb8VbbzvC/nY5t5kfPoDlf/ZhXm2nPkKa9h8Z2pvPC2pwgZPklwPdfm/pXi2mt8n414+YRtUT8j3Mulei12ZFahofEGjSf889RuU/77DH/ANnqx4zXd8RNGOM4+xj/AMmWrNu7kxaxGW4SPVrfn2ZEB/rWp4qz/wALG0jtlbT9J3NYt7eh9BFP2kZf3X/n+p6i54ryPSNreJ9HKjO7UL9/w/eYr1djxXkfhOTzNf0QtyzG7f8AElqd9Gebl6tTqPy/9tkd7ej5Wqz8O/8AkY7j/r1b/wBDWq9+PkarHw8/5GSf/r2b/wBCWlh/40TjrfwZeh6RRRRXvHghRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFYXjvTX1fwZrVhCpeaa1kEaju4GVH5gVu0UmrqzLp1HTmpx3TufH/hV/lwetbl1xdwt/tD+deh+NfhhMurTar4aVWjnYvNZ5ClW7lO2D1x27eg8/1W2uLOdY7uCWCVSCVkUqfyNeLUpSp6SP0/BY6jjffpPVrVdUdt4Nbb4nsD23N/6Ca9rrxvwbpl9daxbT29u5hjYlpSMKOCOteyV6eH+FnwuctOrGz6BRRRXQeOFc94ysYZtLuZ/KT7R5LR+YB823BIGfTIroajmijnjKSqHQ9Qe9TJXVjSjU9nNT7Hz9XQ/DqCaTxxaTRoxiitpvMbHC52gfma9RXw/pCnI0yz/GIGrttbQWylbaGKFT2jQKP0rnjh2mm2e3VzmMoSjGO6a+9WJqKKK6jwAooooAK8/wDjppkmpfDq+aFC8lo6XWB6KcMfwUsfwr0CmSxpNE8cqK8bqVZWGQwPUEVM488XHub4Wu8PWhWX2WmfJ/htwYFHtWlbf8heL/gX8jXZ+IPhdeaVezXPh4fadPYlhb5/eRewz94enf69a4/yZrbWIUuIpIpAeUdSp6Hsa8eVOVNpSR+lUMZRxdOU6Mr3T06rTqj0n4Yvt12VfWPP6/8A169VrzL4daRfx6ob2S3eK22bd0g27uQeB36da9Nr1KCajqfAZrKMq94u+gUUUVseaFcX8SLSIaTLOkaLIWVmYDBYghRn14NdpUF3aW95F5d1Ck0Z6q4yP88VM48ysb4at7Gop9jwGtrwfpeu3kurxaM/2OG+Nvbz3+cNBEBIXMQxzJjCj+6XDc4wfXI9G0yI/u9Os1PqIVz/ACq6iLGoVFCqOgUYArCGH5ZKTex6mJzdVaUqUY/Fp+Kf6EOm2Vvpun21jZx+XbW0axRJknaqjAGTyeB1NWKKK6TxAooooAKKKKACiiigAooooAKKKKAGyossTowyrAqR7Gvn60QwyyRN1Rip/CvoOvCtci+zeJdSjAwBcPgexbIrzcxjpFnq5ZLWUTltfkEV/IDyPtdtKfwwP/Za6bxQmPH2gydS3lj8pD/jXKeLiEvZiOphgc/UO4rr/Gx+z+JfDV10XzgrH0HmR5/Rj+VcHRH1K/5d26xkv/JUegnpXkPgkeZ4m0skfchuGHtlyP6166TXknw7H/FS22eotJ//AEYKq+jPOwH8Gs/L9Geg6hxGam+Hjf8AFS3A/wCnZv8A0Jai1MfuzTvAI2+J2PrAw/VaeH/ixPPq/wAGXoel0UUV7x4QUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVBeWdtexeVeW8NxH/clQOPyNT0UbjTcXdCKoRQqgKoGAAOBS0UUCCiiigAooooAKKKKACiiigAooooAKKKKACopreGZkM0MchQ7lLqDtPqPSpaKBptaoKKKKBBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXi/jpPL8Z347Eo35ote0V5B8SE2+LpTj78SN+mP6Vw5gv3S9T0Mtf71+h534u+a6lx/wA+0YH13vXX/FCGRtJsbmL78M/5ZUkfqorkPEZ33jjriOFfx3tXoPj8Z8IXTYyVeIj2/eKD+hNeYtkfVOfJLD+v52R09pOtzawzp9yVFcfQjNeW+Cz5Xjryyei3MX4iQn+ldv4DuvtfhLTmJy0aeSf+AEqP0ArhtEVoPiSinPzXl2v4ESMKZz4SHIsRT7J/hc9G1Bcxmk8FYXxTGPWFx/Kn3nKGovCbbPFtoP7yOP8Ax0n+lOj/ABY+p5VT+FL0Z6ZRRRXvnhBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV5V8UUC+Jbdh/FbLn/vpq9Vry/4qD/ifWB9YMf8Ajx/xrjxy/cs7svf75fM8r1LMmstF/eu7WP8AAkf416D4+J/4Qu+I7GI/h5qZrz26P/FTKp76jb4/BUNeheJlN7YWenIMtdzqpH+wOWP4cV5S6H1dfSVB9rP8v8g8AW7adFqOmuSTBMsgz2DoCB+hrlNTl+x/EZn+6seoQ8+0kag/qxr0aztzHrOozdpVi/QMK4H4jWrweIPPTj7TahkP/TSJuf0ZfyqluY4OoqmJlf7Uf0V/1PQboZU1V0DCeKtOYnHzMPzU1YSZLu0iuITmOVBIp9QRkVnmT7JqFpcnpDKrn6A81MHyzT7M8txbi4+p6vRSAggEHIPINLX0J4AUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeXfFI58SWK+ltn/AMeavUa8n+IEvn+MynXyYUT+bf8As1ceOdqR3Zcv31/Jnmk2H8W2/HW8z/3zGP8ACvULW387VrSZukELFfq3H8q8ytMS+Jkf+7PcMPwYr/WvXNJUfZ1fHJAFeV1+R9JmM+XkS6Rt+Zd2jJOOTXL/ABBsGutCNxCu6eybzwP7ygEOP++ST9QK6vacVE6hgVYZB4IPenseXRqunNTXQ434e3vn6I1k7Zlsn2DnrGeUP8x/wGtu7hDxsK4C4t7jwR4jSVI5JdPclYyP4oz/AMsyT/EvUZ6gfWvQrO6ttQtVuLOVZYWHBXt7Edj7GlJdTuxdO0/bQ1jLX59TtPCV+L3Rogx/fQDynH06H8Rj9a2a84s7ifTbr7RaYyeHQ9HHoa7nS9UttRi3QPhx96NuGX8P6162FxCqRUXuj57E0HCTktmXqKKK6zkCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvFtSm+3eLNSnzkGYqD7L8o/QV7DqFwLOwublukMbSH8BmvFNEQs5djlmOSfWvNzGWkYnqZbH4pHJ6TxriM33ilwSPQmYV7BouDbRj2ryS7X7J4mlQdRJMmP9/Eo/Su88OawGRY34YVwXs7nt5inNprqjs3AHSqzDmmJciReDS7smqckzyEmivf2NvqFnLa3kQlgkGGU9/wDA+9cFceGta8O3b3OgytdWx+9HwXI9GXgN9Rg16OOaeooR00cVOjdLVPdPY4Kw8XW0v7vUIJbaZTtf5SQp9x94fTFb1vLHOEuLOcHH3ZIm6fiK1NQ0ax1Ef6XaxSnsxX5h9D1FYMvhF7JjNo91JE/9yQ5BHpn/ABzT5OqNHPD1Nvdf3o6qw8TXEACX0XnoP+WicN+I6H9K39O1my1A7YJgJP8Anm/yt+Xf8K82tr6aKf7PqsHkydnUcH/PqP0rRa3jkUMuGHUMK3p4upDSWqOKtgoenpsek0Vw9jrV/Y4V2+1Qj+GQ/MPo3+Oa6fTNYtNQG2J9k3eJ+G/D1/Cu+liYVNFozzquHnT13Ro0UUV0GAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc78QJzb+Er4q2GkCxj3ywBH5ZrzvRotsYOK6n4rXP+j6bZA/6yUyt/wABGB/6EfyrD05MRCvGx0uarbse1go8tC/dnIeObB4LmPUoV+UlRI2OFdfusfY9D+FaGjCC9iS5s24/iU9VPoRXUSRK6sjqGVhggjIIrl28MXOn3v2rQ59g7wueMeme49j09a5d9D1Y1YVaapzdmtn09GdVYlwMMa0oye9YWj3/AJ0nkXcRt7odVPQ/T/P51vxoRTSZwVYuDsyxH1qYLUSCp0FbRRyyY9BUgUGmilDVqjNkVzZw3CbZY1cdeR0rObR1jYm3keMenUVtKQaGWm4pjjVlHRMw2tZk+/tceo4NV5rfJBA5HIPcVvMKheMHtWMoGqqFKz1vUbM4ZhcxD+GT734N/jmtmDxVZMB9oinhbvldw/Mf4VkSWwzmo2tlPBq4YirT0vf1JlRpT1a+46eLxBpcnS8jX/fBX+YFX4LmC4BME0coHdGDfyrgZbFDzxVR7ExuJbd2ilXo6NtIraOPkviRm8FB/DI9OorhNN8VXdlMkGpxtcxk4EiABx+HQ/pXX2ep2d4QIJ1L/wBw8N+RrtpV4VV7rOSrh50t1oXKKKK2MAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8t+Jk2/xRaxdo7cH8Szf4Ck04fuxVf4jkr4yUnoYEx+ZqXTJAYwM14OI1qyPfpK1CNuxpCPNSLFSxsCKmDKKhIhsq3mnx3cYDZWReVcdQafZyyxARXg+ccCQdGqx5qikaZSMHkVadhcza5WWlxTw+KzxMF+6ePSnfaKfMQ4l/zKXfWeJ/epFmHrT5xcheElL5vFUvNo8z3o9oLkLZkzSF6qeZS7/elzhyEzsKgdwBQ2TVG8uUiU7nVcddxqWy4ofJcRqcOwH1NU5S0pP2a5i3eh5qrLLLOC9s9lMv91j/AFrFvZYZJdrRGzux0CNgN9OxqGbRiab6m1tcxrfxCJ1PySHlCfTNXNS1W3+wyPBH+/ZSAwIKrnvWLKtzYvENbi860JwZF5U56A/5xTrXSrTWPENnZaXut7d8mU9eACeAOB0x+NaxUl7q3Y2o/E9kemeCbue98NWc10S0mGXcerAEgH9K3ar6faQ2FlDa2y7Yol2qKsV7VNOMUnueFUkpTbjsFFFFWQFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAea/FuxZJ7DUkUlADA59Ocr/Nq5awvtoHNe06nYW+p2MtneJvgkGGGcH2I98159ffDSRXJ03URs7JOvI/Edfyry8VhZynzwW562ExdNU1TqO1jNh1MY5NTf2mvrTx8PdaUcXdif+Bv/APE0v/Cv9aPW6sR/wN//AImub6vW/lOj21B/aIG1RfWoTqgJ4atOH4c3zkfaNSgQd9iFv54rXtvh5Yx4869upD327VB/Q1SwtaXQl4nDx63OT/tQDq2KjfWUH8degJ4H0JRh7aWQ+rTN/Qig+BfDx62Lf9/5P/iq0WBq90Z/XqPZ/wBfM4GLW4/71XIdXjJ5autbwDoBGFt5kPqJm/qarP8ADzS/+WVzep7F1I/9BpPBVV2D65QfcyI9Rib+IVZS4Rxwwp03w7bdm21VlHo8Of1BqrJ4J1uDP2a8tZl7biyk/oR+tQ8NWW8SlWoPaRbMo7MKabhVPzMB+NZUmgeJoR/x5CQeqSp/jVSbRvEhIH9mS5/3l/xrN0qn8rLTpv7S+8321CFB97J9qqzanbqQHwc1nW/hTxNcsA9vHbKf4pJR/TJrdsvh2GhzqGoSGft5I+UH3z1/Srjh60tkTKrQhvI5zVIYruWJtPVYrpjgOpwD9fWore5g8q5tdUtwZQcuBjrjjr1Fb0vgLU43H2a/t2UHgtuU/oDWla/D20ZhPqV3cz3TAeZscBTjoORmrhhqt9rMJYqjFb3RwWk213rUw0yATSRiXaCzFhGhAPJPoD1r1nw74ZsNCaR7XzHlcYMkpBIHoMAVq2drBZWyW9rGscKDCqtT130MMqer1Z59fFSqrljogooorqOQKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_23_6514=[""].join("\n");
var outline_f6_23_6514=null;
var title_f6_23_6515="Tromethamine: Patient drug information";
var content_f6_23_6515=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Tromethamine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/29/43475?source=see_link\">",
"     see \"Tromethamine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/5/19539?source=see_link\">",
"     see \"Tromethamine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F232038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      THAM&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691689",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat acid problems in the blood.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to tromethamine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are not able to pass urine.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into a vein for a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11897 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-213.131.41.98-64F77B4D5B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_23_6515=[""].join("\n");
var outline_f6_23_6515=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232038\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012527\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012526\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012530\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012531\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012533\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012529\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012535\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/29/43475?source=related_link\">",
"      Tromethamine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/5/19539?source=related_link\">",
"      Tromethamine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_23_6516="Beau lines 2";
var content_f6_23_6516=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85706&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85706&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Transverse grooves of the nail plate (Beau lines)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_23_6516=[""].join("\n");
var outline_f6_23_6516=null;
var title_f6_23_6517="Tiaprofenic acid: Patient drug information";
var content_f6_23_6517=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Tiaprofenic acid: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/40/30343?source=see_link\">",
"     see \"Tiaprofenic acid: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F227611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Tiaprofenic&reg;;",
"     </li>",
"     <li>",
"      Dom-Tiaprofenic;",
"     </li>",
"     <li>",
"      Nu-Tiaprofenic;",
"     </li>",
"     <li>",
"      PMS-Tiaprofenic;",
"     </li>",
"     <li>",
"      Teva-Tiaprofenic Acid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10030134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691600",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain and swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691733",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat arthritis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703029",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to tiaprofenic acid or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703268",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Asthma, Crohn's disease, ulcer disease, or ulcerative colitis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697235",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had an ulcer or bleeding from your stomach or bowel, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696862",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take colestipol or cholestyramine within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697889",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain or heartburn.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling or pain of hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black, tarry, or bloody stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698609",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blood in the urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with food to stop an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12062 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-043A92644E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_23_6517=[""].join("\n");
var outline_f6_23_6517=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227611\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030134\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030136\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030135\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030140\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030141\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030143\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030138\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030139\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030144\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030145\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/40/30343?source=related_link\">",
"      Tiaprofenic acid: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_23_6518="Lateral ankle ligaments";
var content_f6_23_6518=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F72462%7EEM%2F51952&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F72462%7EEM%2F51952&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 498px\">",
"   <div class=\"ttl\">",
"    Lateral ankle ligaments",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 478px; height: 302px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ATFL: anterior talofibular ligament; PTFL: posterior talofibular ligament; CFL: calcaneofibular ligament.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Medial ankle ligaments",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 412px; height: 416px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGgAZwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAorgfi78QT8PbDR7w6cb6C7vRbzhXIaKIIzvIAAdxCqTjiuUi+Nkd+3jN7K1gt7DQ5LZbe+l3TLdLLP5W/YuDtJztIPQg9KAPaaK8x8V/FSGw1+w0nQ7Ke8f+3bTR727khP2aJpWG9FfIzIoIOMEDvVu7+K2hPpM8unyzfbBZ39yEmt2PkfZARJ5yg5A3YGOpzxQB6HRXms/xh8NafLYWuozztcSQWsl1PBAfJtjOqmPfk5AO4HjdgEZxWiPil4YF/bWc11NDcTXV3Z7ZIiPLktgDIH9ByMHvkUAdzRXF6947gtPhZc+NdMtZLi2WzF5BDPmIyKcYz1xkHNcXpPxkuL/AMN+I7+e0023GkmyxfWs73tpIbh1BjyFQ713AEDOCeenIB7RRXDXfxP0G28QtpPl6hKV1GLSWu47cm3W7kIxCXz94ZGeMCub8K/Ga2vrVYtZ0y/i1CWW+S3NvaP9nuDblz5aOc5kKJnA4zx14oA9dorkPh940HjHwLD4jXTLiwLxs3kTZIJAzlHwN69twA5B9K8/8A/HWDXdMvNU1yHSrKyt7bzmgtLuS4uw5lWNEMXlgfMW4wx6j3IAPb6K4P8A4WloX2Td9n1T+0vtv9nf2V9m/wBL8/Zv27M4xs+bdnGO9UT8WtOuNc8I2elaZqF9aeIFuCLhI2DW7REKysm3khs7uRtAB5BFAHpVFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGB4p8Kaf4muNIl1MzEaZdfa440K7JG2MhVwQcqQx4GPrXNaj8IvDd4uuRxteWdvq0VnBJBatGkcKWrK0YjGw4yVGc59sV6JRQB59ffCrSLrxAdTXUtYgjOrQ621hFNH9ma7j2/vCChb5toyN30xT1+FXh5NT8X38bXqT+J7aS1usSLiBJARIYQV+UsTuOd3IHGOK76igDzib4Q6EdQhvLW91SznFtb2sxhaIi5WFAiF98bYbaoBKbelR+IPgv4Y1y98R3VzLqUM2uNG8rQSov2d0Klmhyp2l9g3Zzn2r0uigDn9e8J6drPgmfwtKZ7fS5bVbP9wwDpGoAG0kEZwB1BrlJfg34eNprVnb3mq2ljq62xurWCWMRmSB0dZVBQ7XYoNxHByeM4I9LooA8a1b4V6xefEJNQtL2Cy8O/23BrstuLppDLPGFy3lGIbWYrgnzSMfw+nV2Hww0Syi0WNLjUHTSr25voQ8ifO8+/eHwoyo3nGMHpya7qigDmvBvhC18KeFv7As77ULqwXcsX2t0Z4UIxsUqq/KOSMgnk8mqFt8ONEh+G8HgppL2XSoFAjmaUCdGEnmK4ZVADBsEcduQea1PF+o3Ng2iRWU3lSXmpw27HaG3R4ZnHPqqEZ610FAHn3/AAqrSPI8z+0tY/tj7d/aP9sedH9r87Z5ec7Nm3Z8u3ZjHaprb4X6NZr4ZOn3ep2c2gSTyQTxTKXmM5BmEpZTu3kckYI7EV3dFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFNlbbG7egJrmPhfqV5q/gDRNQ1KYz3lxBvkkIALHJ7DigDqaKKKACiiigAoqC9uorK2ee4YrEuASBnqQB+pqegDkfGP7zxX4Kg7G/ml/75tpf8a66uL8SybviZ4Lg9I76b8o0X/wBnNdpQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBBqDbLG5f+7Gx/Q1zXwni8n4a+G0/wCnGNvzGf61u+IX8rQNTk/uW0rfkhrP+H6eX4E8OJ/d063H/kNaAN+iiigAooooAyvFAzo0gHJMkQ/8iLWrXPeKLmVbi2tV2+S6iV8jncs8AXH/AH01dDQB5tNfzXvx6tLCRIxDp2kyyxsM7iZGQNn/AL5Fek15dpvP7RernH3dEQZ/4Gleo0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAYnjmTyfBWvyf3dPuD/wCQ2qz4ZhNt4b0qAjBjtIkI+iAVjfFSVovh5rmz70kHkj/gbBP/AGauqRQqKo6AYFAC0UUUAFFFFAHMeJjnVIR/dhQ/ncQ/4V09cj4rO3UpGOcC0Q/lcJXXUAeYaWuP2g9XfB+bSVXP0MR/9mr0+vNLBM/Ha+kBP/HhID74Ftx+tel0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcb8V5B/wisVqet5qFnbKPUm4Q/yBrsq434glJtV8HWLctNrCTbfURRSP+hC12VABRRRQAUUUUAcd44dSly8bAkafM2Qc/cliJ/KuxrjNYhiv9YewtovL/d3VpKD0ZpokkDfiQfxBrrrUym2hNwoSYoN6g5AbHIz35oA8+00/wDF7r8d/sMv8rWvRq8yjjuLT4/u0sbrbXulOYZCOGZTEGA9xtX869NoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA4/XFFz8TfC8WM/ZbS8uj7E+XGD/AOPtXYVyOnMbv4pay+crY6bbW49mkeR2/RU/SuuoAKKKKACiiigDkfEEp0/xZp1xyY7gxqVHYqxjLflOPwWuurmPGgtrqOG1dh5odRIB96OOXdEHH0Yg/wDAa6Gy+0fY4Ptnl/adi+b5f3d2Oce2aAPPNavJ3+Ofh22dUFtBYzBGA+YtIrE59v3Ix+Nek15d4oJt/jNoE/ZhCn/fSXa/zIr1GgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiq2p3kenabd3s/ENtE8z/AO6oJP8AKgDlPh1tvL/xZqwyTd6tJCrHukCrEMe2Vau0rmvhrZvY+BtHSb/XSw/aZP8AflJkb9XNdLQAUUUUAFFFFAHNeMrJJxbOzMgm32LkDgeaMIT9JFTB7ZrZ0a7a+0q0uZFCSyRqZFH8L4+Yfgcik1uy/tHSbu0DFWljIRgcbW6qfwODUHhry20iGeOMxNc5nkj3EhJGOXA/4FmgDgviextPFWl3w4MS28mfZLyJW/SU/nXqNea/Gqxe6sLcxEq8lreQKy9d3k+cv/j0ArvdEvU1LRrC+jYMlzBHMpHcMoP9aALtFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVx3xXkd/CZ0uAuJ9YuYdNQp1AkYbz+CBzXY1xupuNV+JmlWAG6HSLWTUJeOBLJ+6iB99vmmgDr4Y0hhSKMBURQqgdgOlPoooAKKKKACiiigDJ8TvNBpD3du0ge0dbhljPLopy6++V3VF4ebybzVLEElEn+0QknIMcvzce2/wAwfhVu5vFGqx6dcQjybmFmRych2B+ZCPoQffn0rM8K2kYEc4dxNaRNpsin+IROdpP4c/8AAqAG+PysOhR3siho7K6hnkBGR5e8LJ/44z1X+FhMfgqzsXYGbTXlsJADnBikZB/46FP410uoWkN/YXNncruguImikHqrAg/oa4vwjA/hrxpqWgyzSTW1/bx6jbSyYy8ihYpwcd8iNv8AgRoA7yiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAR2VEZ3YKqjJJOABXHfDVPt1tqfiV9xfXLozxbuq26fJCP++QW/4HR8UrvboNtpKy+S+tXcens+cbImyZWz2/dq/PvXU6cbRbOKLT2hNtEojRYmBVVAwAMe1AFmiiigAooooAKKKKAMrxJBNJp32izBN3aOLmJQfvleqf8CUsv41V0a4RtcuXtyzWmo28V9E/YnARuO3yiM/jW/XHQebp/iC3tNzbLa5bYAM5t5wxHTssq7foBQB2NeaeO01Sx1yfXI47iSLSTBfwsAShgw0d1EPQlSHx32g9q9LrK8VSXEXhzUZbRI5Jo4Wfy5F3LIo5Zce4BH40AaUEsc8Mc0Lq8Uih0dTkMCMgin1w/wAK7sRabc6EZvNXTGX7JITky2Ug3wPz1wpKfVK7igAooooAKKKKACiiigAorjrfxVfi3bULuwthpI1KXTi8c7GWPbdNbq5UrggsoJweAc84qvqPxE07+ztTfS/3tzb20tzbmQqUnEZAYja24AFh94LkHIyOaAO5orlLbxkkk15C+l33nxX8lhBHHtY3LICxKkkAfKrE7iABjnJxT28Z6eGjdd7wywLIiBD5rSNMIRHtPAbedvJ4PXAGaAOoorE8KaxPrNvfy3Nq1q9veSWwibG4BcfewSM89iRW3QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAYNj4r0u8uIoka5jE0z28Ustu6RSSIxUqHI25yrYGeccZqxf+IdNs7W9nN1FP9iZVuI4HV3jJbADDPBye9c7p/hzWDYWulX66fHp8Gom/M8U7ySybbk3EahCihfm25O5uARjnIyLL4f6jb6S1i7W8ksNp9jhvHvZWMi+bG5LRFMIT5eThm56cE0AdzB4k0aaC6nXU7RYbWZred5JAgjkDFSDuxjkED1xxmrUup2kMkqzTpGkUK3DyudsYQkgHceOxrkIvC+qWd/8AabaDS5/I1K4vYklmZBMswkzuxG2xk34BG7ILfdzVVfA+o26WJgns5Ws7azQRSMyRyPDM8hQ4U7Uw4CnBI2jjigDtdD1iz1uzkutOk823WaSAOCCGKMVJBBIIyODWhWJ4R0y60vTrmO+EAmnvLi62wOXVRJIzgZIBJAPpW3QAUUUUAFFFFABRRRQBwfjueI+NvB8DWr37K11O1rEgdtvlbQ5DEAAFsZJHJrdjf7E7XMPhqWNyu0mDyPMK9ccMM/TNUNIxP8TPEUsqgyWtlZwQn0RjK7fmwH5CuuoAx4r1ItXCXGqIguEDR2U6qkisf7p4J6HjBOe9X7i7Fu0plhn8mOLzTKqbgeuVAGWJ79KndEfG9VbacjIzg+tOoAr2N7bX8HnWcyTR5xlT0PofQ89KsVnX0OovJKIHs5LZ12+VKjK3TB+cE9f92qcPh8LbRLFeahYuBlkhvGlUH0HmA8fgKAN2iufuIJbFo1n1rV3U8/LbRyZAPQlYuK0NTs5LoB01K9tIlXLLbhPm9/mUn8qANCuM1bV00jxWsmo3kEUSyIgMhVT5Ew2gZOPuyxg+war9pHbTqbLOuXcdwPnmmMkaqBz947cZ6fKOfpXN+GbC5bVB5en6baSx/aoA8oM74SZSpPTkBh/EaAOwl8TaPH/y+q49YkaQfmoNNbxPo+zJu8g9hE5P5YpyadqjqwudbkBPT7NbRx4/76300aLdAgjX9Vz7+Qf08ugDzxPL8M6lo+rWUlxJp1tO+nXDtayxqljK+YtzMAD5UjAAj+FjXrtcj4s0bVb/AMPanp5u4r63u7eSHZNEI3QlTht68cHH8J5xV/wBqbaz4J0PUJGLSz2cbSMepfaA36g0Ab9FFFABRRXP+IPFlho87WiiS+1PZ5gsrbBdV/vyEkLGn+05A9M0AdAeOtVtP1Cz1KJ5dPu7e7iRzGzwSK4Vh1UkHgj0ryYad4h+KLf8TO+k03wqT88dixQXY/uq5AaRfWQhUP8ACrffHqmiaTYaHpkGnaRaxWllAu2OKMYA9/cnqSeSeTQBh6f4Zsd+E1a8u7EX018LIvEYhOZ2kbJVA5CSsflLHBAzkimr4GsU0+709L2+XTp4pIRbARYiVzn5W8veccgBmYAfQY5MQa5ZJKbS1vYl87UWkeOA+YIn1YMxQ4zuMBdlA+9wQDxT1vr26t7q0tG1k2S6pLDHcsLt5LdVhjKqyIVlOWZ+WYAY5PIFAHYzeEbdrqW4g1C/tpWuzexGIxHyJWQo5XchyGVjkNuHcAECopPBGmNHCqTXcckMaJHKrruV1mEwl5Ugv5nJyMHJGMGuUt/+EnvdHt7u7k1iG/Sw0lwkatGPOkbF1lMYJC/eBB29cDrT9UXxBBcvaLJqq6NFeXCCYJcTS48uFouYz5rJlp+eRlVB44oA7/QtIj0eC4jjuLi4a4ne4kkn27i7Yz91QAOPStKvNwniEul1Jc6pPPBNpKIVieGOVXeNbpzF0xtLkg52YzxjNbnw2tHsNGubWdb5LiO8ud63SvjBmkKlCwwQVIOVJHPrQB1lFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeX6J4r1GKCzgMhnubmGBEkuG3Iry3U0e5hwTgIOM88DjrXqFZGo+HdPvNOms0t4LVZUWNnit4mOwPv24dGUjJbgg/eJGDzQByV7401SLTJfs8drNqls96ZIY7clZI7Z9hfLSKIwTjOWYjPAappfGGqTTPJZW9klqtzZ2oSbezk3EcbBsggAKZBxg7gOq9a3rDwfodrpcFhLp9reRQySSqbqCNyHdizsBtCrknooAHAAAFai6ZYKCFsbUAukmBEv3kACN06qFUA9sDHSgDhZPGutSSrYWOnw3Opx/azJ5cZKS+RN5QCqXBXdwSSW25HDZq+virUpNWdRb2sdlHqUOmtG2WlJltY5t24HaNrSAYwcjuO/TXmhaRewiK80qwuIhI0uyW3RxvblmwR1OTk96mXTbFSStlbAmVZjiJeZFUKr9PvBVVQeoAA7UAY/w8vtR1Pwfpt7rE0M91cRLIXiTZkEDqOmc56YFcj4r0zVPCPiOTxDoOpvBpN84+3WtwDJawyk/65l6ojHhmU/KfmIYZA9IsbG0sEkSxtYLZJHMrrDGEDOerHHUnA5qaeKOeGSGdFkikUo6MMhlIwQR6UAc9pXiqOS9j03XLV9I1ZziOKZg0Vwf+mMv3ZPpww7qK6SuChsrbSpl8J+III7zw7efJpctyN4U9fsrk/xKOY26kDHVcm99g13wzzo0kmt6UOthdTf6TEvpDMxw4/2ZDn/bHSgDr6KytB8QafriSfYpiLiE4ntZlMc8B9HjPK/yPbNatABRRRQBx17KdM+KWnyPlbfWNPe1yOhmhYyKD7lHkx9K7GvLfj14ks9E0bS4kQza817FcadGh+ZXjYEsf9kglcd92KoW3xmvXt3MvgXXfPiQtKkWH24YKewPUjjGRmgD2GmyyLFE8jnCIpYn2FeTS/GC50+RZNb8I6jaacfLzdxzLIsZfOFYMFw3Byuc/pV34f6m914OknMsjQTWd1eDcTk+ZcTFTz/sgUAejR3kD29vNvCJcBfL38FiwyBj19qsVyuqaig/sZ0RlhhmuJGDDHEMUi5+mcYpZ7u/0nTdBs7dlmuJfLWeScliRlQx69cuKAOporlPHV/crFoFrpd0YZNR1SCEyxHJ8obpHwfdYyPxroNY1CLStJvdQuQ7QWkLzyCNcsVVSxwO5wKALdYunJDb3t5Pcr5LvdvHAZPl37lTIHrkp+laVpeQ3Wnw3sbYt5YlmVm4+UjIJ9OK4/SvFuga94pPl6vp5FmzQ2kRmAaaQ8PIuTyOqjGf4vUUAdxRRTZZEhieWZ1SNFLM7HAUDqSewoA4P4q+IZdITSbXTvMk1Ka48xII32mUAFFU+zSPGMegJ7V0vg3Rv+Ee8KaVpO4M1pbJE7DozAfMR7ZzXKeHLCHxf4wbxhLAyabbKIdMEgObkjP+kkHovzMEHuW7ivQLm4htbeSe6mjhgjG55JGCqo9STwBQBJWdrmt6foVqLjVLlYUY7Y0wWeVv7qIMs7ewBNYP9v6n4h+TwjbrHZNwdXvUIiI9YY+GlP8AtHanoW6VTmi03wvfoYY7nxB4wu0PlmZw07L0JJxtghB64Cr6Bm4IAzXNX1O5sGvNUnk8L6ESEVQA+o3RP3UQDIjLdAoDSH/YNR+H/B4v4lbUrBdN0Tf5sej53SXDdRLeSZJkc9dhJA/iLHpvaH4dlXUF1jxFcJf60ARGVXEFmp6pCp6ehc/M3sMKOkoARVCqFUAADAA7UtFFAEN5a297bSW15BFcW8o2vFKgdHHoQeCKSxs7WwtktrG3htrdM7YoUCIuTk4A4HJNT0UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAUdb0q01rTJ7DUI/Mt5Rzg4ZSDkMp6hgQCCOQQKxvC2q3cV5L4f8AEEivrFsm+K4C7RfQZwJQOgYcB1HRuRwwrp6xvFGh/wBtWcZt5zZ6nav51neKuWhkx6fxKRwy9wSPQ0AGveG9P1qSKedZLfUIQRBfWr+XPD7Bx1Hqpyp7g1k/2xrPhsFfEsJ1DTV6arZRHcg/6bwjJHu6ZHqFFanhXXDrFrNHdwfZNWs38m9tCc+VJjOVP8SMPmVu4PY5A26AILG8ttQs4ruxuIrm1lXdHLE4dXHqCODU9cvfeFfIu5NQ8MXf9kX8jb5Y1Tfa3J/6axZAz/tqVb1JHFFj4rEF5Fp3ie1OkahIdsTs++1uT/0ylwBn/YYK3sRzQBwNlplt46+IHjC+1W0+2WunSR6XaRtGkgj2ZLthuxbIOO2eeOPUY7Iw28UVlMqjkZWPKK3APAIwMBhjsT7V5b4H8RyaNodnNqlu40u4v72ePUo4TIG3TsFB/ulsnkjBXnIIr1OC88147ndOGC+U9mm1wshwwLMucHHfdt5+lAHC/Fq+h0zwffTSPa3cEyywpE6bkldhsVQFPLLtHLZwTkEYxWb8O4WT4bWkOPmfQoF/76ll/wAa0/ijLHdatpml7RJa2atqlxCmRuK5SGM4ODvlYHkceWTUXgRT/wAIdoucYfRrQZHTIlOf50AbOsx+fo0EScNPazgf9tZY1/k5p/i6c2/ieznz8ltZSybe2QQ//tKmTvusdCOfv29ufzubeqPjt93jCGDnDabNn/viagBsJM3jbwtZFv3NikpSIDAVo7ZFJ9zm4x+Fd/qlsL3TLy0bkTwvEf8AgSkf1rhoPLi+J2kqzBWlh1JlB/iIkhH8k/SuouL06XdazPNE8kMcKXQEfLEAFWAHtsB/GgDyjwXcav4i8N2Vpqd6n2VFhs4bZbd1UhAqS5YBg0qkH5WGOCcDGReb4c2FjpM0Og3ohsmX7RLZakoureP7p+ZZBlGKknIKnjGe9bXhLTCZ/FejQyTRraX0zI0TlJVS4USqYnzhc7tvTsTnJrfgtGtNJe51RbiLULrzJJ3TfctCpHKoQpxhVXAxgkdCTQBwfh5tU0ea10ufWLzw9JO3l25kxf2Mr4/1amQ74ZP+mbP9Ca7Wbwdfauoh8VeIbjUrHILWdvAtrFLg9JNpLOv+zux6g1Q8X3ujf2aLa7STUo9TVrhdPhDzXU6EArsjxlUzyc7Qpx8wNcl8Pp9d1bU28F+PNQubaWxtlmit4H2SX8OSMyyqxY44BVSM9SWFAHo154oiFy+l+GLP+19Qh/dukLBLa1I7Sy4IX/dUM3+zTbbwo9/PHeeLrsatco2+O1CbLOA9tsWTuYf33LH029K3YIdP0PShHBHbWGnWsZOFAjjiQck+gFcx5+o+NG22T3GmeGT966XMdzfj0j7xRH+/95h93aMMQCzqWv3mpX8+keE1iluYm2XeoSjdb2Z7rx/rJf8AYBwP4iOh1PDugWmhwSiEyT3c7b7m8nO6a4f1Zv5KMADgACr2mWFppdhDZadbxW1pCu2OKJdqqPpVmgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5Txul2k+kSWmp3toJ72G1kSErtKsWyeVPPTn2qpc+J7uy8RWlhbr9s05buPTZ5Wi2ukrR7smQuNzcqSFjIwfvA8V2U9vDP5fnxRy+W4kTeobaw6MM9CPWqcmi6VLqI1CXTbJ78EEXLQIZQR0+bGeKAOG8N+MbyLwvE1youJoLbTmMsrndIbiUxsT9MZFdB4f1++vPEV1p2qRR2r7ZZbeDyXy8SSBPMEuSkgIZCQApUuAQeta0nh7RZHt3k0jTme2VUgZrZCYlByAvHygHkAd6mstJ06xuZ7my0+0trickyywwqjyEnPzEDJ5JPNAEkl/Zx3yWUl3breSLvSBpAJGXpkLnJHvVmqGr6Ppus2/katYWt7D2W4iVwPcZHB9xWL/AMIk9lz4f1vVNNA6QPL9qg+myXcVHsjLQB1NFct9t8V6aP8ATdMstZiHWXTpfs8pH/XGU7f/ACLUkHjbRPOSDUZ5dJuWOBFqcTWxY+is4CP/AMBY0AdLRSIyuiujBkYZDA5BFLQAUUU2aWOGJpJnWONRlmY4AHqTQBznirSbv7TDrugqDrVmmwwltq3sOcmFz0B7qx+63sSDraFq1rrelw39izeVJkFHXa8bA4ZHX+FlIII7EVl3vjnwvZnbLr2ntIeBFDMJZCfQImSfyrhNV1zWLLU7/X/B+gXsOmSoG1KTUYDFExGALmOLIkZlXO7AG5QO4GQD1LV9TstH0+W+1S6itbSIZeWVsAf4n2rgtYe68a2Ej6qk+keCioLpIuLrUQSMDbjMaE4wB87cdK2NA8KW1zLba1ruonxFfkCWCeQD7NECMgwRDKr/AL3Le9djQB57oOga34a0KFdFjW705lYvoV64zErEnbDMc4wCPkfIJzhlrP0cSRS3CeEb6ysY7YPLJourW5gksWYcuCvO30OGXrgkYx6lXmfxrhstRs9O0loVbULqQsJ4+JoLdceZsYcgvlYgOhMnOaAOMs57m90jUdc1EINQ1VlwsS/Lgx7UxwD/AKss3Tg3CntXY+AmWX4e+GHULltMiX5enyyxjj865fW4Z5r6x8LaTLv1Lymt0k2glHbie4YgABEGVHHVFA7VveDI5bb4e6DFCSxtrS8gz6tFKCP/AEWaAOvZVHgjS3cDMSWjZ9MPGT/KsnxnDC3ieWeWQo8GjzPGB/E3zjH5En8K1NUG74dTmPOY7XcMf7HP9Kg8W2n2jxFZDtc2c8Gfc4/+KoA5PxJPNH440m4t1Utbvfnkcj5rdxj67wD7Ma9Fv2SWfTrvBa1uVNtKuOqyAFSfxAH/AAKvO9djSfXvD7J/x8SyvtycbjLZDC/8C8ll/Gui0LUBeaGdLYsrCXyRJuJaEsC0TH/gQx/3z60Aclq2pQeC9biv9UkuIbe5tH0maa0TfKtxAcwMAQRueJz1FdZZ6/qHjOGZtDuU0bRo3MUt5Lta7Y9CFjPEP1ky3+wOtc74p8NNdTHxBZCWXXJ2E1uZ2B+z3kBDCFBgAK6o0fTJ2rknNbGt3Ub6fp3jrRLRJ7WaBG1O2Kkma34O4qODJER3BIG4DtQB0OjeHNO8OXF1LpVpdT31zGn2iaad3a4wSNzO5wW5J+mB0wK8/wDitBpugaJpfinRZoEvdMula1KbV86EHa8AC8vhQwGeg3c11Wr+KXjuYrTTZP7YurqIvDawx7FMcpHlySyDPlxKDjONzHoD0rJ8S6Ta6V4S8R654ju5NS1BrKSF7naVjtv4fKgTDGNMkZPJOMkmgDa0jT5vGcNnrXiHYdMkCXFjpSNujAPzLJOekj9Dt+6vuea7euQ+ENlc6d8MvDlteqVnW0VmU9VDZYD8iK6+gAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACmTwxXELxTxpLE4wyOoZWHoQetPooA5hvBGlQOZNFa70SXrnTJjDH+MXMR/FDTRD4v00DyrrTNchH8Nwhs58f76BkY/8AUe9dSSACScAVxWueJ59Uu30PwYy3OoN8txqKgPb6evdmPR5PSMd+TgUAVvEnxHj8O6W8mr6JqNjqDHy7aCdVaKeQ9AJkLIB1JLEEAE44xTdC8K6b4mtodV8S6lb+J7hxkCKUNYxE/wxxqdpA/vNknr7VG3hu38PeL/DF5NfanexuZbYve3TSqty0eVlweFZgrrgYHzDArpdR8H6FfXTXT2CW98et3Zu1tOfrJGVY/QnFAGnYaVp2nKF0+wtLUAYAghVP5CrlYWk6Pqem3if8T+5vtPAOYL2FHkHptlUKeD/AHgx963aAOKh/wCKI1VYGO3wvfzbYCB8unzufuH0idj8vZWOOhGO1qC/tLfULKezvYUntZ0McsTjKupGCCK5nw7eXOh6mnhrWJpZ1ZS2mX0pybiMcmJz3lQd/wCJfm6hsAHVyyJDE8krqkaAszMcBQOpNeLHW4ZJdZ8dX4Z4I0VrFSDwmdtrGF7s7M0pHvHXTfFPW1kR/D8LqkDRfaNUmMgRYrfOBFu7NKflHou49qy/DcC6rcaXfXtuW0eKcNptokW03tx/FdspxtjRchAeigHrtFAGn4J0keFNDvvE3iFQmrXkamSMf8sYx/q4V9yTlvVmPpVX4bzvf+C4xIEWVdRv4mRDkKXMr4/8eFS+Mr6TXtUtbC0Yi28xljcNwdvEkv0GGUHvh/VTTPBAWPxH4k0uwjWNbW/trwRMSNsckARjz1b5CT7n1oA6TQJv7S8CzqVwzRTxsv13f0Iq1cHzrzw3cMgZJNwyexMRcH/xyovBysltPbvjy3ignXHo8QB/VG/OqJumt/AWl3k7FHs/KV27gg+UT+poA5/4gWT6bD4MtJ3DWtvqEKG4VcMrZ8tD+HmZ/CpZVa01GZstBHcArLs/5Zupy2AO6uN4/wBnaO9afxeje78H3Bs2Q3Vvm5izz+8iQyqD9QlYkuqwT6G2s3M7W/lNvnld1zEcb1Jzxgp8uTjJjT1oA6gIdShKO3lLqADq68/Z7yPuvsdoYeu0/wB6uC8OeIb4eILvw7oNxb29nqVy7reyIzR2d1gm6t4cjbI2fnXnaAxznG0v0pbrxdN/Z0rXGk+Gb0eZDgbZriRRxjPMcfTA4dlCZ2hub/i/RLddNgvrSH7DDbFLW9itUx9ikjx5V1Eo6FDj/eQ4PFAGhafD688Ks3/CE3qCyuHV72xvmI+0EAglZVGULEgn5SOMDA4rn08Paz4u8bw6P4n+y22i6PbQXE1jYTSNFIxJ8qN92AcFWbIGcYGTXoHgnxJJqqS6dq/kw67ZqPOSM/JOh+7PF6xt19jwaztYuT4R8aXGt3qOdC1WCKG5uEQt9kmj3BGfHSNlYgt2IGeDQB3QGBgdKKhtLmC8to7i0ningkGUkicMrD1BHBqagAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAyfE+uQeH9Je8mjknkLLFBbxDMlxKxwsaj1J/Lk9qw4NL8W6vCJdX1qPRVfn7JpcKu8Y9GmkDbj/uqBTPGo/4rXwKZgWtvttwNuePN+zvsJHthvzrtaAOPPgd35l8V+KWb1F8E/RUApV8FzpxD4t8Tovo11G/6tGTXX0UAcY3w9sLt861qmuavHjBhu75hEfqke0H8RXV6fY2mm2kdrp9tDa20YwkUKBFX6AcVYooAy/E2lDWtFuLISGGZsPDMOsUqkMjj6MAab4X1ga1pKXDx+RdxsYbq3PWGZeHQ/jyD3BB71rVx2t3MOi+JTq1nNE0Z8qDWLZWG5EY4iuCOoK9CT1T/AHRQB2NFFFABXEfF/UtL0/wfN/abH7U7j7AEkEci3C8pIjfw7T8xY8AA5znB2fFHinT/AA8sUdwZbnUJ8i2sLZfMnnP+yvp6scAdzXnenaHHrmuT+LPH0q3b2ziGw0mFTLBAxPEanpNLkDOMjPrjgA5Lw2s2tXUcPiO3aQrdrqU0cqsG1ZySscu0hSY9oCRxAYBBLkAYPrV4JIWmN3OsGozwGS9mRsrp9mMkohxwTjAPUnLdFAFXxRpV3LHba5JKsPiiKULpUKfMkZPWBv7yuM727AZGNoNUNNWLxbYLplyZIZfPWbxCJBtYyg4W1zn7pIGMHBRR/fzQAaCv+i3euXUKxrLEpghPBS3GFgi6Z+cheO4X/aqTSHh0f4ox2Mswed9CD3TjJ3S/ac5P1MrHHYEV0klvGdWgtXkTyLL/AE+7I4G7kRLjsqgE4/2FrgJ2kl8Q2OvuCsmp6ff3CKRgiJHgMfXvsANAHptvbi18SBYQFgexWNUHQeW5x+klZc1pJceFfEdg8fmuktz5aeu7MiD/AMeFbF/KIde0sHP75Zoh9cBv5IaxNV1HUtN1++stJsPt15fpFNAHbZDFgFHeVuoUbU4AJJOB3IAMrXtcstNsobq+HnG7jtLm2s413SzsQVkVV7/J17AZyQK4LwXpFxPNbS+KAfLsp20iS1DYFo0ZxbzsQcSOu5V3EYAdCOhNd74W8M2unfZJNTuH1DUpxPpc9zKSPkGdscYz8iYTgDnnJJPNZGoW6Q/EjxFozuPI1awhu41c5G9QYZDk+oCBvqD2oA0VtMaktpdSJaM0w/eKM+XKMcr6ZyuPQNF/dNdJJJvge/mhRmVTa6pBg4KgctjvjOR6o30rl7OaTUNLlj1BwNS08rbXu/pInPlTtz0IJVj2y/8AdFbuk6i0ZF3ICJYAIL9WbLFAcLKexKnKsfZvQUAZ+l+FxBrljA8U01nYSfadOv4n2vEjcmMt/Eh6Fe+Qcc/L6CQGBBGQeoNUdMs2sTNFGymyJDQJzmPPVf8Ad9PTOOgFGsi9Fn5mmsv2iJhJ5bLkTAdU9s9j2OO2RQBxniDTX8CpeeIvDQWPTEzPqWk4xFIv8UsP9yQDkj7rY5APNd9DKk8KSxMGjdQysO4PINYPie+srnwBqt9PzYS6dLIwYYOwxk4I9e2KseDElj8H6Glznz1sYA+f73lrmgDZooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA43x0wPiTwRF/G2qOwHsLeXP867KuLv1OrfFTTIQoMOiWUl27f8ATWfMaD8FWQ/iK7SgAooooAKKKKACuU8b+EY9fVbyykW11iGJokmIyk0TD5oJgPvRt37jqOa6uqery3EGmXEtlEZbhUJRQu45+mRn6ZGaAON8C+K4LPw4mneLru20zWtLUQXcV1Oq8DhJAxwHVlAO4d896g1Pxpea08Vv4VBt7OfIXVJ4GZpf+vaD70n++2EHqaZr+nWHjq1tpoWg07xTaKXsbpkDrnuo3D50PIKkblPUA9Z/C2rve3F1pdjpqaT4ghCjUGvW8x+mA8fOZU44JIUfpQBW07w9b6Qh+2rcSX1+TvtzKJr3UCP+e0vRUHdVwgzyTnFdTDbx6VEdV1uSMTRoI4oohmO3U4AjiXGSxOBnGW4AAGBVgRWHh62kuriSWa5kwrzSfPPO3ZQAOfZVAHtWB4g1aLRrWTXvEskcLQqXtrY4YWwwfmIH3pT04+g43NQA+6ubxLxLmSNDrVz+5trfO4WyH5tmR/EQNzt2A4/hzTudFGl6pFrlpcqv2I/8TR5FONQJJJ4H/LRC3yHHU7PongaDUpopdZ1SNodW1Rf9Ftn5NlbdQX/22PzN6navReOhEUd/qsVhEC1hpjCWZiciSfqqn1253n3KUAZV7FcGzj0hgx1XXXaW8cHi3hwA/X0TEY9Tz61leISb3x7p1rbofs8enahaxIigLuCRZA98kD04+tbGkXu8av4omGVuCLWwjI5aJWKpj/fkJP0K1mWYit/iV4e0lJTNc2GmXcty+0gGSR4STn3JJx2yKAOv1txEdJuHU5S8jX6F1ZP/AGer9z9ngJvJlUNEhUy7clVJBI9ccD8qo+KnEWh3E5XcLdknx/uOrf0q9qNv9r0+6tiSPOiaPI6jIIoA56/Q2txrIRVUxPFqaE85xw4A+kZ/76rgPicJrLWNE163gEgsb+W3kYMPnhnCN36/fb/vmvRo5opJdB1ByGF3CbVm9d6Bxn8UI/GuT8XabDqPhq9s7pW3+S0TtHk7HgJAb6mJy30FAE3m5dNcsP391Zxjz4OpuLV/vfXGAef4lOeWIrpxp63Op2Wq6Wy/Zp023EZHyuhXg49eFBHsPQg8j4N1W5m0G1vIFs5tXmR45bcRO7xzA7ZRwcKGdNxyVBJz3rodNi1uylg1DxLrNrEg3B7O2hwjZyFAJOeM5PXnvigDq4IkghjihXbHGoVVHYDoKfTYpFljV0OVPI4xXOeLL2e6li8P6TLs1C9XM0o62tvnDyf7x+6vuc9FNAHn0usaVr11B4X0eBoNLvtVeC7vXdmSdIvnMSueN7sGAUHhAT3Ar2bp0rkfGHh61j+H93YaPBFZmwh+0WPljaIZYvnRh75HJ75PrW/oF/8A2roWnaht2/a7aOfb6blDY/WgC/RRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBxvw8k+33nijVyDi61WSCNj3jgVYhj23K5/GuyrjPg25m+GuiTt9+4SSd/955GY/qTXZ0AFFFFABRRRQAVVGoWp1A2Pm4ugu8RspG4cZKkjDYyM4zjNWqp6np0Gowqk+5XjbfFKhw8T9mU9j+h6HI4oAztb8N22otJLE3kXDkMxxuSRgMBmXI+YdmUqw/vVy2reH9Sv44jqtrcS3Fgc22oWcyi7hJ/ijbgSKcAFHAP+/1robTxCLOaS11aeGUQN5b3sH3QR2lTrGenP3fcdK0rvXLGzlUXUjxQsoZblkPknPbzB8oP1IoA82Ou6x4Wgl1DXdMn1xwGWHW4lKqi5xtkhIBgOepAwepPaovD+mjxTNH4q8U3UL6JbnzrePeDHK+eGx1K9AM4ZiANqr8p9Ru7S31RIpormRHjz5U9tNjGevT5WHA4IIrh7/wCYrl76xhjh1BXEi3WmSfZXdgMbnhYNC7deSB17UAdZd6tMlhAY7Qw6rekpb28nLD0d8dAoIZhnjpnJFZeuQPBp9p4Y02dze6hu+0XGf3iQk5mmP8AtEnA92GOlc5b33i3Qby5ur60i1iZ48eZcQNbSIg5Cb4xJFjPJ+7k/hVHRfHdvYR6jqGq6ZqX9tT8POkInhVR91FMbMQg9CBk+/NAHaajcWtvK8uzGl+H4dwQcK0+3CqPdVOPq49K5bwFFPc/E6+ur3Ml5Bpai5lDfL50suWRR2VBGEHrtJrC8QeO9D/sNrax1BDDbnzXDgpJdXBO4sVZc7VIJGRy23050vgKwlsvFepiZJ55LlY3kU7kykQO1T3UFiM9+T3oA9W1eH7RpV7CRnzIXTH1UipLCXz7G3lH/LSNW/MZqLSJ3u9Hsp58GSaBHfAwMlQT/Oq3hXzB4esUmOZIo/JY+6Er/SgDPu0EXhW58ghDYTPKuB08qUvj8hj8aj1tIluppcGaOaNbxIwcbyg2yAeu6NgMVp6fHEL/AFm0PIeRZmU+joB+pVqoRSB/C+n3yBy9jhmCjkhMpIMd+N3HqBQBxnga/u9D13V/DkYhdZGN9ays/wApXhZD+PySE5/5aZwavanqTG9jjtPOv9Rn4h2ffkOeTHniOMd5T/wEZrG8e6ZNYXCX2mRedcaewkjjz/r4tpwgxy26MMmPWFPXNdBoYS30m3vdMlE2parAt1Jd4BKQ4yqjjAHbHTP4YANT7bP4e0KCzgNte65czGG3t4yRH5pGWyTliqDLMx547EgVseHNFXSIJnmlN1qN0/m3d2wwZXxgYHZQOFXsPfJOH4Gso7u6uNZYmSOLdYWJPTy1b95IP+ukgJz6KtdnQBj+LrG61Tw/dadZNse8At5JN2DHGxw7D3Clse+K5iC41LwAsVrqHm6l4TjUJFfKu64sVHAWZQPnjA4DgZA+8O9d/QeetAEFjd29/aRXVlPFcW0qho5YnDKw9QR1qeuRuPA1rb3Et14Zvbrw/dytvcWZBgkb1aFgUP1AB96bHN430yPFxa6PrqKMbreRrOVvcq25P/HhQB2FFcaPGt1byGPVfCXiK1YdXht1uk/OJif0pq/EzwwGKXF1eWrr1W4sLiM/qlAHaUVxR+J/hgvthuL+c/8ATLTbhs/jsqVfH1hIMwaT4jmHqmkT4/VRQB2FFcla/EPw3JM0F9ff2TdqebbVENrJ9cPgEe4JrprO8tb2PzLO5huI/wC9FIHH5igCeiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOE8MXH/CIaw/hfUiUsLmZ5tHumGEcOxZrYnoHUk4H8S4xyDXd1Q1zSLHXNNmsNUt1ntZRyp4II5BBHIIPII5FczoN/qPh7XIPDmvzve290HOmak5+eQKMmGb/poByGH3gD3BoA7WiiigAooooAKKKKAKeoaZZaiqi9topipyrMPmU+obqPwrnH8Hz2Msk3h3WbqwdskxSqJomY9yD1+pya1L3xFDZXhgntroAHG8R8fXnGR9M1GPF2jF9i3Ll/7ohfP8qAMttF1IL9outN097sph5dLuHtZSc9s8N+JFSQX9/aSsktzqMYwMLf6f5qr7eZDx+ZNaR8VaaHVFF9IzdBFYzSf+gqatTamGhPlW9+GYcFbYgj/voYoA5K71U/aRPLdwJcseRZasI93HUxTALmrC39wyf6Sbi8jPIafTEuPw3QNj9Ks3mpHbtvPtwj9Z0tUX/wAfYVSeLS7qPJSKRT6JZt/IGgCldWdtLIZRpWkrjkyCyurdx7/KnH51V+Diu/gnxDqUhyL++uLiM8/6vYoTk8ngDk1jeMDo0WmT2unRj+07oraW8YiRT5sp2KceSOmSeo6V3Wkxw6Z4AvEslJgjWaGEd2CkxKfxCg/jQB02lqttpdjC7BSsSRgE4yQvT9Kp+GHLWl4hP+rvrlR9PNY/1pNYbbqfh+Ad7pj+CwSf4islbuW00rUJbdvLL6lOmQPdh/MCgDc3GPxLt2fLPaZ3e6P0/wDIlR+HyCmpWxQBYb2VMdiGxJ/7PVi9OzU9OfuzSR/mu7/2WmaZgapq6gYzMjH8YlH9KAKVtYxXWmXejTsytbERxyAYZE+9Eyn1XgA+qGvLZp7vwhNqenbAkd87C2k5Atbts7EwOkTuRIh7YZeq4r1vVttleW+p/dRf3FweMeWx4Y/7rYPsC1Zfirwzaa3drFdJJLb3SeVcxJNsYJ/eH+zkDI9cEYI5AL/g94ItEttOij+zzWEaW8tux+aMqMfiDjIbuOa26wtZtYbNtNvYUInt5orcOOWaN2CFCe4+YNz3Ga3aACiiigAooooAKKKKACmyyJFE8kjBEQFmYnAAHU06sfxU4Okm1IJN7Klpgdw7AN/47uP4UAZcXlp4fvNf1G1inu7mMypFMoO1P+WUPPTqM/7TGsrVfAGm2egve6VEmn+IbWJrhL+1/ds0wBYh8YDoTkFTkYPGOK6fxGvmLplksYZZ7yIFewVMyfl+7FbEsayxPHIoZHBVge4PUUAUPDeo/wBseHtM1IoEN5axXBQdF3qGx+taNcZ8MpJLHT73w1dsTdaHMbdCxyXtj80L/wDfB2/VDXZ0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVi+MNBTxFoctn5zW1yrLNa3KfegmQ5Rx9D27gkd62qKAOf8ABWvNrmlN9sRYNWs5Da39uP8AlnMvXH+y3DKe4IroK4jxOH8OeLNP8RW/FhfPHp2qIOnzHEE31VjtJ/uv7V29ABRRRQAUUUUAQXcEswURXUlvjOTGqkn/AL6BrLuLWCwjafUtau1i/vTTrGv/AI6Fq5rZvf7OkGmKxu2wEKlRt56ndxj8D9K5o6QbJv7T8RatDA6g5lypfp0Ejj5fpGqUAbFnZaVq0IuIZbq5jBwGa5m2n8C2P0ocaHBMYFggmnUZMUUfmuPqADj8a42XxLC9qsNhFqutJ5hiVsPHDkc4BJ3yH2JOfYVp20uoWEayapdjTYtm82NpDGPLXuxPKoM9yx9iDQBrTzRwKJG0+w01Gxsa6CmRj6CNOvbjdmsvWtTh062abVZbiSJBk/aJBaQkDklY1+Yj/e4965KTxRqms389l4B0/ddglZr5v3rR8nh5nyF9duGPoDWvo3woguLgX/jbUJ9cvWIdoHci3Vh046vj349hQBk6HrqeMNauNXsEQaH4fVmg8uAolxfOu1ccncFBOCQOXBxXpEtm9lomlaZGRIwkgiZj/EFIZ2+pCn86s+G9CsPDmlJp+lxeXbq7SHJyzMxJLE9zk1YktXk1SK5kceTDGRGgz99urH8BgfU0AVbtUm8TaepwXggmmx6ZKKD+rVzeoyofC1g8Wc32oeYg7t5krNn8jW/eQpZXOoX11dxxy3SLbwyOuFhVVJAJ/wB4scnHYVlurXp09tJtpLq1sVRYS4EUbEY+YM3JGABkAjk0AbmroZL7SFU4K3Rc/QRSA/zFJpDrLqOsSJkgXCxZ91jTP6mrFnHLMyXN/bRQ3aBkURzGQBSR3IHJwO3al1K7i03T7i7lX93EpchRyx7D6k8UAK/2iS8aNoofsOz5mY7mcntt6AD3znPSq32Wz0W1uruC3+cKWds7nfGTgseepqLw9qVxe6dBLew7ZpkaZBGDtKcY56DrwCckDPHID2t7vU7PZf4tEeXcYYyGYxj+Bm6ZJ67foD3oAra5dmTQGvkiOLW4WV0zk7YpsOf++VY1uoyuiujBkYZBByCKr21qLeSYRiNbeQl9gXnexJck55zn+dPs7aGzto7e1jEcEY2og6KPQe1AE1FFFABRRRQAUUUUAFY2qZm8RaNAHwI/OumX1CqEH6y1s1izGOLxFdXspwtrYDJ9Azsx/wDQBQApc3fipUUgxWFuS/8A10kI2/kqN/30K2ayvDELx6PDPcNvu7sC5nf1dgDgewGFA9AK1aAOF1KUW3xf0dowUa7sJrWbB4kA/eJkeo2yf99Gu6rz/wAQRmT4reGbhOUjZ7dm7Bzb3D7frjafxFegUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZPi7Sv7c8Mappina9zbvGjf3Xx8p/BsH8Kg8Daydf8JaXqL4E8sIE65zslX5XX8GBFbtcb4OZNM8WeJ9B+6vnLqluD3SfO8D2Eiv8A99UAdlRRRQAUUUUAMmVnhkSOQxuykBwASp9QDx+dcOnhS1lllv8AxFO80UO795dMcbe/U8D3PXsFHXu6868c+If7N1qztJ7Q6tqc8wGm6RbvheP+W0zH05I4wuM8nkAGp401Wz8LWUV8qJGzp5EAiTzJ5G4CwwR9Mnr6DGSD25fRPBWs+KmXUfG00tjZuwlTSLeU729DPIMEt7DGOgwOK67w34Xli1Aa54mmj1DxCylVdVIhtEP/ACzhU9B6sfmbv6V1dAFbTrC00yzjtNOtYbW2jGEihQIq/gKs0UUAFVi1tfxXMDBZYwTDKhHfHIP4EVZrOvtE0y/n868sLeabGC7oCSPQ+tAEcdlo8V/Gmy2e9ALxiRg8gx1I3En8RWnKSsTsGVCATuboPc+1QWljaWYxaWsEHGP3cYXj8KqPosNxIrahNPeqv3YpyPLB9SgABPuQaAMTxBrLXWkWtppd5bT3d9cC0aaBvkXjLY5PbHfoeD0rVvbcnw3BDJFNIF8nzI2XLsoZdwIHtnpWhcafaXEkTzW6M8X+rJH3eQePxVfyq1QAyGJIYUiiULGihVUdgOAKfRRQAUUUUAFFFFABRRRQAUUUUAFcxfuLiTxYjNtVLRYix7fumbP/AI/XTk4HNcdvE/ha7uHz5mu3GxPlwdkhEaflGAfwNAHTaOc6TZEjBMCHHp8oq3SIoRQqjCgYA9KWgDhp4vtPxO0u0hRNunW8+p3TxjAMso8mMEZPO0SflXc1w3wvuG1GXxRqlwv+lz6q8ROc4iREESj22nP1Y13NABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXG+KUOn+OPC2sISsczy6VcY6FZF3x5+jxgf8Crsq5H4rRSt4E1G5t0Lz2JjvowOuYZFkP6KaAOuoqK1njurWG4gYNFKiyIw6FSMg1LQAUUUUAMlljiXdK6oucZY4Fef/CrSxdS6r4svGae71S4kFtLIOVtlYqmPTdjd9NvpTvjFdsukWlhBIgu76UWtupIyJpCI1bb1O0M7exUH0rtdJhtbOxhsLJ0MVnGtuFVgSgVQAD6cYoAuUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZXiS7e20xorfDXl0fs9uvq7cZ+gGWPsDVWGBZ9ftbaJgbbSIRkA/8ALV12qD9Eyf8AgYqsL6N5bzxBP+9tYAbawRRkuc4Zl/2nfCj2UeprX0Gxew08LcMHu5WM1w46NI3XHsOAPYCgDRoIBBB6GiuR+IviFtI0xdPsBK+s6pm1shH1WRuA5PYDO7/gJoAg+GSxE+JprJdtg+ryJb+hEcccRI9RuRh+FdrWZ4Z0eDw/oFhpVpkw2sQjDHq5/iY+5OSfc1p0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFNljSWJ45UV43BVlYZDA9QRTqKAPP8AS7q78Aj+ydStLu78OoT9gvrWJpmto88QzKoLDb0DgEEYBwRWq3xD8LAHZqqzOP8AlnDDJJJ/3yqk/pXV0UAcaPF2p6lIY/DvhjUplx/x86iPsUIz3w2Xb8Fpp8OeJdWbOv8AiZ7WAkH7JosfkDHoZW3Ofw212lFAHKp8PvC4tpIpdIguHkGHuLgtLOT2PmsS4PuDxWPefC6znuDNDr/iCByACftKSHA6Dc6M35mvQqKAPOU+F/lMJLfxd4mSUdCbiMr+KhBmtGCHxroUQVZdO8R2sYwFYG0uiO3zEsjH67c+tdrRQBg+G/FFjrry26LPZ6nAAZ7C7Ty54vfb3X0Zcg+tb1YfiXwvpviEQyXiSRXtuc297bv5c8B/2XHb1ByD3BrlLy+8V+Frkz6op1bT0AU31tGSSgz/AK6BclWGT+8jBHqvoAej0Vz2i+L9I1WyguY7lIo5R8ruwMZPoJB8ufbOfYV0IIIyDkUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVnazrmk6HHG+s6nZWCSkiM3U6xbyOoXcRk+woA0axdene6lj0a0Z1nuV3TyIcGCDoWz2Lcqvvk/wmsvUfiL4YtLZnh1W2upz8scEDF2kbsOAcfXoKwV8WackTWkF/cz6nfMJL67trOdhbpjGEwh7Dao+rHvkA6uyhj1HU4jDEi6TpZ8q3VfuyTAbSQOmEGVH+1u9BXQ1ydl4r0a0tIbaxsNd8mNQkaJod6BgdMMYsfiTTrnxta28LSvpOveUgyzNp0iAen38Zz7ZoA6eaWOCMyTSJHGMZZzgDJwOa878D2sniTxfqXiy+TfaW8klnpRPIZQxVpl9iAFH/Az/FXO+K/EereNL99AsNG1yCzikR75Ioo1lSE8gEs4AkbspxtHzc8Y72x1fULKzt7Ow8E6zBBAgjjR57JVVQMAfLOx/SgDrKK5r+2vEDHKeFJlH/TW+hB/8dLfzo/tLxUw+Tw5pyk9PN1YjH1xCf0zQB0tFc54nn1dPA+oTRwi31YW7EpZSNOU9TGxVSzbckfKOexrAvdW8OaVpc0/hvUl89zFDJLbXgkWPdIAHlaQsinkgu4LcnqeKAPQqK8eTxPqkjWGpebBPdwWOqw+dH+9jKJeWaCY7QofahLHAUHBwBnFX/Ffi6XTdM/4k/iSK9mjt7i6jupZLdIpygXERZUPmNk/dQKcNyw4JAPUqK89bxFqx1eedLgG2h1eCwWzEa4dJLOKUksRu3B5OCCB6g9sjSfGmstpwvbu/wBOIJs5LuAyoZLLddRJMGQKDGixvJnzCWUrnPXAB6zRXleteNrxbSS9t9UtksI7u7jX7O8PnzrH5fl+UJPkkHzNkAhmyu09a9TRg6KwBAIzgjB/KgBaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDltW8Eabd3M95psk+jalN/rLmwITzT/ANNEIKSf8CBPvWOnhLxRZIV0/X9NweSfsLwEn1xHKFz/AMBr0GigDz6SL4k2gQW0mgXqr186RwW/JBj8zSnXviHbDM/g3TbsD/n11UKfyda9AooA86fxz4qgH+kfDnVvfyLyGT+op9p8TofNCat4d1/ShkBnubJyo98qDmvQqKAOasvHnha8YrFrtgj/ANyeTyW/J8GtnTtSs9SErWFwk6xPsYocjPse/XqOKkvbK0vovLvbaC5j/uzRhx+Rrm7z4d+F7iZpodKjsbkjAn092tXH0MZFAHWUV5/cSal4DvI7q+1K81XwtJtinmu2Dzaee0hYAb4yThiRkcHJGa75HWRFdGDIwBVgcgj1FADqKKKACq+o3sOn2ct1csVijGTgZJPQADuScADuTVisOJDquvSzSMGs9Ofy4UB4afb8zn/dDBR6Et7YAIFL2cE2vayhN5s229sOfIDEARL6ux25PrgdBWjoVjLZ2zyXjiS/uW824cdN3ZV/2VGAPpnqTVXC6t4h5+a10s+xVrhl/wDZFP5v7VuUABOBk9K831nXbvXNaSw8Px+dfY3Qu4zDYxnI+1Sju558uPqRzxmt3xh4mWy097XSIlvtYu5vsNpbkHY8pGWLH+6gyzY6Yx1q/wCD/Dtt4a0kWkDNNcSMZrq6k+/cSn7zt/IDsAB2oAm8MaDa+HtMFpamSV2Yyz3Ep3SXErfekc92P/1hxWtRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFADJoo54ZIpkWSKRSro4yGB4II7ivNpL+8+HFxb2FyDN4VknAs7g5LWqnP+jufQE5Rj2Gw84r0yo7q3hureSC5iSaCRSrxyKGVgeoIPUUAU7TWdPu7hIILgGVwSqspUtjrjIGcelXlkRpGRXUuuNyg8jPTIrj/wDhXum25A0jUNZ0mINvWGzvW8pD6qj7lX8AKtjwrcgHHijXgxGC+bbcR9fJzQB0cc8UsbPFIkiqSCUYHBHUVz2iXseneDEvpikkxhN3KqEZeSQl8fUs2BVE/DzTrgbdU1PXNShJ3GG4vWSNj7rGEB/Gi7+GXhaWKIWenDTJ4mDx3FgxhlUg5HI6jIBwwI4oA3NOMOh6NANUuoo5iDJNI7Bd8jHc2PXkn9K5TX/GyXN0dK0iK6ubx+PsloP9JcerH7tun+05DY6DoavXHw+tL2483Vda17UF2CIxy3YjVlBzg+WqE+/PPeun0jSdP0azW00qzt7O2XkRwoFGfXjqfegDnfCXhq6tr/8AtjXTb/bxF5FrZ2w/cWEROSqEjLOxA3OcZxgYFdfRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The deltoid ligament, located on the medial side of the ankle, is a broad band of connective tissue that has four separate divisions connecting the distal tibia with the talus, calcaneus, and the navicular bones.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_23_6518=[""].join("\n");
var outline_f6_23_6518=null;
var title_f6_23_6519="Physiology of lactation";
var content_f6_23_6519=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Physiology of lactation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/23/6519/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/23/6519/contributors\">",
"     Richard J Schanler, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/23/6519/contributors\">",
"     Debra C Potak, RN, BSN, IBCLC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/23/6519/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/23/6519/contributors\">",
"     Steven A Abrams, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/23/6519/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/23/6519/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/23/6519/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The breast undergoes dramatic changes in size, shape, and function in association with puberty, pregnancy, and lactation. These changes are critical to successful breastfeeding.",
"   </p>",
"   <p>",
"    The physiology of lactation is reviewed here. The stages of breast development and breast anatomy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20649?source=see_link\">",
"     \"Breast development and morphology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMIC CHANGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The breast is composed of a stroma consisting of fat and connective tissue that supports a tubuloalveolar parenchyma (",
"    <a class=\"graphic graphic_figure graphicRef72583 \" href=\"UTD.htm?8/30/8674\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6519/abstract/1\">",
"     1",
"    </a>",
"    ]. The normal breast tissue of adult women contains three types of lobules, known as types 1, 2, and 3. Formation of type 1 lobules (Lob 1) begins with puberty (",
"    <a class=\"graphic graphic_picture graphicRef52636 \" href=\"UTD.htm?37/39/38517\">",
"     picture 1",
"    </a>",
"    ). The changing levels of estrogen and progesterone during menstrual cycles stimulate Lob 1 to sprout new alveolar buds and evolve to more mature structures called type 2 and type 3 lobules (Lob 2 and 3) (",
"    <a class=\"graphic graphic_picture graphicRef76317 \" href=\"UTD.htm?20/50/21284\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef64382 \" href=\"UTD.htm?8/54/9060\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef72142 \" href=\"UTD.htm?13/24/13699\">",
"     picture 4",
"    </a>",
"    ). After puberty is completed, further maturation of the breast does not occur except during pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20649?source=see_link\">",
"     \"Breast development and morphology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The alveolar development and maturation of the epithelium that occurs in response to the hormonal changes of pregnancy is known as stage II mammogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6519/abstract/1\">",
"     1",
"    </a>",
"    ]. Progesterone plays an important role in stimulating alveolar development during this phase [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6519/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The maximum branching capability of the breast is expressed during this period. The secretory acinus that is formed represents a terminal outgrowth that marks the full extent of glandular differentiation.",
"   </p>",
"   <p>",
"    The increased volume of breast tissue during pregnancy results from the development and proliferation of secretory tissue. Normal postpartum mammary function is therefore associated with some increase in the size of the breast during pregnancy.",
"   </p>",
"   <p>",
"    The development of the breast during pregnancy occurs in two distinct phases, with characteristic early and late stages. Ductular sprouting predominates in the first trimester, while lobular formation exceeds ductal sprouting in the second trimester (",
"    <a class=\"graphic graphic_picture graphicRef76317 \" href=\"UTD.htm?20/50/21284\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Early pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Under the influence of chorionic gonadotropin, many secretory glands develop from each bud, forming the type 3 lobule (Lob 3). Further proliferation of the distal elements of the ductal tree marks the progression from Lob 3 to a type 4 lobule (Lob 4) (",
"    <a class=\"graphic graphic_picture graphicRef72142 \" href=\"UTD.htm?13/24/13699\">",
"     picture 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef51142 \" href=\"UTD.htm?22/40/23174\">",
"     picture 5",
"    </a>",
"    ). In these newly formed lobules, the epithelial cells composing each acinus not only increase greatly in number due to active cell division, but also increase in cellular size [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6519/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In mid-pregnancy, the lobules continue to enlarge and increase in number. They surround the ducts so thickly that the chief duct, the terminal or intralobular terminal duct, can no longer be recognized. The transition between the terminal ducts and the budding acini is gradual, making the histological distinction between the two of them difficult. Both also show evidence of early secretory activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Later pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mammary changes that characterize the second half of pregnancy are chiefly continuation and accentuation of secretory activity. Progressive branching continues with less prominent bud formation. The formation of fully differentiated secretory units or acini becomes increasingly evident. Proliferation of new acini is reduced, and the lumen of already formed units becomes distended by the accumulation of secretory material or colostrum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Labor and lactation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Just before and during labor, there is a new wave of mitotic activity within the mammary gland. During labor and lactation, further growth and differentiation may be observed in the lobule along with milk secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6519/abstract/4\">",
"     4",
"    </a>",
"    ]. At this time, the glandular component of the breast has increased to the point where the breast is composed primarily of epithelial elements, with very little stroma (",
"    <a class=\"graphic graphic_picture graphicRef76317 \" href=\"UTD.htm?20/50/21284\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef51142 \" href=\"UTD.htm?22/40/23174\">",
"     picture 5",
"    </a>",
"    ). These changes persist throughout lactation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Involution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following lactation, the mammary gland undergoes involution (",
"    <a class=\"graphic graphic_picture graphicRef76317 \" href=\"UTD.htm?20/50/21284\">",
"     picture 2",
"    </a>",
"    ). The process requires a combination of lactogenic hormone deprivation and local autocrine signals, and is characterized by apoptotic cell death and tissue remodeling. The factors that trigger the cell death pathway have not been clearly defined. The potential of the glands to produce milk in response to regular stimulation is permanently enhanced following a single gestation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20649?source=see_link\">",
"     \"Breast development and morphology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MILK PRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lactogenesis refers to development of the ability to secrete milk and entails activation of the mature alveolar cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Lactogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lactogenesis takes place in two stages, secretory initiation and secretory activation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Secretory initiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stage I lactogenesis occurs during the second half of pregnancy. High levels of circulating progesterone supplied by the placenta inhibit further differentiation. Small amounts of milk containing lactose and casein may be secreted after about 16 weeks' gestation, and lactose derived from the breast begins to appear in maternal urine. During late pregnancy, many women are able to express colostrum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Secretory activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stage II lactogenesis or secretory activation is marked by the onset of copious milk production after delivery. This stage is triggered by the rapid decline in progesterone that follows delivery of the placenta and requires the presence of elevated levels of prolactin and cortisol as well as insulin.",
"   </p>",
"   <p>",
"    Onset of copious milk production is accompanied by swelling of the breasts. For most women, this occurs two to three days postpartum but may be earlier or as late as seven days or longer after delivery. In primiparous compared to multiparous women, secretory activation is slightly delayed, and early milk volume is lower. In a population based study of all single term infants, delayed secretory activation was observed in women who had cesarean births compared to those who delivered vaginally, but this delay was not accompanied with a decline in milk volume [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6519/abstract/5\">",
"     5",
"    </a>",
"    ]. Late onset of milk production has also been reported in women with placental retention, diabetes, and stressful vaginal parturition [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6519/abstract/6\">",
"     6",
"    </a>",
"    ]. Women with retained placental fragments may experience inhibition of lactogenesis II that fails to resolve until the fragments (which continue to secrete progesterone) are removed [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6519/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Maintenance of lactation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lactation or galactopoiesis is the process of continued secretion of copious milk. It requires regular removal of milk and stimulation of the nipple, which triggers prolactin release from the anterior pituitary gland and oxytocin from the posterior pituitary gland. In the absence of milk removal, elevated intramammary pressure and accumulation of a feedback inhibitor of lactation (FIL) reduce milk production and trigger mammary involution. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Feedback inhibition'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MILK COMPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Milk is a complex fluid that is comprised of a variety of chemical and cellular components. The major macronutrients in milk are [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6519/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lactose and oligosaccharides (see",
"      <a class=\"local\" href=\"#H24\">",
"       'Lactose synthesis'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Milk fat, including triglycerides, cholesterol, phospholipids, and steroid hormones",
"     </li>",
"     <li>",
"      Proteins, including several caseins, alpha-lactalbumin, lactoferrin, secretory IgA, and lysozyme",
"     </li>",
"     <li>",
"      Minerals, including sodium, potassium, chloride, calcium, magnesium, and phosphate",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The nutritional composition of human milk is discussed in greater detail separately for both term and preterm infants. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/36/6727?source=see_link\">",
"     \"Nutritional composition of human milk for full-term infants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/28/458?source=see_link\">",
"     \"Nutritional composition of human milk and preterm formula for the premature infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of the nutritional components of human milk are multifunctional. They include the following properties:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bacteriostatic and immune modulating properties, which are activated prior to",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      during the process of digestion",
"     </li>",
"     <li>",
"      Anti-inflammatory",
"     </li>",
"     <li>",
"      Growth promotion of crypt cells in the infant's gut or other cells in the body",
"     </li>",
"     <li>",
"      Aid in digestion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cellular components of human milk vary in cell numbers and type over time. Cell counts in colostrum are approximately 10(6) per mL dropping to 10(5) per ml by six months. Cells include macrophages, lymphocytes, neutrophil, and epithelial cells. Living leukocytes are present in human milk in approximately the same order of magnitude as seen in peripheral blood, but the predominant leukocyte is the macrophage rather than the neutrophil. The number of leukocytes declines sharply after the first two to three months, and thereafter, epithelial cells make up a larger portion of the total cell population.",
"   </p>",
"   <p>",
"    Human milk macrophages are capable of chemotaxis, phagocytosis, and secretion of complement, lysozyme and lactoferrin. Both B and T lymphocytes are in human milk and aid in protecting the infant's intestinal tract from invading organisms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=see_link&amp;anchor=H4#H4\">",
"     \"Infant benefits of breastfeeding\", section on 'Anti-microbial components'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SYNTHESIS AND SECRETION OF MILK COMPONENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Milk components are secreted into the alveolar lumen by the combination of five distinct mechanisms. These pathways work in parallel to form",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    transport the milk constituents from the blood, interstitial fluid, or the mammary epithelial cell.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Exocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exocytosis is thought to be the primary mechanism for determining the aqueous composition of milk. In this process, proteins and lactose are synthesized, then transported in vesicles formed by the Golgi complex and secreted into the alveolar lumen. As lactose accumulates with the vesicles, both water and electrolytes enter into the vesicles and are also secreted into the lumen. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Lactose synthesis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Reverse pinocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fat is secreted into the milk by reverse pinocytosis, a process unique to the mammary gland. Lipid formed in the smooth endoplasmic reticulum (ER) coalesces into large droplets. These droplets push against and gradually become enveloped in the apical plasma membrane, finally budding from the cell as a milk-fat globule. A crescent of cytoplasm is often included within the globule and may contain cellular elements such as ER, ribosomes, and mitochondria. Both the lipid droplets and the cellular components (membrane and cytoplasm) contribute to the lipid composition of milk. The membrane fragments are the primary dietary source of phospholipids for breastfed infants [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6519/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Transcytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intact proteins (eg, immunoglobulins, albumin, and hormones) are secreted into the milk by transcytosis. In this process, interstitial proteins bind to receptors at the basal membrane of the alveolar cell are transported across the cell and released at the apical membrane. The prototype for transcytosis is secretory IgA, which is synthesized by plasma cells in the interstitial spaces of the mammary gland. This mechanism is thought to apply to other proteins as well. [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6519/abstract/8\">",
"     8",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Apical transport",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transport across the apical membrane is not a major mechanism of milk secretion and is poorly understood. It is limited to a small number of small molecules, including sodium, potassium, chlorides, some monosaccharides, and water [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6519/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Paracellular movement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some components of interstitial fluid enter the lumen by moving between the alveolar cells in a process known as paracellular movement. During normal lactation, passage of even low molecular weight molecules is impeded by a structure called the tight junction that joins the epithelial cells tightly together.",
"   </p>",
"   <p>",
"    However, immune cells can enter the milk through a process called diapedesis or extravasation. In this process, paracellular movement occurs across a transiently open tight junction that seals tightly behind the cell, leaving no permanent gap and no further movement across the junction.",
"   </p>",
"   <p>",
"    Increased paracellular movement due to increased leakiness of the tight junctions occurs in specific physiologic states (pregnancy, the immediate postpartum period, and mammary involution) and during mastitis. Components of the interstitial fluid (such as sodium and chloride) pass unimpeded into the milk, resulting in elevated milk sodium concentrations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     REGULATION OF MILK PRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Milk production is regulated by the interaction of a number of physical and biochemical forces. In most circumstances, emptying of the breast by the infant's suckling is the most important factor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Breast emptying",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following secretory activation, maintenance of milk production depends upon the removal of milk on a regular basis. Failure to remove milk results in excessive and prolonged accumulation of milk within the alveolar lumen, leading to alveolar distension and elevation of intramammary pressure. This may impede blood flow through the mammary capillaries, reducing the supply of nutrients and stimulatory hormones and decreasing milk production. In addition, increased intramammary pressure disrupts connections between cells and their attachment to the basement membrane, disrupting the synthesis and secretion of milk components [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6519/abstract/9\">",
"     9",
"    </a>",
"    ]. Thus, distension of the mammary gland due to abnormally prolonged interfeeding intervals (such as what might occur when a mother returns to the workforce) reduces milk production. Continued failure to remove milk triggers involution of the gland.",
"   </p>",
"   <p>",
"    Changes in infant demand affect breast emptying and regulate milk production. This is illustrated by a study of the association of lipid content and milk volume [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6519/abstract/10\">",
"     10",
"    </a>",
"    ]. Lipid content was reduced in the milk of nursing mothers with little body fat, so that caloric density was approximately 15 percent lower than milk from well-nourished mothers. &nbsp;Increased suckling of the hungry infant, leading to increased emptying of the breast, was associated with an increased milk volume of 5 to 15 percent.",
"   </p>",
"   <p>",
"    The frequency of stimulation and degree of emptying required for adequate milk production vary with maternal and infant characteristics. Premature infants and infants with abnormal or poorly developed oral-motor musculature or coordination are less able to modulate breast emptying and milk volume. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/4/21576?source=see_link\">",
"     \"Sucking and swallowing disorders in the newborn\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/21/13657?source=see_link\">",
"     \"Breast milk expression for the preterm infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Prolactin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The plasma prolactin concentration increases rapidly during suckling [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6519/abstract/3,11,12\">",
"     3,11,12",
"    </a>",
"    ] and is mediated through stimulation of nerve endings in the nipple-areolar complex. Plasma prolactin concentrations do not correlate with the volume of milk produced [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6519/abstract/11\">",
"     11",
"    </a>",
"    ] and does not appear to regulate milk production. However, the hormone level in the lactocyte may play a role in regulating milk production. In a full breast, there is reduced uptake of plasma prolactin into the lactocyte, whereas, when the breast is emptied, prolactin levels in milk are higher, suggesting higher levels within the lactocyte.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Feedback inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another mechanism that limits milk production is feedback inhibition by a milk protein known as feedback inhibitor of lactation (FIL) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6519/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. FIL is synthesized by mammary epithelial cells in response to increased intramammary pressure and has been isolated from goat, bovine, and human milk. The mechanism of inhibition is reversible blockade of the secretory pathway by down regulation of cell-surface prolactin receptors. In addition to acutely decreasing secretion of milk, FIL may modulate mammary cell differentiation so that a sustained change in milk removal results in a sustained secretory response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Lactose synthesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lactose, the disaccharide unique to milk, is the primary determinant of volume, as it is the major osmotic component of milk [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6519/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. Lactose is formed by lactose synthetase within the Golgi complex from glucose and UDP-galactose and is placed within the Golgi-derived secretory vesicle. The Golgi membrane and the vesicle are both impermeable to lactose. As lactose accumulates within the vesicle, water is drawn into the vesicle to maintain osmotic equilibrium. Contents of the vesicles are released into the milk compartment by exocytosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     MILK EJECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The alveoli are surrounded by a basket-like network of blood vessels and myoepithelial cells. The alveolar lumen serves as a temporary milk-holding reservoir. The lumens empty through a series of increasingly larger ducts within each lobe. The final large central collecting duct from the lobe opens into a nipple pore through which milk leaves the breast (",
"    <a class=\"graphic graphic_figure graphicRef72583 \" href=\"UTD.htm?8/30/8674\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Oxytocin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tactile stimulation of the nipple-areolar complex by the suckling infant leads to afferent signals to the hypothalamus that trigger release of oxytocin. Oxytocin delivered via the blood stream to the mammary gland interacts with its receptor on the myoepithelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6519/abstract/3\">",
"     3",
"    </a>",
"    ]. This results in contraction of the myoepithelial cells, forcing milk into the ducts from the alveolar lumens and out through the nipple. At the same time, the ducts expand rapidly to facilitate milk flow. If the breasts are sufficiently engorged to restrict blood flow to the alveoli, normal milk ejection is blocked. If milk is not removed through the nipple pore, backflow of milk toward the lumen can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6519/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the first several days postpartum, oxytocin release also triggers uterine contractions. These reduce maternal blood loss and promote uterine involution, although they may be painful. In a randomized controlled trial, mothers who initiated frequent feedings immediately after delivery of the placenta experienced less blood loss than those who initiated breastfeeding two hours or more after delivery due to oxytocin release [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6519/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/27/1461?source=see_link&amp;anchor=H3#H3\">",
"     \"Maternal and economic benefits of breastfeeding\", section on 'Lactation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oxytocin also binds to receptors within the brain functioning as a neurotransmitter. A variety of physiological and behavioral effects have been reported, including an animal study that suggested oxytocin's central effects may be important for the initiation of maternal and sexual behaviors [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6519/abstract/17\">",
"     17",
"    </a>",
"    ]. However, species differ in the behavioral effects of oxytocin, perhaps related to differences in the location of oxytocin receptors in the brain [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6519/abstract/18\">",
"     18",
"    </a>",
"    ]. Little data are available regarding the role of oxytocin in human behavior.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/63/34805?source=see_link\">",
"       \"Patient information: Deciding to breastfeed (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/61/37845?source=see_link\">",
"       \"Patient information: Common breastfeeding problems (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/25/17813?source=see_link\">",
"       \"Patient information: Breast pumps (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/54/31588?source=see_link\">",
"       \"Patient information: Maternal health and nutrition during breastfeeding (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The breast is composed of a stroma consisting of fat and connective tissue that supports a tubuloalveolar structure. The breast undergoes anatomic changes involving new lobule formation and maturation during puberty, pregnancy, and lactation, as well as involution including apoptosis after lactation is terminated (",
"      <a class=\"graphic graphic_picture graphicRef76317 \" href=\"UTD.htm?20/50/21284\">",
"       picture 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomic changes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Milk production or lactogenesis occurs in two stages. Stage I, or secretory initiation, takes place during the second half of pregnancy with the formation of fully differentiated secretory units and production of small amounts of milk. Stage II, or secretory activation, occurs after delivery and is marked by the onset of copious milk production. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Milk production'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Milk is a complex fluid with both chemical and cellular components. The major milk components include lactose (main sugar), fat, proteins (casein, alpha-lactalbumin, lactoferrin and secretory IgA) and cells (macrophages, neutrophils, lymphocytes and epithelial cells). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Milk composition'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/36/6727?source=see_link\">",
"       \"Nutritional composition of human milk for full-term infants\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/28/458?source=see_link\">",
"       \"Nutritional composition of human milk and preterm formula for the premature infant\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The synthesis and secretion of components that make up breast milk are carried out by the following five processes: exocytosis, reverse pinocytosis, transcytosis, apical transport, and paracellular movement. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Synthesis and secretion of milk components'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Milk production is primarily regulated by the emptying of the breast. Other important factors include prolactin levels, feedback inhibition, and lactose synthesis. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Regulation of milk production'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Myoepithelial cell contraction, under the influence of oxytocin, forces milk into the ducts from the alveolar lumens. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Milk ejection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Judy Hopkinson, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6519/abstract/1\">",
"      Neville MC. Anatomy and physiology of lactation. Pediatr Clin North Am 2001; 48:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6519/abstract/2\">",
"      Plath A, Einspanier R, Peters F, et al. Expression of transforming growth factors alpha and beta-1 messenger RNA in the bovine mammary gland during different stages of development and lactation. J Endocrinol 1997; 155:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6519/abstract/3\">",
"      Neville MC, McFadden TB, Forsyth I. Hormonal regulation of mammary differentiation and milk secretion. J Mammary Gland Biol Neoplasia 2002; 7:49.",
"     </a>",
"    </li>",
"    <li>",
"     Russo, J, Russo, IH. In: The Mammary Gland, Neville, MC, Daniel, CW, (Eds), Plenum Publishing Corporation, New York 1987. p.67.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6519/abstract/5\">",
"      Dewey KG, Nommsen-Rivers LA, Heinig MJ, Cohen RJ. Risk factors for suboptimal infant breastfeeding behavior, delayed onset of lactation, and excess neonatal weight loss. Pediatrics 2003; 112:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6519/abstract/6\">",
"      Neville MC, Morton J, Umemura S. Lactogenesis. The transition from pregnancy to lactation. Pediatr Clin North Am 2001; 48:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6519/abstract/7\">",
"      Anderson AM. Disruption of lactogenesis by retained placental fragments. J Hum Lact 2001; 17:142.",
"     </a>",
"    </li>",
"    <li>",
"     Lawrence, RA, Lawrence, RM. Breastfeeding, a guide for the medical profession, Mosby, Philadelphia, 2005. p. 966.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6519/abstract/9\">",
"      Nguyen DA, Neville MC. Tight junction regulation in the mammary gland. J Mammary Gland Biol Neoplasia 1998; 3:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6519/abstract/10\">",
"      Butte NF, Villalpando S, Wong WW, et al. Human milk intake and growth faltering of rural Mesoamerindian infants. Am J Clin Nutr 1992; 55:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6519/abstract/11\">",
"      Howie PW, McNeilly AS, McArdle T, et al. The relationship between suckling-induced prolactin response and lactogenesis. J Clin Endocrinol Metab 1980; 50:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6519/abstract/12\">",
"      Johnston JM, Amico JA. A prospective longitudinal study of the release of oxytocin and prolactin in response to infant suckling in long term lactation. J Clin Endocrinol Metab 1986; 62:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6519/abstract/13\">",
"      Wilde CJ, Addey CV, Bryson JM, et al. Autocrine regulation of milk secretion. Biochem Soc Symp 1998; 63:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6519/abstract/14\">",
"      Peaker M, Wilde CJ. Feedback control of milk secretion from milk. J Mammary Gland Biol Neoplasia 1996; 1:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6519/abstract/15\">",
"      Ramsay DT, Kent JC, Owens RA, Hartmann PE. Ultrasound imaging of milk ejection in the breast of lactating women. Pediatrics 2004; 113:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6519/abstract/16\">",
"      Sobhy SI, Mohame NA. The effect of early initiation of breast feeding on the amount of vaginal blood loss during the fourth stage of labor. J Egypt Public Health Assoc 2004; 79:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6519/abstract/17\">",
"      Insel TR, Young L, Wang Z. Central oxytocin and reproductive behaviours. Rev Reprod 1997; 2:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6519/abstract/18\">",
"      Insel TR, Gingrich BS, Young LJ. Oxytocin: who needs it? Prog Brain Res 2001; 133:59.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4999 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.69.132.100-BE5EBB4FC7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_23_6519=[""].join("\n");
var outline_f6_23_6519=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMIC CHANGES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Early pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Later pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Labor and lactation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Involution",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MILK PRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Lactogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Secretory initiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Secretory activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Maintenance of lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MILK COMPOSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SYNTHESIS AND SECRETION OF MILK COMPONENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Exocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Reverse pinocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Transcytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Apical transport",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Paracellular movement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      REGULATION OF MILK PRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Breast emptying",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Prolactin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Feedback inhibition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Lactose synthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      MILK EJECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Oxytocin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/4999\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/4999|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/30/8674\" title=\"figure 1\">",
"      Breastfeeding anatomy PI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/4999|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/39/38517\" title=\"picture 1\">",
"      Type 1 breast lobule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/50/21284\" title=\"picture 2\">",
"      Development of mammary gland",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/54/9060\" title=\"picture 3\">",
"      Type 2 breast lobule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/24/13699\" title=\"picture 4\">",
"      Type 3 breast lobule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/40/23174\" title=\"picture 5\">",
"      Type 4 breast lobule",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20649?source=related_link\">",
"      Breast development and morphology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/21/13657?source=related_link\">",
"      Breast milk expression for the preterm infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=related_link\">",
"      Infant benefits of breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/27/1461?source=related_link\">",
"      Maternal and economic benefits of breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/28/458?source=related_link\">",
"      Nutritional composition of human milk and preterm formula for the premature infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/36/6727?source=related_link\">",
"      Nutritional composition of human milk for full-term infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/25/17813?source=related_link\">",
"      Patient information: Breast pumps (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/61/37845?source=related_link\">",
"      Patient information: Common breastfeeding problems (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/63/34805?source=related_link\">",
"      Patient information: Deciding to breastfeed (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/54/31588?source=related_link\">",
"      Patient information: Maternal health and nutrition during breastfeeding (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/4/21576?source=related_link\">",
"      Sucking and swallowing disorders in the newborn",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_23_6520="Toxocariasis life cycle";
var content_f6_23_6520=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F51830&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F51830&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 632px\">",
"   <div class=\"ttl\">",
"    Toxocariasis life cycle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 612px; height: 460px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <em>",
"     Toxocara canis",
"    </em>",
"    accomplishes its life cycle in dogs, with humans acquiring the infection as accidental hosts. Unembryonated eggs are shed in the feces of the definitive host",
"    <strong>",
"     (1)",
"    </strong>",
"    . Eggs embryonate and become infective in the environment",
"    <strong>",
"     (2)",
"    </strong>",
"    . Following ingestion by dogs",
"    <strong>",
"     (3)",
"    </strong>",
"    , the infective eggs hatch and larvae penetrate the gut wall. In younger dogs, the larvae migrate through the lungs, bronchial tree, and esophagus; adult worms develop and oviposit in the small intestine",
"    <strong>",
"     (4)",
"    </strong>",
"    . In older dogs, patent infections can also occur, but larval encystment in tissues is more common. Encysted stages are reactivated in female dogs during late pregnancy and infect by the transplacental and transmammary routes the puppies",
"    <strong>",
"     (5)",
"    </strong>",
"    , in whose small intestine adult worms become established",
"    <strong>",
"     (6)",
"    </strong>",
"    . Puppies are a major source of environmental egg contamination.",
"    <em>",
"     Toxocara canis",
"    </em>",
"    can also be transmitted through ingestion of paratenic hosts: eggs ingested by small mammals (eg, rabbits) hatch and larvae penetrate the gut wall and migrate into various tissues where they encyst",
"    <strong>",
"     (7)",
"    </strong>",
"    . The life cycle is completed when dogs eat these hosts",
"    <strong>",
"     (8)",
"    </strong>",
"    and the larvae develop into egg-laying adult worms in the small intestine. Humans are accidental hosts who become infected by ingesting infective eggs in contaminated soil",
"    <strong>",
"     (9)",
"    </strong>",
"    or infected paratenic hosts",
"    <strong>",
"     (10)",
"    </strong>",
"    . After ingestion, the eggs hatch and larvae penetrate the intestinal wall and are carried by the circulation to a wide variety of tissues (liver, heart, lungs, brain, muscle, eyes)",
"    <strong>",
"     (11)",
"    </strong>",
"    . While the larvae do not undergo any further development in these sites, they can cause severe local reactions that are the basis of toxocariasis. The two main clinical presentations of toxocariasis are visceral larva migrans and ocular larva migrans. Diagnosis is usually made by serology or the finding of larvae in biopsy or autopsy specimens.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Toxocariasis. Available at:",
"     <a href=\"file://www.dpd.cdc.gov/dpdx/html/Toxocariasis.htm\" target=\"_blank\">",
"      file://www.dpd.cdc.gov/dpdx/html/Toxocariasis.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_23_6520=[""].join("\n");
var outline_f6_23_6520=null;
var title_f6_23_6521="Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegeners) and microscopic polyangiitis";
var content_f6_23_6521=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/23/6521/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/23/6521/contributors\">",
"     John H Stone, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/23/6521/contributors\">",
"     Ronald J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/23/6521/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/23/6521/contributors\">",
"     Gerald B Appel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/23/6521/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/23/6521/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/23/6521/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H14726233\">",
"    <span class=\"h1\">",
"     NEW TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In January 2011, the Boards of Directors of the American College of Rheumatology, the American Society of Nephrology, and the European League Against Rheumatism recommended that the name Wegener&rsquo;s granulomatosis be changed to granulomatosis with polyangiitis (Wegener&rsquo;s), abbreviated as GPA [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6521/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. This change reflects a plan to gradually shift from honorific eponyms to a disease-descriptive or etiology-based nomenclature. The parenthetic reference to Wegener&rsquo;s will be phased out after several years as the new name becomes more widely known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granulomatosis with polyangiitis (Wegener's), abbreviated as GPA, and microscopic polyangiitis (MPA) are related systemic vasculitides. Both are associated with antineutrophil cytoplasmic antibodies (ANCA), have similar features on renal histology (eg, a focal necrotizing, pauci-immune glomerulonephritis), and have similar outcomes. There are, however, several differences between these disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link&amp;anchor=H11698538#H11698538\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Therapy of GPA and MPA has two components: induction of remission with initial immunosuppressive therapy; and maintenance immunosuppressive therapy for a variable period to prevent relapse.",
"   </p>",
"   <p>",
"    Maintenance immunosuppressive therapy of GPA and MPA will be reviewed here. Initial immunosuppressive therapy, the treatment of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    resistant or relapsing disease, clinical manifestations and diagnosis, and patient and renal outcomes are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3321?source=see_link\">",
"     \"Treatment of cyclophosphamide-resistant granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/58/9130?source=see_link\">",
"     \"Relapsing disease in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=see_link\">",
"     \"Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24824?source=see_link\">",
"     \"Patient and renal outcomes in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    has significant treatment-related toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6521/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Thus, after attainment of remission, almost all patients with granulomatosis with polyangiitis (Wegener&rsquo;s) or microscopic polyangiitis (GPA or MPA) are switched to a less toxic non-cyclophosphamide maintenance regimen, most often",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , to reduce the risk of relapse. A notable exception is drug-induced ANCA-associated vasculitis in which relapse should not occur if the responsible drug is discontinued. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\", section on 'Drug-induced ANCA-associated vasculitis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Assessment of disease activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disease activity can be assessed by use of the Birmingham Vasculitis Activity Score (BVAS) that has been applied to patients with GPA [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6521/abstract/6\">",
"     6",
"    </a>",
"    ]. Complete remission is defined as a",
"    <span class=\"nowrap\">",
"     BVAS/GPA",
"    </span>",
"    score of 0, which generally means there is no clinical, radiologic, or pathologic evidence of active disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6521/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complete remission does NOT mean that all parameters have to return to baseline, since persistent abnormalities may reflect irreversible injury induced during the period of active inflammation. As an example, a patient in whom the systemic symptoms and signs resolve and the urine sediment becomes inactive is considered to be in remission, even if there is persistent proteinuria or persistent or even slowly worsening renal insufficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link&amp;anchor=H4#H4\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Definition of complete remission'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Monitoring serum ANCA titers alone is NOT helpful in assessing disease activity. In the largest prospective study, the correlation between changes in disease activity and ANCA levels was evaluated in 156 patients with GPA enrolled during periods of active disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6521/abstract/8\">",
"     8",
"    </a>",
"    ]. Changes in ANCA levels explained less than 10 percent of the variation in disease activity. In addition, only about 40 percent of patients relapsed within one year of an increase in PR3-ANCA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/58/9130?source=see_link&amp;anchor=H8#H8\">",
"     \"Relapsing disease in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\", section on 'ANCA titers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some clinicians monitor changes in&nbsp;the ANCA&nbsp;titer along with changes in the ESR and CRP levels as indicators of disease activity.",
"   </p>",
"   <p>",
"    The combination of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and glucocorticoids induces remission in 85 to 90 percent of patients, with approximately 75 percent experiencing complete remission, usually within three to six months after the initiation of cyclophosphamide and glucocorticoid therapy. Patients in whom remission is not attained within six months may be maintained on cyclophosphamide for a few more months unless toxicity is limiting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link&amp;anchor=H15#H15\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Rate and time to remission'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MAINTENANCE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preferred drugs for maintenance therapy in patients who have attained a complete or remission with a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    -based regimen are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , which seem to have equal efficacy. Glucocorticoids do not appear to provide benefit during maintenance therapy, and tapering should begin once there is a significant response to initial immunosuppressive therapy. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Glucocorticoid therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Some patients who present with or develop dialysis-dependent renal failure show no evidence of return of renal function after two to three months of immunosuppressive drug therapy. In such patients, excess immunosuppression should be AVOIDED to minimize morbidity and mortality unless indicated for extrarenal manifestations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24824?source=see_link\">",
"     \"Patient and renal outcomes in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weekly oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    can be used for maintenance therapy after induction of remission with a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    -based regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6521/abstract/9-13\">",
"     9-13",
"    </a>",
"    ]. The potential efficacy of methotrexate was illustrated in a series of 42 patients in whom remission was induced with cyclophosphamide and glucocorticoids (at a median period of three months) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6521/abstract/11\">",
"     11",
"    </a>",
"    ]. Patients with a persistent serum creatinine above 2.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (221",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    at the time of remission were excluded from the study.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    was started within one to two days of the last",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    dose at an oral dose of 0.3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per week (maximum dose 15 mg). If tolerated, the dose was increased in 2.5 mg increments each week to a dose of 20 to 25 mg per week. Patients were also treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    (5 to 10 mg) once per week given 24 hours after methotrexate. If remission was sustained for two years or longer, methotrexate was tapered by 2.5 mg each month until discontinuation.",
"   </p>",
"   <p>",
"    The following findings were noted at a median follow-up of 32 months [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6521/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One patient died from a cause unrelated to vasculitis, two were withdrawn because of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      pneumonitis, and one was lost to follow-up.",
"     </li>",
"     <li>",
"      Relapse occurred in 22 (58 percent) of the remaining 38 patients. Among 16 patients with a renal relapse, only four had elevations in serum creatinine, all of whom returned to baseline kidney function following retreatment.",
"     </li>",
"     <li>",
"      Of the 16 patients who did not relapse, 15 were in remission a median period of 16 months after all immunosuppressive therapy had been discontinued. The remaining patient was being tapered off",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      after two years of remission.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The effectiveness of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    in maintaining remission is lower in patients who are not treated initially with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . This was illustrated in the randomized NORAM trial, which used methotrexate and cyclophosphamide for both induction and maintenance of remission in patients with early clinical disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6521/abstract/14\">",
"     14",
"    </a>",
"    ]. Patients with a serum creatinine &ge;1.7",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (150",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    were excluded. Treatment with oral methotrexate for 12 months was associated with a significantly higher relapse rate at 18 months than cyclophosphamide for 12 months (70 versus 47 percent).",
"   </p>",
"   <p>",
"    In summary,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    appears to be reasonably effective in maintaining a remission in patients with no or mild renal disease who are initially treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . However, prolonged treatment is required. In addition, use of methotrexate for both induction and maintenance immunosuppression is associated with a high relapse rate.",
"   </p>",
"   <p>",
"    Given the risk of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    toxicity in patients with impaired renal function,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    is preferred to methotrexate in patients with an estimated GFR less than 50",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    The major side effects of low-dose methotrexate therapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Azathioprine",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have evaluated the efficacy of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    for maintenance of remission in patients with granulomatosis with polyangiitis (Wegener's), abbreviated as GPA, or MPA [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6521/abstract/7,15-17\">",
"     7,15-17",
"    </a>",
"    ]. This was best shown in the CYCAZAREM trial of 155 patients with ANCA-positive vasculitis who received induction therapy with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    (initial 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day and tapered to 0.25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day by 12 weeks) for a minimum period of three months [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6521/abstract/15\">",
"     15",
"    </a>",
"    ]. The 144 patients in whom remission was achieved (77 and 16 percent in three months and between three and six months, respectively) were randomly assigned to either continued cyclophosphamide (1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) or azathioprine (2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day); prednisolone was also given at 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in each regimen. At one year, both groups were treated with azathioprine (1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) plus prednisolone (7.5",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"   </p>",
"   <p>",
"    At",
"    18 months, the rates of relapse were not significantly different with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (15.5 versus 13.7 percent) and, during the maintenance phase, both groups had a similar number of severe adverse events (eight and seven patients, respectively).",
"   </p>",
"   <p>",
"    In contrast to these findings, the rate of relapse with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or, in patients with a serum creatinine concentration less than 2.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (177",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    was much higher (57 percent) in the Wegener's Granulomatosis",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     Etanercept",
"    </a>",
"    Trial (WGET) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6521/abstract/7\">",
"     7",
"    </a>",
"    ]. The proportion of relapses that were severe was also higher than in CYCAZAREM (22 versus 7 percent). The addition of etanercept to azathioprine or methotrexate had no effect on the rate of relapse.",
"   </p>",
"   <p>",
"    A number of factors may have contributed to the higher rate of relapse in WGET [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6521/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A relapse in WGET required only one minor manifestation compared to three minor manifestations in CYCAZAREM.",
"     </li>",
"     <li>",
"      MPA, which is less likely to relapse than GPA, was present in 39 percent of patients in CYCAZAREM compared to none in WGET.",
"     </li>",
"     <li>",
"      Not all patients received induction therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , as those with limited disease were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      The duration of follow-up was longer in WGET (27 versus 18 months in CYCAZAREM).",
"     </li>",
"     <li>",
"      Patients continued to receive 7.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"       prednisolone",
"      </a>",
"      in CYCAZAREM. In contrast, glucocorticoid therapy was terminated after six months in WGET if the patients were in clinical remission.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Azathioprine versus methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    provide comparable efficacy and are similarly safe when administered for maintenance therapy. In the only well-designed trial (WEGENT) that directly compared these agents, 126 patients with GPA or MPA who were in remission after treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and oral glucocorticoids were randomly assigned to azathioprine (2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) or methotrexate (0.3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per week, progressively increased by 2.5 mg every week to a maximum of 25 mg per week) for 12 months followed by gradual withdrawal over three months [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6521/abstract/18\">",
"     18",
"    </a>",
"    ]. The mean serum creatinine was approximately 2.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (176",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    at baseline and 1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (129",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    at randomization.",
"   </p>",
"   <p>",
"    At a mean follow-up of 29 months, both drugs were associated with a similar number of adverse effects that required drug discontinuation (11 and 19 percent for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , respectively) and a similar relapse rate (36 and 33 percent). The majority of relapses (73 percent) occurred after the cessation of maintenance therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64742581\">",
"    <span class=\"h2\">",
"     Azathioprine versus mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    appears to be more effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (MMF) in maintaining remission. This was shown in an open-label, randomized multicenter trial (IMPROVE) that included 156 patients with newly diagnosed ANCA-associated vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6521/abstract/19\">",
"     19",
"    </a>",
"    ]. After induction of remission with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and glucocorticoids, patients received either azathioprine (starting at 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, then reduced to 1.5 and 1.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day after 12 and 18 months, respectively) or MMF (starting at 2000 mg per day and reduced to 1500 and 1000 mg per day after 12 and 18 months respectively). Both agents were withdrawn after 42 months of treatment. At a median follow-up of 39 months, relapses were significantly less frequent among those who received azathioprine (38 versus 55 percent, adjusted hazard ratio 0.56, 95% CI 0.34-0.91). The rate of adverse events was not significantly different for those who received azathioprine (16 versus 8 percent, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Choice of maintenance agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;As indicated by the preceding observations,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    appear to have equivalent efficacy for maintaining remission in patients with GPA or MPA and appear to be associated with a similar rate of adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6521/abstract/18\">",
"     18",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil does not appear to be as effective as azathioprine in maintaining remission and no trials have directly compared MMF and methotrexate [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6521/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most nephrologists prefer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , in part because they have limited or no experience with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    . In contrast, rheumatologists have extensive experience with methotrexate in rheumatoid arthritis and other rheumatic diseases and are therefore comfortable with both drugs.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    is preferred in women who want to become pregnant, since",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    is contraindicated in pregnancy. The choice between these drugs may also be affected by renal function, since methotrexate requires dose adjustment and is more difficult to use in patients with a substantially reduced glomerular filtration rate (GFR). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=see_link&amp;anchor=H9#H9\">",
"     \"Use of methotrexate in the treatment of rheumatoid arthritis\", section on 'Dosing of MTX'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In different studies, patients were excluded from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    therapy if the serum creatinine was above 1.7",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (150",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6521/abstract/14\">",
"     14",
"    </a>",
"    ], 2.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (177",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6521/abstract/7,12\">",
"     7,12",
"    </a>",
"    ], or 2.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (221",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6521/abstract/11\">",
"     11",
"    </a>",
"    ], and, in the trial directly comparing methotrexate to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    for maintenance therapy, there was no mentioned exclusion criteria for serum creatinine, but almost all patients had a serum creatinine less than 2.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (221",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    at randomization [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6521/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is difficult to use the serum creatinine to determine which patients should be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    rather than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , since the relationship between the serum creatinine and GFR varies importantly with muscle mass. This and other factors are partially taken into account with estimation equations, such as MDRD (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/61/10194?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) and Cockcroft-Gault (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?29/57/30609?source=see_link\">",
"     calculator 2",
"    </a>",
"    ). These equations can only be used in patients with a stable serum creatinine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=see_link&amp;anchor=H20659769#H20659769\">",
"     \"Assessment of kidney function\", section on 'Estimation equations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    rather than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    for maintenance therapy in patients with an estimated GFR below 50",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    In patients who cannot tolerate azathioprine, we suggest switching to methotrexate if the estimated GFR is greater than 30 to 40",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    Although data are limited,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil is preferred if neither azathioprine nor methotrexate can be used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32727?source=see_link&amp;anchor=H6#H6\">",
"     \"Alternative agents in the treatment of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Mycophenolate mofetil'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Initiation of maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    induction therapy is usually continued for one to two months after the first documentation of remission, as defined above. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Assessment of disease activity'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Maintenance therapy should not be started until",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    has been discontinued, since excess immunosuppression can lead to neutropenia and infection. The risk of infection is increased when the absolute neutrophil count is less than 1000",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef63903 \" href=\"UTD.htm?10/19/10555\">",
"     table 1",
"    </a>",
"    ). The absolute neutrophil count is equal to the product of the total white blood cell count and the fraction of polymorphonuclear cells and band forms noted on the differential analysis (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?12/1/12305?source=see_link\">",
"     calculator 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The time period between cessation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and initiation of maintenance therapy varies with the cyclophosphamide induction regimen that was used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients treated with daily oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      for induction of remission, maintenance therapy can be started as soon as the following criteria are met after the cessation of cyclophosphamide: the white blood cell count is &gt;4000",
"      <span class=\"nowrap\">",
"       cells/microL;",
"      </span>",
"      and the absolute neutrophil count is &gt;1500",
"      <span class=\"nowrap\">",
"       cells/microL.",
"      </span>",
"      In some patients, maintenance therapy can be started the day after oral cyclophosphamide is stopped.",
"     </li>",
"     <li>",
"      For patients treated with monthly intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , maintenance therapy, maintenance therapy is started at two to four weeks (the time of the leukocyte nadir) after the last dose of cyclophosphamide if the above criteria are met.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Duration of maintenance therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance therapy in patients with newly diagnosed GPA or MPA is usually given for 12 to 18 months after stable remission has been induced [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6521/abstract/7,15,18\">",
"     7,15,18",
"    </a>",
"    ]. However, there are no randomized trials that have compared different durations of maintenance therapy. Furthermore, risk factors for relapse have been identified. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/58/9130?source=see_link&amp;anchor=H4#H4\">",
"     \"Relapsing disease in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The magnitude of the effect of risk factors was evaluated in a series of 258 patients with newly diagnosed ANCA-associated vasculitis who attained remission [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6521/abstract/20\">",
"     20",
"    </a>",
"    ]. Antiproteinase-3 (PR3)-ANCA compared to antimyeloperoxidase (MPO)-ANCA, and upper respiratory tract",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pulmonary involvement were each associated with a significantly increased risk of relapse (hazard ratio 1.71 to 1.87). Upper respiratory tract involvement was considered likely with clinical or radiologic studies showing sinusitis, otitis media, nasal crusting",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    subglottic disease, Pulmonary involvement was defined by the presence of hemoptysis, pulmonary hemorrhage, respiratory failure, nodules,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cavities without evidence of infection.",
"   </p>",
"   <p>",
"    The rate of relapse was much higher in patients with all three of these risk factors compared to those with none (73 percent at a median of 17 months versus 26 percent at a much longer median of 62 months). The duration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    induction therapy (&le;6 versus &gt;6 months) was NOT a significant risk factor for relapse, even in patients at high risk.",
"   </p>",
"   <p>",
"    Based upon such observations, some experts would vary the duration of maintenance therapy, based upon the estimated risk of relapse. As an example, some suggest continuing maintenance therapy after induction of remission in new onset disease for three years or more in patients with PR3-ANCA. In addition, prolonged or even indefinite immunosuppressive therapy may be warranted in patients with multiple relapses.",
"   </p>",
"   <p>",
"    Some clinicians believe that a shorter duration of maintenance therapy (eg, six to nine months) can be given to patients at very low risk for relapse, such as those with MPO-ANCA and no upper respiratory tract or pulmonary involvement as confirmed by chest CT scan. However, we are concerned about the ability to replicate these findings outside of centers with expertise in ANCA-associated vasculitis.",
"   </p>",
"   <p>",
"    Patients who progress to end-stage renal disease and are treated with chronic dialysis have a substantially lower rate of relapse than the same patients before they reached end-stage renal disease or patients with preserved renal function. In addition, maintenance therapy is associated with an increased risk of infection in dialysis patients. As a result, a shorter duration of maintenance therapy is suggested in such patients. The rate of relapse is even lower in patients who receive a renal transplantation, presumably due to the immunosuppressive therapy given to prevent rejection. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/58/9130?source=see_link&amp;anchor=H16#H16\">",
"     \"Relapsing disease in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\", section on 'Chronic renal replacement therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Glucocorticoid therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low-dose oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (or its equivalent) is initially continued in most patients receiving maintenance therapy. The goal is to attain the minimum prednisone dose required for control of systemic symptoms, and varies among patients. We strongly prefer daily to alternate day prednisone therapy, since most patients develop aches and pains on the on the off day. However, some patients tolerate alternate day therapy, which is begun when the daily prednisone dose is 5 to 10",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p>",
"    Patients",
"    who remain asymptomatic can be slowly tapered off",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    . Once the prednisone dose reaches 5",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    tapering should proceed at a rate of 1",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    reduction in dose every four weeks.",
"   </p>",
"   <p>",
"    The median duration of glucocorticoid therapy is less than six to eight months [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6521/abstract/7,21\">",
"     7,21",
"    </a>",
"    ]. However, some experts recommend long-term, low dose maintenance therapy in patients who have had multiple relapses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/58/9130?source=see_link\">",
"     \"Relapsing disease in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of drugs other than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    have been evaluated for maintenance therapy in GPA and MPA. These include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (MMF),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , and, in selected patients, possibly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The main indications for the use of MMF or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    for maintenance therapy are an inability to tolerate or relative contraindications to both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    or continued relapses despite use of these drugs. Based upon the available data, the authors of this topic prefer MMF ahead of rituximab due in part to uncertain long-term dosing and higher cost, but some of the reviewers prefer rituximab. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32727?source=see_link\">",
"     \"Alternative agents in the treatment of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    as maintenance therapy is unproven, but a trial may be reasonable in patients with disease limited to the upper respiratory tract [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6521/abstract/22\">",
"     22",
"    </a>",
"    ]. An appreciable proportion of patients treated with trimethoprim-sulfamethoxazole maintenance (20 percent in one trial) discontinue therapy due to side effects, most of which are minor (anorexia, nausea, rash) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6521/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32727?source=see_link&amp;anchor=H4#H4\">",
"     \"Alternative agents in the treatment of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Trimethoprim-sulfamethoxazole'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     Etanercept",
"    </a>",
"    should NOT be used for maintenance therapy, since there was no benefit in the WGET trial mentioned above [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6521/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     PCP prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    for induction of remission, we continue PCP prophylaxis until the CD4-positive T cell count exceeds",
"    <span class=\"nowrap\">",
"     300/microL.",
"    </span>",
"    The suggested regimens are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link&amp;anchor=H26#H26\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'PCP prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/15/27889?source=see_link\">",
"       \"Patient information: Granulomatosis with polyangiitis (Wegener&rsquo;s) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/22/44389?source=see_link\">",
"       \"Patient information: Vasculitis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of granulomatosis with polyangiitis (Wegener's), abbreviated as GPA, and microscopic polyangiitis (MPA) usually begins with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and glucocorticoid therapy to induce remission. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=see_link\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    is discontinued one to two months after complete remission is achieved, which usually occurs within three to six months. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Assessment of disease activity'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    After",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    has been discontinued:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maintenance therapy should not be started until the white blood cell count is &gt;4000",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      and the absolute neutrophil count is &gt;1500",
"      <span class=\"nowrap\">",
"       cells/microL.",
"      </span>",
"      If these criteria are met, maintenance can be begun within days after cessation of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      and within two to four weeks after the last monthly dose of intravenous cyclophosphamide (the time of the leukocyte nadir). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Initiation of maintenance therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend initiation of maintenance therapy with either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      to sustain the remission (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). These drugs are preferred to long-term",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      therapy, which is associated with significantly greater toxicity. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Azathioprine versus methotrexate'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      for initial maintenance therapy in patients with an estimated GFR less than 50",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Choice of maintenance agent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       Azathioprine",
"      </a>",
"      is administered at an initial dose of 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in most patients. The dose can be lowered to 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day at one year from the time of initiation of induction therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?6/23/6521/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Azathioprine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      is used, one regimen consists of an initial dose of 0.3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      once per week (maximum 15 mg) that is progressively increased by 2.5 mg per week to a maximum dose of 25 mg once per week. Because methotrexate is a structural analogue of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      that can competitively inhibit the binding of dihydrofolic acid (FH2) to the enzyme dihydrofolate reductase (DHFR), folic acid (1 to 2",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or folinic acid (2.5 to 5",
"      <span class=\"nowrap\">",
"       mg/week,",
"      </span>",
"      24 hours after methotrexate) should be given concurrently to reduce potential toxicity. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Methotrexate'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maintenance immunosuppressive therapy should be continued for 12 to 18 months. Longer term or indefinite maintenance therapy may be warranted in patients with multiple relapses. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Duration of maintenance therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend concurrent glucocorticoid therapy (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      or equivalent), using the lowest dose required for control of extrarenal symptoms (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Patients who remain asymptomatic can be slowly tapered off glucocorticoid therapy. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Glucocorticoid therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6521/abstract/1\">",
"      Falk RJ, Gross WL, Guillevin L, et al. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. J Am Soc Nephrol 2011; 22:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6521/abstract/2\">",
"      Falk RJ, Gross WL, Guillevin L, et al. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Arthritis Rheum 2011; 63:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6521/abstract/3\">",
"      Falk RJ, Gross WL, Guillevin L, et al. Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Ann Rheum Dis 2011; 70:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6521/abstract/4\">",
"      Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6521/abstract/5\">",
"      Andrassy K, Erb A, Koderisch J, et al. Wegener's granulomatosis with renal involvement: patient survival and correlations between initial renal function, renal histology, therapy and renal outcome. Clin Nephrol 1991; 35:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6521/abstract/6\">",
"      Mahr AD, Neogi T, Lavalley MP, et al. Assessment of the item selection and weighting in the Birmingham vasculitis activity score for Wegener's granulomatosis. Arthritis Rheum 2008; 59:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6521/abstract/7\">",
"      Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6521/abstract/8\">",
"      Finkielman JD, Merkel PA, Schroeder D, et al. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med 2007; 147:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6521/abstract/9\">",
"      de Groot K, Reinhold-Keller E, Tatsis E, et al. Therapy for the maintenance of remission in sixty-five patients with generalized Wegener's granulomatosis. Methotrexate versus trimethoprim/sulfamethoxazole. Arthritis Rheum 1996; 39:2052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6521/abstract/10\">",
"      Langford CA, Talar-Williams C, Barron KS, Sneller MC. A staged approach to the treatment of Wegener's granulomatosis: induction of remission with glucocorticoids and daily cyclophosphamide switching to methotrexate for remission maintenance. Arthritis Rheum 1999; 42:2666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6521/abstract/11\">",
"      Langford CA, Talar-Williams C, Barron KS, Sneller MC. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 2003; 114:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6521/abstract/12\">",
"      Villa-Forte A, Clark TM, Gomes M, et al. Substitution of methotrexate for cyclophosphamide in Wegener granulomatosis: a 12-year single-practice experience. Medicine (Baltimore) 2007; 86:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6521/abstract/13\">",
"      Metzler C, Miehle N, Manger K, et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford) 2007; 46:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6521/abstract/14\">",
"      De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52:2461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6521/abstract/15\">",
"      Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6521/abstract/16\">",
"      Gaskin G, Savage CO, Ryan JJ, et al. Anti-neutrophil cytoplasmic antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis. Nephrol Dial Transplant 1991; 6:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6521/abstract/17\">",
"      Hoffman GS. Treatment of Wegener's granulomatosis: time to change the standard of care? Arthritis Rheum 1997; 40:2099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6521/abstract/18\">",
"      Pagnoux C, Mahr A, Hamidou MA, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008; 359:2790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6521/abstract/19\">",
"      Hiemstra TF, Walsh M, Mahr A, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA 2010; 304:2381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6521/abstract/20\">",
"      Hogan SL, Falk RJ, Chin H, et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 2005; 143:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6521/abstract/21\">",
"      Langford CA, Talar-Williams C, Sneller MC. Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum 2000; 43:1836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6521/abstract/22\">",
"      Stegeman, CA, Cohen Tervaert, JW, de Jong, PE, Kallenberg, CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 1996; 335:16.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3096 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-3A7D25EF8E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_23_6521=[""].join("\n");
var outline_f6_23_6521=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14726233\">",
"      NEW TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Assessment of disease activity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MAINTENANCE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Azathioprine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Azathioprine versus methotrexate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64742581\">",
"      Azathioprine versus mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Choice of maintenance agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Initiation of maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Duration of maintenance therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Glucocorticoid therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PCP prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3096\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3096|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/19/10555\" title=\"table 1\">",
"      Neutropenia and infectious risk",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/61/10194?source=related_link\" title=\"calculator 1\">",
"      Calculator: Glomerular filtration rate estimate by abbreviated MDRD study equation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?29/57/30609?source=related_link\" title=\"calculator 2\">",
"      Calculator: Creatinine clearance estimate by Cockcroft-Gault equation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?12/1/12305?source=related_link\" title=\"calculator 3\">",
"      Calculator: Absolute neutrophil count",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/61/32727?source=related_link\">",
"      Alternative agents in the treatment of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17386?source=related_link\">",
"      Clinical manifestations and diagnosis of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=related_link\">",
"      Clinical spectrum of antineutrophil cytoplasmic antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/32/34314?source=related_link\">",
"      Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24824?source=related_link\">",
"      Patient and renal outcomes in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/15/27889?source=related_link\">",
"      Patient information: Granulomatosis with polyangiitis (Wegener&rsquo;s) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/22/44389?source=related_link\">",
"      Patient information: Vasculitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/58/9130?source=related_link\">",
"      Relapsing disease in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3321?source=related_link\">",
"      Treatment of cyclophosphamide-resistant granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=related_link\">",
"      Use of methotrexate in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_23_6522="Structure and function of the insulin receptor";
var content_f6_23_6522=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Structure and function of the insulin receptor",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/23/6522/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/23/6522/contributors\">",
"     Jonathan Whittaker, MD, MRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/23/6522/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/23/6522/contributors\">",
"     Irl B Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/23/6522/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/23/6522/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/23/6522/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin initiates its cellular responses by binding to its cellular receptor, a transmembrane, multi-subunit glycoprotein that contains insulin-stimulated tyrosine kinase activity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/1\">",
"     1",
"    </a>",
"    ]. The cellular content of insulin receptors is variable, with the highest level of expression in cells that are most responsive to insulin for glucose, lipid, and protein metabolism, especially adipose, skeletal muscle, and liver. Initially identified over 25 years ago [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/2\">",
"     2",
"    </a>",
"    ], the insulin receptor cDNA was cloned in 1985 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Crystal structures of its protein tyrosine and of its extracellular domains were determined in 1994 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/5\">",
"     5",
"    </a>",
"    ] and 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/6\">",
"     6",
"    </a>",
"    ], respectively. Since insulin has profound importance in metabolic control, studies of its receptor protein have been the subject of intense investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EXPRESSION AND SUBUNIT STRUCTURE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Receptor gene and mRNA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The insulin receptor gene maps to human chromosome 19 and spans more than 150 kilobases (kb) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/8\">",
"     8",
"    </a>",
"    ]. The 22 exons of the receptor gene are transcribed into several mRNA species ranging from 4.2 to 9.5 kb in length due to variation in their 3'-untranslated regions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/9\">",
"     9",
"    </a>",
"    ]. Exon 11, which encodes a 12 amino acid segment localized to the C-terminus of the &alpha;-subunit, is subject to tissue-specific alternative splicing in a pattern conserved between humans and lower mammals (",
"    <a class=\"graphic graphic_figure graphicRef72096 \" href=\"UTD.htm?42/44/43724\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The abundance of receptor mRNA and protein are up-regulated by differentiation of adipocyte and muscle precursor cells as they acquire an insulin-sensitive phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/13\">",
"     13",
"    </a>",
"    ]. In some cells, exposure to insulin reduces receptor mRNA abundance, which may play a role in regulation of receptor number in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. In rare cases of severe insulin resistance due to mutations in the receptor gene, extreme reduction in receptor abundance has been shown [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/16\">",
"     16",
"    </a>",
"    ]. However, altered receptor abundance is not believed to play a major role in common forms of insulin resistance in obesity or type 2 diabetes.",
"   </p>",
"   <p>",
"    The primary translation product of the insulin receptor mRNA is a linear &alpha;-&szlig; sequence of the insulin receptor precursor (proreceptor). The signal sequence of 27 hydrophobic amino acids at the N-terminus of the &alpha;-subunit allows the receptor to enter the endoplasmic reticulum, during which process the signal peptide is cleaved. The proreceptor is further proteolytically-processed by furin in the Golgi apparatus into distinct &alpha; and &szlig;-subunits at a cleavage site consisting of four basic amino acids (Arg-Lys-Arg-Arg) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/17-20\">",
"     17-20",
"    </a>",
"    ], apparently after disulfide linkage of two proreceptor molecules [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Receptor structure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The receptor is composed of two extracellular &alpha;-subunits that are each linked to a &szlig;-subunit and to each other by disulfide bonds (",
"    <a class=\"graphic graphic_figure graphicRef58299 \" href=\"UTD.htm?40/38/41568\">",
"     figure 2",
"    </a>",
"    ). Reduction of the bonds that link the &alpha;-subunits produces an &alpha;-&szlig; monomer that binds insulin with reduced affinity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/22,23\">",
"     22,23",
"    </a>",
"    ] and that is devoid of insulin stimulated tyrosine kinase activity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Reconstitution of such hetero-dimers into hetero-tetramers restores both high affinity insulin binding and insulin stimulated kinase activity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mature &alpha;-subunit contains either 719 or 731 amino acids (due to alternative mRNA splicing of exon 11, as indicated above) and has a molecular mass of approximately 130 kDa. The amino acid numbering system for the insulin receptor typically refers to the form that includes the 12 additional amino acids encoded by exon 11 in the &alpha;-subunit [",
"      <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/3\">",
"       3",
"      </a>",
"      ]. The &alpha;-subunit is entirely extracellular, and contains the binding sites for insulin.",
"     </li>",
"     <li>",
"      The transmembrane-spanning &szlig;-subunit contains 620 amino acids and has an approximate molecular mass of 95 kDa. The &szlig;-subunit has three components: extracellular, transmembrane, and cytosolic. The cytosolic component contains the receptor's tyrosine kinase catalytic activity that is regulated by insulin, and is very structurally homologous to other members of the tyrosine protein kinase family [",
"      <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/4\">",
"       4",
"      </a>",
"      ]. The cytosolic component of the &szlig;-subunit has several sub-domains: a juxtamembrane domain; the tyrosine kinase catalytic domain, which contains an ATP binding site and an &ldquo;activation loop&rdquo; with three closely spaced tyrosines that become phosphorylated; and a carboxy-terminal domain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both receptor-subunits are glycosylated during the process of translation and contain complex N-linked carbohydrate side chains with terminal sialic acid residues [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/26\">",
"     26",
"    </a>",
"    ], which are necessary for normal folding and hence function of the receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/27\">",
"     27",
"    </a>",
"    ]. The extracellular component of the &beta;-subunit also contains O-linked oligosaccharides [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2006, elucidation of the crystal structure of recombinant receptor ecto-domain revealed that it has a unique structure (",
"    <a class=\"graphic graphic_figure graphicRef82549 \" href=\"UTD.htm?20/54/21350\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/29\">",
"     29",
"    </a>",
"    ]. The N-terminus is composed of two globular leucine-rich repeat domains, L1 and L2, flanking the cysteine-rich domain, which is formed from eight modular cystine linked repeats. The C-terminus is formed from three Type III fibronectin repeat domains (FnIII 1, -2, and -3), a common structural motif in the extracellular domains of membrane proteins. The first of these is located in the &alpha;-subunit and the third is located in the &beta;-subunit. The second domain is atypical containing a disordered 120 amino acid insertion, the Insert Domain, which contains the &alpha;-&beta; cleavage site. These are folded into an inverted V, with the apex of the V being formed from the L2 and the first Type III fibronectin repeat domains.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Insulin receptor isoforms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although it is encoded by a single gene, the alternative pre-mRNA splicing of exon 11 in the insulin receptor transcript generates two isoforms, one with exon 11 (HIR-B or EX11+) and one without exon 11 (HIR-A or EX11-). Thus, the protein forms differ by the presence or absence, respectively, of the 12 amino acids at the carboxy-terminus of the &alpha;-subunit encoded by exon 11 (",
"    <a class=\"graphic graphic_figure graphicRef72096 \" href=\"UTD.htm?42/44/43724\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Interestingly, the relative abundance of the two alternatively spliced mRNAs [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/11,12\">",
"     11,12",
"    </a>",
"    ] and their encoded proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/30\">",
"     30",
"    </a>",
"    ] is tissue-specific and developmentally regulated. The smaller EX11- form predominates in hematopoietic cells and the larger EX11+ form predominates in liver [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Differences in isoform function",
"    </span>",
"    &nbsp;&mdash;&nbsp;The conservation of the exon 11 mRNA splicing in different species suggests the possibility that the two receptor forms have functionally distinct properties; in spite of intensive studies, the functional differences identified have been of small magnitude. The Ex 11-form is agreed to display a one and a half- to twofold higher affinity for insulin and may exhibit accelerated internalization [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. Whether the two forms differ with respect to kinase activity is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Role of isoforms in disease states",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of receptor splice forms in disease states is controversial. Different levels of expression in muscle from insulin resistant (90 percent \"B\" form) versus insulin sensitive individuals (81 percent) have been shown [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/35\">",
"     35",
"    </a>",
"    ]. Whether these changes alter level of the receptor isoforms or have biological consequences is presently unknown. In myotonic muscular dystrophy, which is associated with insulin resistance, a splicing defect results in all insulin receptors being of the A form [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/36\">",
"     36",
"    </a>",
"    ]. Impaired insulin stimulated glucose uptake by striated muscle has been demonstrated in a murine model of this disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     INSULIN BINDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of the binding of insulin to the receptor have shown that binding kinetics are complex, due to heterogeneity of insulin binding sites, negative cooperativity in the binding function, or a combination of the two [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/37\">",
"     37",
"    </a>",
"    ]. Further structural insights into the insulin-insulin receptor interaction have been gained from mutational analysis and crystallization data described below [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Negative cooperativity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kinetic experiments, in which insulin binding at high concentrations induces a low affinity state and increases the rate of hormone dissociation, support the existence of negative cooperativity of insulin binding [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. It has been proposed that each &alpha;-subunit of the receptor dimer contains two distinct, non-identical insulin binding sites [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/38\">",
"     38",
"    </a>",
"    ]. Thus, at low \"physiologic\" insulin concentrations, one molecule of insulin would simultaneously bind to both receptor monomers in an asymmetrical manner (using nonidentical binding sites), giving a stoichiometry of one for the holoreceptor at \"physiologic\" conditions. The two-site binding would account for the binding being of high affinity. As it is further posited that only one two-site binding event can occur, binding of a second molecule of insulin, in the presence of higher (nonphysiologic) levels of insulin, would result in a conformational change leading to disruption of two-site binding of the first molecule of insulin, thereby reducing binding affinity and potentially accounting for negative cooperativity. Experimental studies of insulin binding to &alpha;-&szlig; heterodimers confirms the prediction that insulin binding to this species occurs as a single class of low affinity sites [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/21,41\">",
"     21,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Binding site",
"    </span>",
"    &nbsp;&mdash;&nbsp;The location of the binding site(s) in the &alpha;-subunit was initially inferred from the fact that this subunit is entirely extracellular; it is also the only subunit ever identified in affinity labeling protocols [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. Mutational analysis, including alanine-scanning mutagenesis, experiments with recombinant mini-receptors, and reconstitution studies provide evidence that a major insulin binding site, Site 1, is formed from elements of the L1 domain amino acids 704 to 717 and in the Insert Domain at the C-terminus of the &alpha;-subunit [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/45-51\">",
"     45-51",
"    </a>",
"    ]. Complementation studies with truncated secreted receptors and affinity labeling studies suggest that the L1 component and Insert Domain components are contributed by separate receptor monomers.",
"   </p>",
"   <p>",
"    <br/>",
"    A second insulin binding site, Site 2 with lower affinity, is formed from residues in the first and second Type III fibronectin repeats and the linker between them [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. The crystal structure shows that the Site 1 of one monomer is close enough to Site 2 of the second monomer to permit simultaneous binding of one molecule of insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/29\">",
"     29",
"    </a>",
"    ]. Complementation studies with reconstituted mutant holoreceptor confirm this and also show that this is essential for the generation of high affinity interactions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/53\">",
"     53",
"    </a>",
"    ]. This bivalent binding mechanism is consistent with negative cooperativity as described above and with biochemical findings that the holoreceptor only binds one molecule of insulin with high affinity at physiological insulin concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     INSULIN RECEPTOR-SUBUNIT INTERACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The binding of insulin to the receptor causes rapid receptor autophosphorylation on specific tyrosine side-chains [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/44,55\">",
"     44,55",
"    </a>",
"    ], an event that appears to be critical to both activation of the tyrosine kinase towards exogenous substrates and most or all of the actions of insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/7\">",
"     7",
"    </a>",
"    ]. The insulin mediated cross-linking of the receptor described above provides an attractive mechanism for receptor activation. The cross-linking of the two receptor monomers may potentially stabilize them in a conformation that facilitates the trans-phosphorylation of the tyrosine kinase catalytic domains that is essential for activation of their catalytic activity. The structural details of this process remain obscure.",
"   </p>",
"   <p>",
"    The extracellular domain crystal structure and molecular dynamic simulations suggest that the insulin binding sites undergo see-saw movements, which lead to their opening and closing with consequent changes in the topology of the two monomers [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/29,56\">",
"     29,56",
"    </a>",
"    ]. Binding of insulin stabilizes one binding site in the &ldquo;closed&rdquo; active conformation. This is accompanied by the opening of the second site to allow access of a second molecule of insulin. Receptor cross-linking by the second molecule of insulin reverses the conformational changes with dissociation of the first insulin molecule [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/29\">",
"     29",
"    </a>",
"    ]. Analyses of crystal structures of the insulin-insulin receptor complexes will be needed to further illuminate the mechanism of insulin binding.",
"   </p>",
"   <p>",
"    How these conformational changes are transmitted to the transmembrane domains, and hence to the intracellular domains of the receptor, is not well understood. Numerous substitution and deletion mutations introduced into the transmembrane domain fail to alter receptor processing, binding, kinase activity, or ability to activate downstream pathways, suggesting a \"passive role\" [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. However, certain substitutions can activate the receptor kinase, suggesting that this domain is able to influence the conformation or orientation of the kinase domain(s) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MECHANISM OF KINASE DOMAIN REGULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The crystal structure of the tyrosine kinase domain of the human insulin receptor has provided unique insight into the regulation of the insulin receptor enzyme activity and mechanism of autophosphorylation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/5\">",
"     5",
"    </a>",
"    ]. One group analyzed a 306 amino acid fragment of the &szlig; chain of the human insulin receptor, which contains the tri-tyrosine sites whose autophosphorylation is required for receptor kinase activity towards exogenous substrates. This fragment becomes an active tyrosine kinase when auto-phosphorylated [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Crystallization data revealed a novel auto-inhibitory mechanism. Tyr-1162, one of the tri-tyrosines in the kinase domain that becomes phosphorylated early following insulin binding, occupies a space in the active site of the enzyme, seemingly poised for a cis-autophosphorylation event (phosphorylated by its own &szlig;-subunit). However, the hydroxyl group of the Tyr-1162 phenolic ring that is the target of phosphorylation is hydrogen bonded to the carboxylate group of the catalytic base of its own &szlig;-subunit (residue Asp-1132), rendering the binding pocket for ATP blocked in this state. Thus, in the unphosphorylated (basal) form of the receptor, the Tyr-1162 of each &szlig;-subunit sits in that &szlig;-subunit's substrate binding site and functions in a cis-autoinhibition mechanism.",
"   </p>",
"   <p>",
"    When insulin binds to the &alpha;-subunit, the quaternary structure of the &szlig;-subunit undergoes a conformational change, moving Tyr-1162 out of the receptor kinase domain catalytic pocket. As a result, the phosphorylation sites (in the tri-tyrosine domain) of one &szlig; chain come within reach of the active site of the other &szlig; chain. The movement of Tyr-1162 allows ATP to bind and a trans-phosphorylation event takes place involving the kinase activity of one &szlig;-subunit and the Tyr-1162 residue of the corresponding adjacent &szlig;-subunit in the receptor heterotetramer. Ultimately, the three tyrosines in the kinase domain become phosphorylated and the receptor kinase becomes fully activated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     RECEPTOR AUTOPHOSPHORYLATION AND SIGNAL TRANSDUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The insulin receptor is a member of the large receptor tyrosine kinase gene family that includes the receptors for EGF and platelet-derived growth factor (PDGF) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/4\">",
"     4",
"    </a>",
"    ]. It is of interest to draw distinctions between these receptors and the larger \"insulin receptor family,\" including the IGF-1 receptor and the insulin receptor-related receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The EGF and PDGF receptors exist as monomers that are induced to form noncovalent dimers as a consequence of ligand binding, in contrast to the insulin receptor, which exists as a covalent dimer of two &alpha;-&szlig; monomers when ligand in not bound [",
"      <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/61,62\">",
"       61,62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second difference between these classes of receptors is that the EGF and PDGF receptors form complexes between specific tyrosine phosphorylated residues in the receptor and downstream mediators via signaling domains in the effector proteins that specifically attach to the phosphorylated receptor tyrosines (eg, src homology (SH2) domains) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/63\">",
"       63",
"      </a>",
"      ]. In contrast, the activated insulin receptor phosphorylates one or more principal substrate proteins on tyrosine residues, of which insulin receptor substrate-1 (IRS-1) and IRS-2 are the best characterized [",
"      <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies in mice with combined heterozygosity for the insulin receptor, IRS-1,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    IRS-2 report tissue-specific differences between the two substrates, with IRS-1 playing a prominent role in skeletal muscle and IRS-2 in the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/65\">",
"     65",
"    </a>",
"    ]. IRS-2 also appeared to be important in the beta cell, since the IRS-2, but not the IRS-1 heterozygotes, showed attenuated compensatory beta cell hyperplasia in response to the associated insulin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/64\">",
"     64",
"    </a>",
"    ]. Other tissue-specific IRS-2 knockout mouse models suggest that IRS-2 signaling may play an important role in hypothalamic regulation of leptin, peripheral insulin sensitivity, and possibly, regeneration of beta cells [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Sites of tyrosine autophosphorylation and functional domains",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each receptor cytoplasmic domain has 13 tyrosine residues, and considerable effort has been expended in order to characterize the importance of phosphorylation of these sites. Seven of the 13 tyrosines, occurring in three domains, are phosphorylated in response to insulin binding [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/68-71\">",
"     68-71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most important sites for autophosphorylation and tyrosine kinase activity are the three tyrosine residues (1158, 1162, and 1163) that lie in the tyrosine kinase catalytic domain (",
"      <a class=\"graphic graphic_figure graphicRef51047 \" href=\"UTD.htm?24/54/25454\">",
"       figure 4",
"      </a>",
"      ). Phosphorylation of these sites is temporally correlated with a 10 to 20-fold increase in tyrosine kinase activity [",
"      <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/72-74\">",
"       72-74",
"      </a>",
"      ]. Mutagenesis of these residues has led to the conclusion that maximal activation requires tri-phosphorylation, since the absence of one or two tyrosines limits activation and the capacity to maximally mediate downstream signals in transfected cells [",
"      <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/75-77\">",
"       75-77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Like all protein kinases, the insulin receptor has a consensus amino acid sequence encoding an ATP binding domain (",
"      <a class=\"graphic graphic_figure graphicRef51047 \" href=\"UTD.htm?24/54/25454\">",
"       figure 4",
"      </a>",
"      ). This includes a glycine rich motif (Gly-X-Gly-X-X-Gly) followed by a lysine residue (Lys 1030) that has been shown to be cross-linked with ATP affinity reagents [",
"      <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/68\">",
"       68",
"      </a>",
"      ]. Substitution of this lysine with other amino acids abolishes autophosphorylation and kinase activity [",
"      <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An intracellular juxtamembrane domain encoded by exon 16 contains several tyrosines, and has been implicated in both signal transduction [",
"      <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/70\">",
"       70",
"      </a>",
"      ] and internalization of the receptor [",
"      <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/71\">",
"       71",
"      </a>",
"      ]. In vitro, phosphorylation of this region accounts for 15 percent of the total insulin-stimulated phosphorylation, occurring primarily on tyrosine 972 [",
"      <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/78\">",
"       78",
"      </a>",
"      ]. Mutation of this residue does not affect autophosphorylation or exogenous kinase activity, but markedly impairs the ability of activated receptor to phosphorylate IRS-1 and mediates downstream events [",
"      <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/70\">",
"       70",
"      </a>",
"      ]. It is likely, therefore, that this domain participates in substrate recognition.",
"     </li>",
"     <li>",
"      The role of the insulin receptor C-terminal domain, which extends beyond the tyrosine kinase domain, is unclear [",
"      <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/79\">",
"       79",
"      </a>",
"      ]. The domain contains two tyrosines (1328 and 1334) that are phosphorylated and account for as much as 40 percent of the insulin-stimulated phosphorylation [",
"      <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/72,80\">",
"       72,80",
"      </a>",
"      ]. The C-terminus has been implicated in the regulation of receptor kinase activity [",
"      <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/81\">",
"       81",
"      </a>",
"      ] and receptor aggregation and internalization [",
"      <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/82\">",
"       82",
"      </a>",
"      ]. In some studies, deletion of a C-terminal segment impairs insulin stimulation of glucose transport but augments the stimulation of mitogenesis [",
"      <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/83\">",
"       83",
"      </a>",
"      ], suggesting a regulatory effect of this region on postreceptor signaling events. In other studies that used a different fibroblast cell line, no effects of C-terminal deletion were noted [",
"      <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/84\">",
"       84",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Cis- versus trans-phosphorylation in the activation process",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the insulin holoreceptor exists as a covalently linked dimer of two &alpha;-&szlig; halves, it is important to understand whether the initial act of autophosphorylation and kinase activation occurs as a cis- process (ie, self-phosphorylation of each &szlig;-subunit) or a trans- process (ie, one &szlig;-subunit phosphorylating the other).",
"   </p>",
"   <p>",
"    Several lines of evidence, including studies with chimeric receptors in which inactive receptor halves are detectable via a mutation-induced size change, suggest that the initial event is a transphosphorylation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. If the half being phosphorylated is inactive as a kinase, then activation of the holoreceptor would be prevented. Such a mechanism could explain the capacity of kinase defective receptor halves (as can occur in patients with certain receptor mutations) to behave in a dominant negative manner [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Hybrid insulin receptor molecules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin and IGF-1 share a spectrum of biologic activities, in part mediated by the affinity each ligand exhibits for the other's primary receptor, and the insulin and IGF-1 receptors can form hybrid species, in which &alpha;-&szlig; halves of insulin and IGF-1 receptors exist as covalently linked receptor heterotetramers [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/88-90\">",
"     88-90",
"    </a>",
"    ]. The enhanced IGF-1 binding affinity in some forms of the hybrid receptors may play a role in their postulated involvement in growth and metastasis of certain types of cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/91-93\">",
"     91-93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     EVIDENCE AGAINST THE OBLIGATORY ROLE OF KINASE ACTIVITY IN INSULIN SIGNALING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the evidence favoring an obligatory role of insulin-stimulated kinase activity in the biological actions of insulin is in general overwhelming, historically, several observations have challenged this view.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One reported that a site-directed mutant of the receptor with no kinase activity had normal ability to regulate pyruvate dehydrogenase activity [",
"      <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/94\">",
"       94",
"      </a>",
"      ]. This observation is very difficult to understand in light of all other work.",
"     </li>",
"     <li>",
"      Some anti-insulin receptor monoclonal antibodies stimulated glucose transport without apparent activation of receptor autophosphorylation or kinase activity [",
"      <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/95,96\">",
"       95,96",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cells overexpressing an insulin receptor mutant with markedly impaired kinase activity had a normal dose response for insulin stimulation of glycogen synthesis [",
"      <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/97\">",
"       97",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     NEGATIVE REGULATION AND TERMINATION OF THE INSULIN RECEPTOR SIGNAL",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Serine phosphorylation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The insulin receptor is phosphorylated on serine and threonine residues in the absence of insulin, and this increases in the presence of phorbol esters [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/98\">",
"     98",
"    </a>",
"    ], overexpression of protein kinase C isoforms [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/99\">",
"     99",
"    </a>",
"    ], activation of cyclic AMP-dependent protein kinase [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/100\">",
"     100",
"    </a>",
"    ], and insulin itself [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/98\">",
"     98",
"    </a>",
"    ]. One of the sites is serine 1305 or 1306 in the C-terminus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/101\">",
"     101",
"    </a>",
"    ], and another is in the juxtamembrane region. Serine phosphorylation appears capable of inhibiting insulin signal transduction [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/98\">",
"     98",
"    </a>",
"    ]. Similarly,",
"    <span class=\"nowrap\">",
"     serine/threonine",
"    </span>",
"    phosphorylation of IRS proteins by a variety of cellular kinases has major negative effects on the transmission of the insulin signal, probably more so than that of the receptor itself [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Receptor internalization and turnover",
"    </span>",
"    &nbsp;&mdash;&nbsp;The apparent receptor number present at the cell surface is subject to regulation, and insulin itself, through a process described as homologous down-regulation or desensitization, is a major regulator of this process [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/15\">",
"     15",
"    </a>",
"    ]. An inverse relationship between the ambient insulin concentration and the receptor density on the cell surface has been demonstrated with cultured cells in vitro and in many in vivo models in animals and humans.",
"   </p>",
"   <p>",
"    The major control exerted by insulin on receptor number is at the level of degradation of internalized receptors. In addition to its role as initiator of the insulin signal transduction cascade, the insulin receptor mediates the internalization of the insulin-receptor complex via endocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/103,104\">",
"     103,104",
"    </a>",
"    ]. Within the cell, insulin is degraded and the empty receptors are largely recycled to the plasma membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More prolonged exposure to insulin also increases the rate of receptor degradation, which accounts in large part for the phenomenon of down-regulation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/106,107\">",
"     106,107",
"    </a>",
"    ]. Since internalized receptors appear to be active as kinases [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/108\">",
"     108",
"    </a>",
"    ], it is possible that kinase activity at some intracellular site could play a role in insulin action.",
"   </p>",
"   <p>",
"    There appear to be at least two functionally distinct pathways for insulin internalization. The first, involving structures called coated pits, requires a functionally competent insulin receptor kinase, triphosphorylation in the regulatory domain of the &szlig;-subunit, and two specific tyrosine containing sequences in the juxtamembrane domain [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/109\">",
"     109",
"    </a>",
"    ]. In some cells, including fibroblastic cell lines frequently used in transfection studies, an additional pathway that is constitutive, nonsaturable, and independent of receptor phosphorylation plays a major role [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Reversal of the insulin receptor phosphorylation state",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since tyrosine phosphorylated insulin receptors and IRS proteins retain their tyrosine phosphorylation and lack the intrinsic ability to dephosphorylate and return to a basal state, cellular enzymes with protein-tyrosine phosphatase activity (PTPases) are required to account for the rapid receptor dephosphorylation observed in intact cells following dissociation of insulin from the receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/110\">",
"     110",
"    </a>",
"    ]. PTPases thus have an important role in the regulation of insulin receptor signaling by exerting a negative regulatory \"tone\" to balance the activation state of the insulin signaling pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/111\">",
"     111",
"    </a>",
"    ]. The prediction that inhibition of PTPase(s) that act on the receptor and its tyrosine-phosphorylated substrate proteins would enhance insulin action has been provided by experiments using oxidants such as hydrogen peroxide or vanadate derivatives, which can serve as cellular PTPase inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/112-114\">",
"     112-114",
"    </a>",
"    ]. PTPases have been identified as novel targets for the therapeutic enhancement of insulin action in insulin-resistant disease states [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/115,116\">",
"     115,116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PTPases comprise a large family of transmembrane and intracellular enzymes that dephosphorylate phosphotyrosine side-chains on substrate proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/117\">",
"     117",
"    </a>",
"    ]. Among the large family of transmembrane and intracellular PTPases, newer studies have provided compelling evidence that the intracellular enzyme PTP1B serves a major role in the cellular regulation of the tyrosine phosphorylation state of the insulin receptor and IRS proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/118-120\">",
"     118-120",
"    </a>",
"    ]. Pivotal studies in mice packing expression of PTP1B revealed enhanced insulin sensitivity and improved glucose metabolism, indicating that PTP1B plays a key role in the negative regulation of insulin signaling [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/121,122\">",
"     121,122",
"    </a>",
"    ]. Interestingly, mice lacking PTP1B were also protected against obesity induced by high-fat feeding, due to enhanced signaling via the leptin receptor, whose post-receptor cellular substrates are also a target of the dephosphorylation action of PTP1B [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/123\">",
"     123",
"    </a>",
"    ]. Inhibition of PTP1B in insulin target tissues with pharmaceutical agents and novel antisense oligonucleotides has shown enhanced insulin signaling and glucose tolerance in preclinical models and have now advanced to early clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/124\">",
"     124",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to PTP1B, newer studies have also implicated the TC-PTP [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/125\">",
"     125",
"    </a>",
"    ], the low molecular weight PTPase [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/126\">",
"     126",
"    </a>",
"    ] and SHP-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/127\">",
"     127",
"    </a>",
"    ] in the negative regulation of the insulin action cascade. Thus, PTPase inhibitors may eventually find an important clinical role as novel insulin sensitizers in the management of type 2 diabetes and the metabolic syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Role of cellular proteins that physically interact with insulin receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of proteins have been identified that bind to insulin receptors at the cell surface and play a regulatory role in the transmission of the insulin receptor signal. Growth factor receptor-bound protein 14 (Grb14) is a cellular insulin receptor binding protein that protects certain sites of the tyrosine-phosphorylated insulin receptor from dephosphorylation by PTP1B, but at the same time, Grb 14 impairs receptor kinase activity towards exogenous substrates [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/128\">",
"     128",
"    </a>",
"    ]. The interaction between Grb14 and the insulin receptor is stimulated by cellular insulin binding, and Grb14 was shown to protect the three tyrosine of the receptor kinase loop from dephosphorylation by PTP1B, while favoring dephosphorylation of tyrosine 972 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/129\">",
"     129",
"    </a>",
"    ]. Consistent with these cellular studies, Grb14-deficient mice were found to have improved glucose homeostasis and enhanced insulin signaling [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/130\">",
"     130",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ectonucleotide pyrophosphatase phosphodiesterase-1 (ENPP1), also called plasma cell membrane glycoprotein (PC-1), is a cell surface protein that interacts with the insulin receptor, inhibits receptor &szlig;-subunit autophosphorylation, and has been implicated by genetic and tissue studies to play a role in clinical insulin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/131,132\">",
"     131,132",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hepatic plasma membrane protein carcinoembryonic antigen-related cell adhesion molecule (CEACAM1, also called pp120 in earlier literature) undergoes tyrosine phosphorylation by the insulin receptor and functions as a tumor suppressor, blocking the mitogenic actions of insulin and epidermal growth factor [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/133,134\">",
"     133,134",
"    </a>",
"    ]. Blockade of CEACAM1 signaling in mice by hepatic overexpression of an inactive form of the protein resulted in insulin resistance and hyperinsulinemia associated with blunted hepatic insulin clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?6/23/6522/abstract/135\">",
"     135",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial step in insulin action is binding to the insulin receptor, a transmembrane, multi-subunit glycoprotein that contains insulin-stimulated tyrosine kinase activity. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The receptor is composed of two extracellular &alpha;-subunits that are each linked to a &szlig;-subunit and to each other by disulfide bonds (",
"      <a class=\"graphic graphic_figure graphicRef58299 \" href=\"UTD.htm?40/38/41568\">",
"       figure 2",
"      </a>",
"      ). Reduction of the bonds that link the &alpha;-subunits produces an &alpha;-&szlig; heterodimer that binds insulin with reduced affinity. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Receptor structure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although it is encoded by a single gene, the alternative pre-mRNA splicing of exon 11 in the insulin receptor transcript generates two isoforms, one with exon 11 (HIR-B or EX11+) and one without exon 11 (HIR-A or EX11-) (",
"      <a class=\"graphic graphic_figure graphicRef72096 \" href=\"UTD.htm?42/44/43724\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Insulin receptor isoforms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Studies of the binding of insulin to the receptor have shown that binding kinetics are complex, due to heterogeneity of insulin binding sites, negative cooperativity in the binding function, or a combination of the two. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Insulin binding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The binding of insulin to the receptor causes rapid receptor autophosphorylation on specific tyrosine side-chains, an event that appears to be critical to both activation of the tyrosine kinase activity towards exogenous substrates and most or all of the actions of insulin. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Insulin receptor-subunit interactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Since tyrosine phosphorylated insulin receptors and IRS proteins retain their tyrosine phosphorylation and lack the intrinsic ability to dephosphorylate and return to a basal state, cellular enzymes with protein-tyrosine phosphatase activity (PTPases) are required to account for the rapid receptor dephosphorylation observed in intact cells following dissociation of insulin from the receptor. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Reversal of the insulin receptor phosphorylation state'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/1\">",
"      Kido Y, Nakae J, Accili D. Clinical review 125: The insulin receptor and its cellular targets. J Clin Endocrinol Metab 2001; 86:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/2\">",
"      Freychet P, Roth J, Neville DM Jr. Insulin receptors in the liver: specific binding of ( 125 I)insulin to the plasma membrane and its relation to insulin bioactivity. Proc Natl Acad Sci U S A 1971; 68:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/3\">",
"      Ebina Y, Ellis L, Jarnagin K, et al. The human insulin receptor cDNA: the structural basis for hormone-activated transmembrane signalling. Cell 1985; 40:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/4\">",
"      Ullrich A, Bell JR, Chen EY, et al. Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 1985; 313:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/5\">",
"      Hubbard SR, Wei L, Ellis L, Hendrickson WA. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 1994; 372:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/6\">",
"      Lou M, Garrett TP, McKern NM, et al. The first three domains of the insulin receptor differ structurally from the insulin-like growth factor 1 receptor in the regions governing ligand specificity. Proc Natl Acad Sci U S A 2006; 103:12429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/7\">",
"      Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001; 414:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/8\">",
"      Seino S, Seino M, Nishi S, Bell GI. Structure of the human insulin receptor gene and characterization of its promoter. Proc Natl Acad Sci U S A 1989; 86:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/9\">",
"      Goldstein BJ, Kahn CR. Analysis of mRNA heterogeneity by ribonuclease H mapping: application to the insulin receptor. Biochem Biophys Res Commun 1989; 159:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/10\">",
"      Seino S, Bell GI. Alternative splicing of human insulin receptor messenger RNA. Biochem Biophys Res Commun 1989; 159:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/11\">",
"      Moller DE, Yokota A, Caro JF, Flier JS. Tissue-specific expression of two alternatively spliced insulin receptor mRNAs in man. Mol Endocrinol 1989; 3:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/12\">",
"      Goldstein BJ, Dudley AL. The rat insulin receptor: primary structure and conservation of tissue-specific alternative messenger RNA splicing. Mol Endocrinol 1990; 4:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/13\">",
"      Sibley E, Kastelic T, Kelly TJ, Lane MD. Characterization of the mouse insulin receptor gene promoter. Proc Natl Acad Sci U S A 1989; 86:9732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/14\">",
"      Mamula PW, McDonald AR, Brunetti A, et al. Regulating insulin-receptor-gene expression by differentiation and hormones. Diabetes Care 1990; 13:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/15\">",
"      Gavin JR 3rd, Roth J, Neville DM Jr, et al. Insulin-dependent regulation of insulin receptor concentrations: a direct demonstration in cell culture. Proc Natl Acad Sci U S A 1974; 71:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/16\">",
"      Imano E, Kadowaki H, Kadowaki T, et al. Two patients with insulin resistance due to decreased levels of insulin-receptor mRNA. Diabetes 1991; 40:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/17\">",
"      Alarc&oacute;n C, Cheatham B, Lincoln B, et al. A Kex2-related endopeptidase activity present in rat liver specifically processes the insulin proreceptor. Biochem J 1994; 301 ( Pt 1):257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/18\">",
"      Bass J, Turck C, Rouard M, Steiner DF. Furin-mediated processing in the early secretory pathway: sequential cleavage and degradation of misfolded insulin receptors. Proc Natl Acad Sci U S A 2000; 97:11905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/19\">",
"      Bravo DA, Gleason JB, Sanchez RI, et al. Accurate and efficient cleavage of the human insulin proreceptor by the human proprotein-processing protease furin. Characterization and kinetic parameters using the purified, secreted soluble protease expressed by a recombinant baculovirus. J Biol Chem 1994; 269:25830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/20\">",
"      Robertson BJ, Moehring JM, Moehring TJ. Defective processing of the insulin receptor in an endoprotease-deficient Chinese hamster cell strain is corrected by expression of mouse furin. J Biol Chem 1993; 268:24274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/21\">",
"      Olson TS, Lane MD. Post-translational acquisition of insulin binding activity by the insulin proreceptor. Correlation to recognition by autoimmune antibody. J Biol Chem 1987; 262:6816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/22\">",
"      Salzman A, Wan CF, Rubin CS. Biogenesis, transit, and functional properties of the insulin proreceptor and modified insulin receptors in 3T3-L1 adipocytes. Use of monensin to probe proreceptor cleavage and generate altered receptor subunits. Biochemistry 1984; 23:6555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/23\">",
"      Sweet LJ, Morrison BD, Pessin JE. Isolation of functional alpha beta heterodimers from the purified human placental alpha 2 beta 2 heterotetrameric insulin receptor complex. A structural basis for insulin binding heterogeneity. J Biol Chem 1987; 262:6939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/24\">",
"      B&ouml;ni-Schnetzler M, Kaligian A, DelVecchio R, Pilch PF. Ligand-dependent intersubunit association within the insulin receptor complex activates its intrinsic kinase activity. J Biol Chem 1988; 263:6822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/25\">",
"      Morrison BD, Swanson ML, Sweet LJ, Pessin JE. Insulin-dependent covalent reassociation of isolated alpha beta heterodimeric insulin receptors into an alpha 2 beta 2 heterotetrameric disulfide-linked complex. J Biol Chem 1988; 263:7806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/26\">",
"      Sparrow LG, Lawrence MC, Gorman JJ, et al. N-linked glycans of the human insulin receptor and their distribution over the crystal structure. Proteins 2008; 71:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/27\">",
"      Elleman TC, Frenkel MJ, Hoyne PA, et al. Mutational analysis of the N-linked glycosylation sites of the human insulin receptor. Biochem J 2000; 347 Pt 3:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/28\">",
"      Sparrow LG, Gorman JJ, Strike PM, et al. The location and characterisation of the O-linked glycans of the human insulin receptor. Proteins 2007; 66:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/29\">",
"      McKern NM, Lawrence MC, Streltsov VA, et al. Structure of the insulin receptor ectodomain reveals a folded-over conformation. Nature 2006; 443:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/30\">",
"      Pilch PF, Czech MP. The subunit structure of the high affinity insulin receptor. Evidence for a disulfide-linked receptor complex in fat cell and liver plasma membranes. J Biol Chem 1980; 255:1722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/31\">",
"      Benecke H, Flier JS, Moller DE. Alternatively spliced variants of the insulin receptor protein. Expression in normal and diabetic human tissues. J Clin Invest 1992; 89:2066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/32\">",
"      Mosthaf L, Grako K, Dull TJ, et al. Functionally distinct insulin receptors generated by tissue-specific alternative splicing. EMBO J 1990; 9:2409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/33\">",
"      Yamaguchi Y, Flier JS, Yokota A, et al. Functional properties of two naturally occurring isoforms of the human insulin receptor in Chinese hamster ovary cells. Endocrinology 1991; 129:2058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/34\">",
"      Vogt B, Carrascosa JM, Ermel B, et al. The two isotypes of the human insulin receptor (HIR-A and HIR-B) follow different internalization kinetics. Biochem Biophys Res Commun 1991; 177:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/35\">",
"      Kellerer M, Lammers R, Ermel B, et al. Distinct alpha-subunit structures of human insulin receptor A and B variants determine differences in tyrosine kinase activities. Biochemistry 1992; 31:4588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/36\">",
"      Savkur RS, Philips AV, Cooper TA. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet 2001; 29:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/37\">",
"      Sell SM, Reese D, Ossowski VM. Insulin-inducible changes in insulin receptor mRNA splice variants. J Biol Chem 1994; 269:30769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/38\">",
"      De Meyts P. The structural basis of insulin and insulin-like growth factor-I receptor binding and negative co-operativity, and its relevance to mitogenic versus metabolic signalling. Diabetologia 1994; 37 Suppl 2:S135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/39\">",
"      de Meyts P, Roth J, Neville DM Jr, et al. Insulin interactions with its receptors: experimental evidence for negative cooperativity. Biochem Biophys Res Commun 1973; 55:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/40\">",
"      DeMeyts P, Bainco AR, Roth J. Site-site interactions among insulin receptors. Characterization of the negative cooperativity. J Biol Chem 1976; 251:1877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/41\">",
"      Siegfried W. Perspectives in gene therapy with recombinant adenoviruses. Exp Clin Endocrinol 1993; 101:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/42\">",
"      De Meyts P, Gu JL, Shymko RM, et al. Identification of a ligand-binding region of the human insulin receptor encoded by the second exon of the gene. Mol Endocrinol 1990; 4:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/43\">",
"      Schumacher R, Soos MA, Schlessinger J, et al. Signaling-competent receptor chimeras allow mapping of major insulin receptor binding domain determinants. J Biol Chem 1993; 268:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/44\">",
"      Kasuga M, Karlsson FA, Kahn CR. Insulin stimulates the phosphorylation of the 95,000-dalton subunit of its own receptor. Science 1982; 215:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/45\">",
"      Mynarcik DC, Yu GQ, Whittaker J. Alanine-scanning mutagenesis of a C-terminal ligand binding domain of the insulin receptor alpha subunit. J Biol Chem 1996; 271:2439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/46\">",
"      Whittaker J, Whittaker L. Characterization of the functional insulin binding epitopes of the full-length insulin receptor. J Biol Chem 2005; 280:20932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/47\">",
"      Williams PF, Mynarcik DC, Yu GQ, Whittaker J. Mapping of an NH2-terminal ligand binding site of the insulin receptor by alanine scanning mutagenesis. J Biol Chem 1995; 270:3012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/48\">",
"      Kristensen C, Andersen AS, Ostergaard S, et al. Functional reconstitution of insulin receptor binding site from non-binding receptor fragments. J Biol Chem 2002; 277:18340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/49\">",
"      Kristensen C, Wiberg FC, Andersen AS. Specificity of insulin and insulin-like growth factor I receptors investigated using chimeric mini-receptors. Role of C-terminal of receptor alpha subunit. J Biol Chem 1999; 274:37351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/50\">",
"      Kristensen C, Wiberg FC, Sch&auml;ffer L, Andersen AS. Expression and characterization of a 70-kDa fragment of the insulin receptor that binds insulin. Minimizing ligand binding domain of the insulin receptor. J Biol Chem 1998; 273:17780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/51\">",
"      Menting JG, Ward CW, Margetts MB, Lawrence MC. A thermodynamic study of ligand binding to the first three domains of the human insulin receptor: relationship between the receptor alpha-chain C-terminal peptide and the site 1 insulin mimetic peptides. Biochemistry 2009; 48:5492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/52\">",
"      Hao C, Whittaker L, Whittaker J. Characterization of a second ligand binding site of the insulin receptor. Biochem Biophys Res Commun 2006; 347:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/53\">",
"      Whittaker L, Hao C, Fu W, Whittaker J. High-affinity insulin binding: insulin interacts with two receptor ligand binding sites. Biochemistry 2008; 47:12900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/54\">",
"      Chan SJ, Nakagawa S, Steiner DF. Complementation analysis demonstrates that insulin cross-links both alpha subunits in a truncated insulin receptor dimer. J Biol Chem 2007; 282:13754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/55\">",
"      Luo RZ, Beniac DR, Fernandes A, et al. Quaternary structure of the insulin-insulin receptor complex. Science 1999; 285:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/56\">",
"      Vashisth H, Abrams CF. Docking of insulin to a structurally equilibrated insulin receptor ectodomain. Proteins 2010; 78:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/57\">",
"      Frattali AL, Treadway JL, Pessin JE. Evidence supporting a passive role for the insulin receptor transmembrane domain in insulin-dependent signal transduction. J Biol Chem 1991; 266:9829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/58\">",
"      Yamada K, Goncalves E, Kahn CR, Shoelson SE. Substitution of the insulin receptor transmembrane domain with the c-neu/erbB2 transmembrane domain constitutively activates the insulin receptor kinase in vitro. J Biol Chem 1992; 267:12452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/59\">",
"      Wei L, Hubbard SR, Hendrickson WA, Ellis L. Expression, characterization, and crystallization of the catalytic core of the human insulin receptor protein-tyrosine kinase domain. J Biol Chem 1995; 270:8122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/60\">",
"      Olefsky JM. The insulin receptor. A multifunctional protein. Diabetes 1990; 39:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/61\">",
"      Hubbard SR, Mohammadi M, Schlessinger J. Autoregulatory mechanisms in protein-tyrosine kinases. J Biol Chem 1998; 273:11987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/62\">",
"      Hubbard SR, Till JH. Protein tyrosine kinase structure and function. Annu Rev Biochem 2000; 69:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/63\">",
"      Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000; 103:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/64\">",
"      White MF. IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab 2002; 283:E413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/65\">",
"      Kido Y, Burks DJ, Withers D, et al. Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2. J Clin Invest 2000; 105:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/66\">",
"      Kubota N, Terauchi Y, Tobe K, et al. Insulin receptor substrate 2 plays a crucial role in beta cells and the hypothalamus. J Clin Invest 2004; 114:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/67\">",
"      Lin X, Taguchi A, Park S, et al. Dysregulation of insulin receptor substrate 2 in beta cells and brain causes obesity and diabetes. J Clin Invest 2004; 114:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/68\">",
"      Hanks SK, Quinn AM, Hunter T. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 1988; 241:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/69\">",
"      Chou CK, Dull TJ, Russell DS, et al. Human insulin receptors mutated at the ATP-binding site lack protein tyrosine kinase activity and fail to mediate postreceptor effects of insulin. J Biol Chem 1987; 262:1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/70\">",
"      White MF, Livingston JN, Backer JM, et al. Mutation of the insulin receptor at tyrosine 960 inhibits signal transmission but does not affect its tyrosine kinase activity. Cell 1988; 54:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/71\">",
"      Rajagopalan M, Neidigh JL, McClain DA. Amino acid sequences Gly-Pro-Leu-Tyr and Asn-Pro-Glu-Tyr in the submembranous domain of the insulin receptor are required for normal endocytosis. J Biol Chem 1991; 266:23068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/72\">",
"      White MF, Shoelson SE, Keutmann H, Kahn CR. A cascade of tyrosine autophosphorylation in the beta-subunit activates the phosphotransferase of the insulin receptor. J Biol Chem 1988; 263:2969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/73\">",
"      Flores-Riveros JR, Sibley E, Kastelic T, Lane MD. Substrate phosphorylation catalyzed by the insulin receptor tyrosine kinase. Kinetic correlation to autophosphorylation of specific sites in the beta subunit. J Biol Chem 1989; 264:21557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/74\">",
"      Lee J, O'Hare T, Pilch PF, Shoelson SE. Insulin receptor autophosphorylation occurs asymmetrically. J Biol Chem 1993; 268:4092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/75\">",
"      Zhang B, Roth RA. Binding properties of chimeric insulin receptors containing the cysteine-rich domain of either the insulin-like growth factor I receptor or the insulin receptor related receptor. Biochemistry 1991; 30:5113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/76\">",
"      Zhang B, Tavar&eacute; JM, Ellis L, Roth RA. The regulatory role of known tyrosine autophosphorylation sites of the insulin receptor kinase domain. An assessment by replacement with neutral and negatively charged amino acids. J Biol Chem 1991; 266:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/77\">",
"      Wilden PA, Siddle K, Haring E, et al. The role of insulin receptor kinase domain autophosphorylation in receptor-mediated activities. Analysis with insulin and anti-receptor antibodies. J Biol Chem 1992; 267:13719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/78\">",
"      Feener EP, Backer JM, King GL, et al. Insulin stimulates serine and tyrosine phosphorylation in the juxtamembrane region of the insulin receptor. J Biol Chem 1993; 268:11256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/79\">",
"      Faria TN, Blakesley VA, Kato H, et al. Role of the carboxyl-terminal domains of the insulin and insulin-like growth factor I receptors in receptor function. J Biol Chem 1994; 269:13922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/80\">",
"      Tornqvist HE, Pierce MW, Frackelton AR, et al. Identification of insulin receptor tyrosine residues autophosphorylated in vitro. J Biol Chem 1987; 262:10212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/81\">",
"      Kaliman P, Baron V, Alengrin F, et al. The insulin receptor C-terminus is involved in regulation of the receptor kinase activity. Biochemistry 1993; 32:9539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/82\">",
"      Smith RM, Sasaoka T, Shah N, et al. A truncated human insulin receptor missing the COOH-terminal 365 amino acid residues does not undergo insulin-mediated receptor migration or aggregation. Endocrinology 1993; 132:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/83\">",
"      Thies RS, Ullrich A, McClain DA. Augmented mitogenesis and impaired metabolic signaling mediated by a truncated insulin receptor. J Biol Chem 1989; 264:12820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/84\">",
"      Myers MG, Backer JM, Siddle K, White MF. The insulin receptor functions normally in Chinese hamster ovary cells after truncation of the C terminus. J Biol Chem 1991; 266:10616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/85\">",
"      Treadway JL, Morrison BD, Soos MA, et al. Transdominant inhibition of tyrosine kinase activity in mutant insulin/insulin-like growth factor I hybrid receptors. Proc Natl Acad Sci U S A 1991; 88:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/86\">",
"      Frattali AL, Treadway JL, Pessin JE. Transmembrane signaling by the human insulin receptor kinase. Relationship between intramolecular beta subunit trans- and cis-autophosphorylation and substrate kinase activation. J Biol Chem 1992; 267:19521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/87\">",
"      Moller DE, Yokota A, White MF, et al. A naturally occurring mutation of insulin receptor alanine 1134 impairs tyrosine kinase function and is associated with dominantly inherited insulin resistance. J Biol Chem 1990; 265:14979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/88\">",
"      King GL, Rechler MM, Kahn CR. Interactions between the receptors for insulin and the insulin-like growth factors on adipocytes. J Biol Chem 1982; 257:10001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/89\">",
"      Moxham CP, Duronio V, Jacobs S. Insulin-like growth factor I receptor beta-subunit heterogeneity. Evidence for hybrid tetramers composed of insulin-like growth factor I and insulin receptor heterodimers. J Biol Chem 1989; 264:13238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/90\">",
"      Bailyes EM, Nav&eacute; BT, Soos MA, et al. Insulin receptor/IGF-I receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting. Biochem J 1997; 327 ( Pt 1):209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/91\">",
"      Slaaby R, Sch&auml;ffer L, Lautrup-Larsen I, et al. Hybrid receptors formed by insulin receptor (IR) and insulin-like growth factor I receptor (IGF-IR) have low insulin and high IGF-1 affinity irrespective of the IR splice variant. J Biol Chem 2006; 281:25869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/92\">",
"      Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007; 28:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/93\">",
"      Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 2007; 6:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/94\">",
"      Gottschalk WK. The pathway mediating insulin's effects on pyruvate dehydrogenase bypasses the insulin receptor tyrosine kinase. J Biol Chem 1991; 266:8814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/95\">",
"      Hawley DM, Maddux BA, Patel RG, et al. Insulin receptor monoclonal antibodies that mimic insulin action without activating tyrosine kinase. J Biol Chem 1989; 264:2438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/96\">",
"      Steele-Perkins G, Roth RA. Insulin-mimetic anti-insulin receptor monoclonal antibodies stimulate receptor kinase activity in intact cells. J Biol Chem 1990; 265:9458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/97\">",
"      Moller DE, Benecke H, Flier JS. Biologic activities of naturally occurring human insulin receptor mutations. Evidence that metabolic effects of insulin can be mediated by a kinase-deficient insulin receptor mutant. J Biol Chem 1991; 266:10995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/98\">",
"      Takayama S, White MF, Kahn CR. Phorbol ester-induced serine phosphorylation of the insulin receptor decreases its tyrosine kinase activity. J Biol Chem 1988; 263:3440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/99\">",
"      Chin JE, Dickens M, Tavare JM, Roth RA. Overexpression of protein kinase C isoenzymes alpha, beta I, gamma, and epsilon in cells overexpressing the insulin receptor. Effects on receptor phosphorylation and signaling. J Biol Chem 1993; 268:6338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/100\">",
"      Stadtmauer L, Rosen OM. Increasing the cAMP content of IM-9 cells alters the phosphorylation state and protein kinase activity of the insulin receptor. J Biol Chem 1986; 261:3402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/101\">",
"      Lewis RE, Cao L, Perregaux D, Czech MP. Threonine 1336 of the human insulin receptor is a major target for phosphorylation by protein kinase C. Biochemistry 1990; 29:1807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/102\">",
"      Zick Y. Ser/Thr phosphorylation of IRS proteins: a molecular basis for insulin resistance. Sci STKE 2005; 2005:pe4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/103\">",
"      Posner BI, Kahn MN, Bergeron JJ. Internalization of insulin: structures involved and significance. Adv Exp Med Biol 1985; 189:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/104\">",
"      Duckworth WC. Insulin degradation: mechanisms, products, and significance. Endocr Rev 1988; 9:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/105\">",
"      Backer JM, Shoelson SE, Haring E, White MF. Insulin receptors internalize by a rapid, saturable pathway requiring receptor autophosphorylation and an intact juxtamembrane region. J Cell Biol 1991; 115:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/106\">",
"      Backer JM, Kahn CR, White MF. The dissociation and degradation of internalized insulin occur in the endosomes of rat hepatoma cells. J Biol Chem 1990; 265:14828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/107\">",
"      Doherty, JJ, Kay, DG, Lai, WH, et al. Selective degradation of insulin within rat liver endosomes. J Cell Biol 1990; 110:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/108\">",
"      Khan MN, Baquiran G, Brule C, et al. Internalization and activation of the rat liver insulin receptor kinase in vivo. J Biol Chem 1989; 264:12931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/109\">",
"      Wilden PA, Kahn CR, Siddle K, White MF. Insulin receptor kinase domain autophosphorylation regulates receptor enzymatic function. J Biol Chem 1992; 267:16660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/110\">",
"      Mooney RA, Anderson DL. Phosphorylation of the insulin receptor in permeabilized adipocytes is coupled to a rapid dephosphorylation reaction. J Biol Chem 1989; 264:6850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/111\">",
"      Goldstein, BJ. Protein-tyrosine phosphatases and the regulation of insulin action. LeRoith D, Taylor SI, Olefsky JM, editors. Diabetes Mellitus: A Fundamental and Clinical Text 2003; 3:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/112\">",
"      Bevan AP, Drake PG, Yale JF, et al. Peroxovanadium compounds: biological actions and mechanism of insulin-mimesis. Mol Cell Biochem 1995; 153:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/113\">",
"      Fantus IG, Tsiani E. Multifunctional actions of vanadium compounds on insulin signaling pathways: evidence for preferential enhancement of metabolic versus mitogenic effects. Mol Cell Biochem 1998; 182:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/114\">",
"      Goldwaser I, Gefel D, Gershonov E, et al. Insulin-like effects of vanadium: basic and clinical implications. J Inorg Biochem 2000; 80:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/115\">",
"      Asante-Appiah E, Kennedy BP. Protein tyrosine phosphatases: the quest for negative regulators of insulin action. Am J Physiol Endocrinol Metab 2003; 284:E663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/116\">",
"      Goldstein BJ, Mahadev K, Kalyankar M, Wu X. Redox paradox: insulin action is facilitated by insulin-stimulated reactive oxygen species with multiple potential signaling targets. Diabetes 2005; 54:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/117\">",
"      Andersen JN, Mortensen OH, Peters GH, et al. Structural and evolutionary relationships among protein tyrosine phosphatase domains. Mol Cell Biol 2001; 21:7117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/118\">",
"      Goldstein BJ. Protein-tyrosine phosphatases: emerging targets for therapeutic intervention in type 2 diabetes and related states of insulin resistance. J Clin Endocrinol Metab 2002; 87:2474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/119\">",
"      Tonks NK. PTP1B: from the sidelines to the front lines! FEBS Lett 2003; 546:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/120\">",
"      Ramachandran C, Kennedy BP. Protein tyrosine phosphatase 1B: a novel target for type 2 diabetes and obesity. Curr Top Med Chem 2003; 3:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/121\">",
"      Klaman LD, Boss O, Peroni OD, et al. Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol Cell Biol 2000; 20:5479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/122\">",
"      Elchebly M, Payette P, Michaliszyn E, et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 1999; 283:1544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/123\">",
"      Zabolotny JM, Bence-Hanulec KK, Stricker-Krongrad A, et al. PTP1B regulates leptin signal transduction in vivo. Dev Cell 2002; 2:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/124\">",
"      Zinker BA, Rondinone CM, Trevillyan JM, et al. PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc Natl Acad Sci U S A 2002; 99:11357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/125\">",
"      Galic S, Hauser C, Kahn BB, et al. Coordinated regulation of insulin signaling by the protein tyrosine phosphatases PTP1B and TCPTP. Mol Cell Biol 2005; 25:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/126\">",
"      Pandey SK, Yu XX, Watts LM, et al. Reduction of low molecular weight protein-tyrosine phosphatase expression improves hyperglycemia and insulin sensitivity in obese mice. J Biol Chem 2007; 282:14291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/127\">",
"      Dubois MJ, Bergeron S, Kim HJ, et al. The SHP-1 protein tyrosine phosphatase negatively modulates glucose homeostasis. Nat Med 2006; 12:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/128\">",
"      B&eacute;r&eacute;ziat V, Kasus-Jacobi A, Perdereau D, et al. Inhibition of insulin receptor catalytic activity by the molecular adapter Grb14. J Biol Chem 2002; 277:4845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/129\">",
"      Nouaille S, Blanquart C, Zilberfarb V, et al. Interaction with Grb14 results in site-specific regulation of tyrosine phosphorylation of the insulin receptor. EMBO Rep 2006; 7:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/130\">",
"      Cooney GJ, Lyons RJ, Crew AJ, et al. Improved glucose homeostasis and enhanced insulin signalling in Grb14-deficient mice. EMBO J 2004; 23:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/131\">",
"      Maddux BA, Chang YN, Accili D, et al. Overexpression of the insulin receptor inhibitor PC-1/ENPP1 induces insulin resistance and hyperglycemia. Am J Physiol Endocrinol Metab 2006; 290:E746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/132\">",
"      Abate N, Chandalia M, Di Paola R, et al. Mechanisms of disease: Ectonucleotide pyrophosphatase phosphodiesterase 1 as a 'gatekeeper' of insulin receptors. Nat Clin Pract Endocrinol Metab 2006; 2:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/133\">",
"      Poy MN, Ruch RJ, Fernstrom MA, et al. Shc and CEACAM1 interact to regulate the mitogenic action of insulin. J Biol Chem 2002; 277:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/134\">",
"      Najjar SM. Regulation of insulin action by CEACAM1. Trends Endocrinol Metab 2002; 13:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/23/6522/abstract/135\">",
"      Park SY, Cho YR, Kim HJ, et al. Mechanism of glucose intolerance in mice with dominant negative mutation of CEACAM1. Am J Physiol Endocrinol Metab 2006; 291:E517.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1759 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-125.39.66.147-2DA2A50332-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_23_6522=[""].join("\n");
var outline_f6_23_6522=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EXPRESSION AND SUBUNIT STRUCTURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Receptor gene and mRNA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Receptor structure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Insulin receptor isoforms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Differences in isoform function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Role of isoforms in disease states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      INSULIN BINDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Negative cooperativity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Binding site",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      INSULIN RECEPTOR-SUBUNIT INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MECHANISM OF KINASE DOMAIN REGULATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      RECEPTOR AUTOPHOSPHORYLATION AND SIGNAL TRANSDUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Sites of tyrosine autophosphorylation and functional domains",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Cis- versus trans-phosphorylation in the activation process",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Hybrid insulin receptor molecules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      EVIDENCE AGAINST THE OBLIGATORY ROLE OF KINASE ACTIVITY IN INSULIN SIGNALING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      NEGATIVE REGULATION AND TERMINATION OF THE INSULIN RECEPTOR SIGNAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Serine phosphorylation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Receptor internalization and turnover",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Reversal of the insulin receptor phosphorylation state",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Role of cellular proteins that physically interact with insulin receptors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1759\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1759|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/44/43724\" title=\"figure 1\">",
"      Insulin receptor isoforms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/38/41568\" title=\"figure 2\">",
"      3D view of insulin receptor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/54/21350\" title=\"figure 3\">",
"      Structure of the insulin receptor extra-cellular domain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/54/25454\" title=\"figure 4\">",
"      Insulin receptor subunits",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_23_6523="VIN grading";
var content_f6_23_6523=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F67918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F67918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Histological grades of squamous vulvar intrapeithelial neoplasia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        VIN 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cytological atypia is most often represented by koilocytosis or basal cell hyperplasia and increased mitotic activity, with squamous maturation occurring in the upper two-thirds of the epithelium.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single \">",
"        VIN 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Loss of maturation is confined to the lower two thirds of the epithelium with some surface maturation present.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single \">",
"        VIN 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Full thickness loss of squamous maturation of the squamous epithelium is",
"present. Cytological changes may be significant with bizarre mitotic",
"figures and significant pleomorphism. Stromal invasion is not present.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_23_6523=[""].join("\n");
var outline_f6_23_6523=null;
var title_f6_23_6524="Associations with E nodosum";
var content_f6_23_6524=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F63580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F63580&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Conditions associated with erythema nodosum",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Idiopathic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Familial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pregnancy (particularly second trimester)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Systemic diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Inflammatory bowel disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sarcoidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Collagen vascular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sweet's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Antibiotics (penicillin, sulfonamides)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Birth control pills",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Omeprazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Immunizations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Streptococcal pharyngitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Tuberculosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Salmonella gastroenteritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cat scratch fever",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Leprosy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Yersinia colitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Psittacosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Histoplasmosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Blastomycosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Coccidiomycosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_23_6524=[""].join("\n");
var outline_f6_23_6524=null;
var title_f6_23_6525="pt variability BTMS";
var content_f6_23_6525=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F68633&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F68633&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Determinants of the preanalytical variability of bone turnover",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Controllable determinants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Circadian variation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Menstrual variation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Seasonal variation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fasting and food intake (serum",
"        <sub>",
"         &beta;",
"        </sub>",
"        -CTX-1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Exercise and physical activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Determinants that cannot be easily modified",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sex",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Menopausal status",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vitamin D deficit and secondary hyperparathyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Diseases characterized by an acceleration of bone turnover",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Primary hyperparathyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Thyrotoxicosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Acromegaly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Paget's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Bone metastases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Diseases characterized by a dissociation of bone turnover",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Cushing's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Multiple myeloma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Diseases characterized by a low bone turnover",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Hypothyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Hypoparathyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Hypopituitarism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Growth hormone deficit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Renal impairment (depending on the stage)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Recent fracture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Chronic diseases associated with limited mobility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Stroke",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Hemiplegia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Dementia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Alzheimer's disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Oral corticosteroids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Inhaled corticosteroids (only osteocalcin)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Aromatase inhibitors (anti-aromatases)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        GnRH agonists",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Anti-epileptic drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Thiazolidinediones",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Heparin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Vitamin K antagonists",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Szulc P, Delmas PD. 2008 Biochemical Markers of Bone Turnover in Osteoporosis. In: Rosen C (ed.) Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 7th ed. Copyright &copy; 2008. Reproduced with permission of John Wiley &amp; Sons, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_23_6525=[""].join("\n");
var outline_f6_23_6525=null;
var title_f6_23_6526="Time course cerebral hemorrhage";
var content_f6_23_6526=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F61491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F61491&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Time course of neurologic changes in intracerebral hemorrhage",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 355px; height: 324px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of rapid downhill course in terms of unusual behavior (green), hemimotor function (blue), and consciousness (red) in a patient with intracerebral (intraparenchymal) hemorrhage.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_23_6526=[""].join("\n");
var outline_f6_23_6526=null;
var title_f6_23_6527="Antigen presentation";
var content_f6_23_6527=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F63541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F63541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Representation of T cell activation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 253px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of initiation of the immunologic response to an antigen. The antigen binds to a groove in MHC class II molecules on antigen-presenting cells (APCs, such as macrophages). This binding allows the antigen to be presented to antigen receptors on autoreactive CD4 inducer or helper T cells which, in type 1 diabetes mellitus, initiate autoimmune injury to the pancreatic beta-cells. In addition, the respective binding of B7 proteins and LFA-3 (lymphocyte functional antigen-3) on APCs to CD28 and CD2 on T cells are important",
"    <strong>",
"     costimulatory pathways",
"    </strong>",
"    that further increase T-cell activation. Other molecules also can participate in the immune response, such as the binding of interleukin-2 to its receptor (IL-2R).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_23_6527=[""].join("\n");
var outline_f6_23_6527=null;
